Investigation of hypoxia in syngeneic rat prostate tumors after irradiation with photons or carbon ions by multimodal imaging and histology by Bendinger, Alina Leandra
  
 
 
Dissertation 
 
Submitted to the 
Combined Faculty of Natural Sciences and Mathematics 
of the Ruperto Carola University Heidelberg, Germany 
for the degree of 
Doctor of Natural Sciences 
 
 
 
 
 
 
Presented by 
Alina Leandra Bendinger, M.Sc. 
Born in Osnabrück, Germany 
Oral examination: 21.10.2019 
  
  
  
  
Investigation of hypoxia in syngeneic rat prostate     
tumors after irradiation with photons or carbon ions 
by multimodal imaging and histology 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Referees:  PD Dr. rer. nat. Karin Müller-Decker 
  Prof. Dr. rer. nat. Christian Karger 
  
  
Publications of this dissertation 
Bendinger AL, Debus C, Glowa C, Karger CP, Peter J, Storath M: Bolus arrival time 
estimation in dynamic contrast-enhanced magnetic resonance imaging of small animals 
based on spline models. Phys Med Biol, 2019 Feb 5; 64(4): 045003.  
 
Bendinger AL, Glowa C, Peter J, Karger CP: Photoacoustic imaging to assess pixel-based 
sO2 distributions in experimental prostate tumors. J Biomed Opt, 2018 Mar; 23(3): 036009. 
 
Manuscripts in preparation 
Bendinger AL, Seyler L, Saager M, Debus C, Peschke P, Komljenovic D, Debus J, Peter J, 
Floca R, Karger CP, Glowa C: Impact of single dose photons and carbon ions on perfusion 
and vascular permeability: A dynamic contrast-enhanced MRI study in the anaplastic rat 
prostate tumor R3327-AT1. Submitted. 
 
Bendinger AL, Peschke P, Peter J, Debus J, Karger CP, Glowa C: High doses of photons and 
carbon ions induce comparable increase of vascular permeability in R3327-HI prostate 
tumors: A dynamic contrast enhanced MRI study. In preparation. 
 
Conference contributions 
27
th
 Annual Meeting of the International Society for Magnetic Resonance in Medicine 
(ISMRM) 2019, Montreal, Canada (Posters, Trainee Stipend): 
Bendinger AL, Seyler L, Saager M, Debus C, Peschke P, Komljenovic D, Debus J, Peter J, 
Floca R, Karger CP, Glowa C: Response monitoring by DCE-MRI in an experimental pros-
tate tumor after single dose 
12
C-ion and photon radiotherapy. In: Proc. Intl. Soc. Mag. 
Reson. Med. 27: 2337, 2019. 
Bendinger AL, Debus C, Glowa C, Karger CP, Peter J, Storath M: Bolus arrival time estima-
tion for DCE-MRI signals without fast up-slope. In: Proc. Intl. Soc. Mag. Reson. Med. 27: 
2350, 2019. 
 
26
th
 Annual Meeting of the ISMRM 2018, Paris, France (Poster, Trainee Stipend): 
Bendinger AL, Karger CP, Debus C, Floca R, Debus J, Peter J, Glowa C: Longitudinal 
response monitoring in experimental prostate tumors by DCE-MRI after C-12 ion and 
photon radiotherapy. In: Proc. Intl. Soc. Mag. Reson. Med. 26: 1470, 2018.  
 
10
th
 World Molecular Imaging Congress, 2017, Philadelphia, USA (Poster, Travel 
Award): 
Bendinger AL, Glowa C, Peter J, Karger CP: Photoacoustic imaging to assess pixel-based 
sO2 distributions in experimental prostate tumors.  
  
 
 
 I 
 
Table of Contents 
List of Figures V 
List of Tables VIII 
Abbreviations IX 
Summary XIII 
Zusammenfassung XV 
 
1 Introduction 1 
1.1 Prostate cancer............................................................................................................. 1 
1.2 Radiotherapy with photons and carbon ions ............................................................... 1 
1.3 Hypoxia as a resistance factor ..................................................................................... 5 
1.4 Imaging of hypoxia ..................................................................................................... 6 
1.5 Aim of the thesis ......................................................................................................... 9 
2 Materials and Methods 11 
2.1 Tumor model ............................................................................................................. 11 
2.1.1 Animal keeping ............................................................................................... 11 
2.1.2 The Dunning R3327 prostate tumor model ..................................................... 11 
2.1.3 Tumor induction by transplantation ................................................................ 12 
2.2 Photoacoustic imaging (PAI) .................................................................................... 12 
2.2.1 Basics of PAI .................................................................................................. 12 
2.2.2 Experimental set-up for PAI ........................................................................... 13 
2.2.3 A new pixel-based oxygen saturation (sO2) analysis protocol ........................ 14 
2.2.4 Dependency of sO2-distributions on signal gain and threshold ...................... 14 
2.2.5 Characterization of the hypoxic status of the H-, HI-, and AT1-tumor .......... 15 
2.2.6 Histology and immunohistochemistry ............................................................ 15 
2.3 Tumor irradiation ...................................................................................................... 16 
2.3.1 Photon irradiation............................................................................................ 16 
2.3.2 Carbon ion irradiation ..................................................................................... 16 
2.4 Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) ................... 17 
2.4.1 MRI basics ...................................................................................................... 17 
2.4.2 DCE-MRI basics ............................................................................................. 17 
2.4.3 Pharmacokinetic modeling basics ................................................................... 18 
2.4.4 Delay correction by bolus arrival time (BAT) estimation .............................. 21 
2.4.5 Experimental set-up for DCE-MRI ................................................................. 24 
Table of Contents  
II 
 
2.4.6 Signal-to-concentration conversion of DCE-MRI data ................................... 25 
2.4.7 Pharmacokinetic modeling of DCE-MRI data ................................................ 25 
2.5 Longitudinal DCE-MRI studies after irradiation....................................................... 26 
2.5.1 DCE-MRI study of the AT1-tumor ................................................................. 26 
2.5.2 DCE-MRI study of the HI-tumor .................................................................... 27 
2.6 Histology and immunohistochemistry ....................................................................... 29 
2.6.1 Tumor dissection and preparation of cryo sections ......................................... 29 
2.6.2 Staining protocols ........................................................................................... 29 
2.6.3 Fluorescence microscopy and image preparation for analysis ........................ 33 
2.6.4 Quantitative analyses of histological stainings ............................................... 34 
2.7 Longitudinal histology study of the AT1-tumor after irradiation .............................. 41 
2.8 Statistical analysis ..................................................................................................... 42 
3 Results 43 
3.1 Photoacoustic imaging (PAI) .................................................................................... 43 
3.1.1 New protocol for the assessment of sO2-distributions .................................... 43 
3.1.2 Dependency of sO2-distributions on signal gain and threshold ...................... 44 
3.1.3 Characterization of the tumor sublines H, HI, and AT1 ................................. 47 
3.1.4 Histology and immunohistochemistry ............................................................ 52 
3.2 DCE-MRI: a novel method for bolus arrival time (BAT) estimation ....................... 53 
3.2.1 The new approximation model for BAT estimation ....................................... 53 
3.2.2 Discretization and computation of the approximating function ...................... 55 
3.2.3 Parameter estimation by generalized cross validation .................................... 57 
3.2.4 Assessment of BAT estimation accuracy on simulated data ........................... 57 
3.2.5 Assessment of BAT estimation accuracy on in vivo data ............................... 60 
3.3 Longitudinal DCE-MRI study of the AT1-tumor after irradiation ............................ 62 
3.3.1 Tumor growth after irradiation........................................................................ 62 
3.3.2 Non-compartment analysis and pharmacokinetic modeling ........................... 63 
3.3.3 Histology 21 days after irradiation .................................................................. 66 
3.4 Longitudinal DCE-MRI study of the HI-tumor after irradiation ............................... 70 
3.4.1 Tumor growth after irradiation........................................................................ 71 
3.4.2 Pharmacokinetic modeling of DCE-MRI data ................................................ 71 
3.4.3 Principle component analysis and Gaussian mixture modeling ...................... 72 
3.4.4 Treatment response after irradiation ............................................................... 73 
3.4.5 Histology 21 days after irradiation .................................................................. 76 
3.5 Longitudinal histology study of the AT1-tumor after irradiation .............................. 77 
3.5.1 Tumor growth after irradiation........................................................................ 77 
Table of Contents 
III 
 
3.5.2 Tumor morphology ......................................................................................... 78 
3.5.3 Tumor hypoxia ................................................................................................ 80 
3.5.4 Vascular density and maturity ........................................................................ 84 
3.5.5 Tumor perfusion.............................................................................................. 86 
3.5.6 Proliferation .................................................................................................... 89 
3.5.7 DNA double-strand breaks ............................................................................. 91 
4 Discussion 93 
4.1 New analysis protocol for photoacoustic imaging (PAI) .......................................... 93 
4.1.1 Feasibility of the new analysis protocol .......................................................... 93 
4.1.2 Dependency of sO2-distributions on signal gain and threshold ...................... 94 
4.2 New method for BAT estimation of DCE-MRI data ................................................ 94 
4.3 Characterization of the three sublines H, HI, and AT1 by PAI ................................. 96 
4.3.1 Initial oxygenation, temporal changes, and response to external changes in 
oxygen supply ................................................................................................. 96 
4.3.2 Comparison of tumor sublines and normal tissue (skin) ................................. 97 
4.4 Longitudinal DCE-MRI study of the AT1-tumor ..................................................... 97 
4.4.1 Selection of pharmacokinetic model ............................................................... 97 
4.4.2 Longitudinal monitoring of treatment response by DCE-MRI ....................... 98 
4.4.3 Re-oxygenation after irradiation ..................................................................... 99 
4.4.4 Correlation with histology after 21 days ......................................................... 99 
4.4.5 The role of endothelial cells ............................................................................ 99 
4.4.6 Curative vs. sub-curative doses ..................................................................... 100 
4.4.7 Statistical analysis ......................................................................................... 100 
4.5 Longitudinal DCE-MRI study of the HI-tumor ...................................................... 101 
4.5.1 Principle component analysis for the HI-tumor ............................................ 101 
4.5.2 Treatment response ....................................................................................... 102 
4.6 Comparison of the AT1- and HI-tumor’s treatment response ................................. 104 
4.7 Longitudinal histology study of the AT1-tumor after irradiation ........................... 105 
4.7.1 General tumor development after irradiation ................................................ 105 
4.7.2 Tumor hypoxia, vascularization, and perfusion ............................................ 105 
4.7.3 Cellular response ........................................................................................... 108 
4.8 High LET vs. low LET irradiation .......................................................................... 109 
4.9 Conclusion ............................................................................................................... 110 
5 Outlook 111 
References 113 
Appendix 131 
Table of Contents  
IV 
 
List of Figures 
V 
 
List of Figures 
Figure 1 Depth-dose profiles of photons, protons, and 
12
C-ions .......................................... 2 
Figure 2 Set-up for photoacoustic imaging (PAI) .............................................................. 14 
Figure 3 Schematic illustration of the oxygenation conditions during PAI ....................... 15 
Figure 4 Schema of the two compartment exchange model (2CXM) and the extended 
Tofts model (ETM) .............................................................................................. 20 
Figure 5 Simulated concentration curves for bolus arrival time (BAT) estimation ........... 23 
Figure 6 Schematic illustration of the longitudinal DCE-MRI studies .............................. 27 
Figure 7 First two principle components (PCs) of the DCE-MRI concentration-time 
curves of the HI-tumors ....................................................................................... 28 
Figure 8 Illustration of the automated vessel counting process from multi-channel 
fluorescence images ............................................................................................. 35 
Figure 9 Illustration of the quantification of the hypoxic fraction from pimonidazole 
fluorescence images ............................................................................................. 36 
Figure 10 Illustration of the classification and quantification of perfused areas based 
on Hoechst 33342 fluorescence images ............................................................... 38 
Figure 11 Exemplary cell segmentation results from fluorescence images in 
CellProfiler™ ....................................................................................................... 39 
Figure 12  Illustration of the classification of γH2AX
+
-cells ............................................... 40 
Figure 13 Schematic illustration of the longitudinal histology study of the AT1-tumor...... 41 
Figure 14 Normalized PAI-derived sO2-distributions of two HI-tumors ............................. 46 
Figure 15 Pooled normalized sO2-distributions of two tumors per subline .......................... 47 
Figure 16 Temporal development of sO2-distributions for one tumor per subline ............... 48 
Figure 17 sO2-distributions of oxygen challenge and clamping experiments for each of 
the three sublines and the skin ............................................................................. 51 
Figure 18  The similarity measure earth mover’s distance (EMD) for the oxygen 
challenge experiment ........................................................................................... 52 
Figure 19 Histological images of the H-, HI-, and AT1-tumors .......................................... 53 
Figure 20 Graphical illustration of the proposed approximation model for bolus arrival 
time (BAT) estimation ......................................................................................... 55 
Figure 21 Exemplary results for BAT estimation in rats ...................................................... 58 
Figure 22 Illustration of the accuracy of BAT estimation for rat data ................................. 59 
Figure 23 Illustration of the accuracy of BAT estimation for patient data ........................... 60 
List of Figures  
VI 
 
Figure 24 Exemplary pixel-based concentration curves of animal 2 with HI-tumors .......... 62 
Figure 25 Relative tumor volumes of AT1-tumors up to 21 days after irradiation .............. 63 
Figure 26 1-weighted MR-images of AT1-tumors after contrast agent injection along 
with their calculated ETM parameter maps ......................................................... 64 
Figure 27 Pooled longitudinal results of voxel-wise non-compartment analysis and 
pharmacokinetic modeling after irradiation ......................................................... 65 
Figure 28 Histological images of AT1-tumors 21 days after irradiation .............................. 67 
Figure 29 Quantitative results of immunohistochemistry stainings of AT1-tumors 21 
days after irradiation............................................................................................. 68 
Figure 30 Fluorescence images of AT1-tumors stained for CD31 and SMA ....................... 69 
Figure 31 Fluorescence images of AT1-tumors stained for CD31 and pimonidazole.......... 70 
Figure 32 Relative tumor volumes of HI-tumors up to 21 days after irradiation ................. 71 
Figure 33 Results for principle component analysis and clustering of DCE-MRI data of 
HI-tumors ............................................................................................................. 72 
Figure 34 1-weighted images of HI-tumors after CA administration with respective 
clustering results ................................................................................................... 74 
Figure 35 Pooled clustering results for the HI-tumor at different time points after 
irradiation ............................................................................................................. 75 
Figure 36 Histological images of HI-tumors 21 days after irradiation ................................. 76 
Figure 37 Relative tumor volumes of AT1-tumors after irradiation..................................... 78 
Figure 38 Structural changes in AT1-tumors at several time points after irradiation 
with either photons or 
12
C-ions assessed by Hematoxylin/Eosin ......................... 79 
Figure 39 Exemplary fluorescence image of hypoxic microregions in the AT1-tumor ....... 80 
Figure 40 Quantification of the hypoxic fraction in AT1-tumors of different volumes ....... 80 
Figure 41 Fluorescence images of the hypoxic fraction in AT1-tumors of different 
volumes ................................................................................................................ 81 
Figure 42 Quantification of the hypoxic fraction in AT1-tumors at several time points 
after irradiation ..................................................................................................... 82 
Figure 43 Fluorescence images of the hypoxic fraction in AT1-tumors at several time 
points after irradiation .......................................................................................... 83 
Figure 44 Quantification of the vascular density and maturity in AT1-tumors at several 
time points after irradiation .................................................................................. 84 
Figure 45 Fluorescence images of CD31 and SMA stained AT1-tumors at several time 
points after irradiation .......................................................................................... 85 
List of Figures 
VII 
 
Figure 46 Quantification and classification of the perfusion in AT1-tumors at several 
time points after irradiation .................................................................................. 87 
Figure 47 Fluorescence images and perfusion classification of AT1-tumors at several 
time points after irradiation. ................................................................................. 88 
Figure 48 Quantification of the proliferative activity in AT1-tumors at several time 
points after irradiation .......................................................................................... 89 
Figure 49 Fluorescence images of BrdU stained AT1-tumors at several time points 
after irradiation ..................................................................................................... 90 
Figure 50 Quantification and classification of DNA double strand breaks in AT1-
tumors at several time points after irradiation ...................................................... 91 
Figure 51 Fluorescence images of γH2AX stained AT1-tumors at several time points 
after irradiation. .................................................................................................... 92 
Figure 52 Correlation of the HI-tumor histology with the determined cluster ................... 103 
Figure 53 Individual results per animal and imaging time point from non-compartment 
analysis and ETM parameters ............................................................................ 133 
Figure 54 Results of quantitative immunohistochemistry analysis for non-irradiated 
control tumors and treated tumors 21 days after RT including tumor 23 .......... 134 
Figure 55 ETM fit parameters of the DCE-MRI study of the HI-tumor pooled per 
treatment group and imaging time point ............................................................ 135 
List of Tables  
VIII 
 
List of Tables 
Table 1 Histology and immunohistochemistry stainings which were performed on 
the AT1-tumors of the longitudinal DCE-MRI study .......................................... 27 
Table 2 Standard protocol for immunohistochemistry ...................................................... 31 
Table 3 Exposure times for fluorescence microscopy ....................................................... 34 
Table 4 Parameters for cell segmentation and counting in CellProfiler™ for BrdU
+
-
cells and DAPI
+
-cells ........................................................................................... 39 
Table 5 Histology and immunohistochemistry stainings which were performed on 
the AT1-tumors of the longitudinal histology study ............................................ 42 
Table 6 Medians and 25
th
/75
th
 percentiles of the PAI sO2-distributions for the 
investigated combinations of signal gain and threshold ....................................... 45 
Table 7 Summary of oxygen challenge and clamping experiments for the H-, HI-, 
and AT1-tumor and the skin ................................................................................. 49 
Table 8 Estimated BATs for five HI-tumor bearing rats of the longitudinal DCE-
MRI study ............................................................................................................. 61 
Table 9 Results from the Kruskal-Wallis test and post hoc Bonferroni correction on 
normalized AUC, Ktrans, ve, and vp values for each imaging time point after 
irradiation (RT) with either photons (ph) or 
12
C-ions (
12
C) ................................ 132 
Abbreviations 
IX 
 
Abbreviations 
12
C-ions Carbon ions 
2CXM Two compartment exchange model 
3D Three dimensional 
AIF Arterial input function 
aqua dest. Distilled water 
a.u. Arbitrary unit 
AUC Area under the curve 
BAT Bolus arrival time 
BOLD Blood oxygen level dependent 
BrdU 5-bromo-2’-deoxyuridine 
BrdU
+
 5-bromo-2’-deoxyuridine-positive 
BSA Bovine serum albumin 
CA Contrast agent 
CA IX Carbonic anhydrase 9 
CD31
+
/SMA
+
 CD31-positive/ smooth muscle actin-positive 
CT Computed tomography 
DAPI 4’,6-diamidino-2-phenylindole 
DCE-MRI Dynamic contrast-enhanced magnetic resonance imaging 
DNA Deoxyribonucleic acid 
DOF Degrees of freedom 
DSB Double-strand break 
EES Extracellular, extravascular space 
EMD Earth mover’s distance 
eq. Equation 
ESR Electron spin resonance 
ETM Extended Tofts model 
FAZA [
18
F]fluoroazomycin arabinoside 
FMISO [
18
F]fluoromisonidazole 
GCV Generalized cross validation 
GMM Gaussian mixture modeling 
H&E Hematoxylin & Eosin 
Abbreviations  
X 
 
HCl Hydrochloric acid 
Hct Hematocrit 
hdf5 Hierarchical data format 5 
HIF-1 Hypoxia-inducible factor-1 
HIT Heidelberg Ion Beam Therapy Center 
Hoechst 33342 BisBenzimide H 33342 trihydrochloride 
IMRT Intensity-modulated radiotherapy 
i.p. Intraperitoneal 
i.v. Intravenously 
IVC Individually ventilated cage 
LET Linear energy transfer 
MITK Medical Imaging Interaction Toolkit 
MRI Magnetic resonance imaging 
MSE Mean squared error 
O2 Oxygen 
PA Photoacoustic 
PAI Photoacoustic imaging 
PBS Phosphate-buffered saline 
PC Principle component 
PCA Principle component analysis 
PET Positron emission tomography 
PMMA Polymethylmethacrylate 
pO2 Partial pressure of oxygen 
px Pixel 
r1 Relaxivity  Longitudinal relaxation rate  Transversal relaxation rate ∗ Effective transversal relaxation rate 
RBE Relative biological effectiveness 
ROI Region of interest 
room temp Room temperature 
ROS Reactive oxygen species 
RT Radiotherapy 
SEM Standard error of the mean 
SMA Smooth muscle actin 
Abbreviations 
XI 
 
SNR Signal-to-noise ratio 
sO2 Oxygen saturation 
SOBP Spread-out Bragg-peak 1 Longitudinal relaxation time 2 Transversal relaxation time 2∗ Effective transversal relaxation time 
TCC Tissue concentration curve 
TE Echo time 
TIFF Tagged image file format 
TOLD Tissue oxygen level dependent 
TR Repetition time 
TURBO FLASH Ultrafast fast low angle shot 
US Ultrasound 
VDT Volume doubling time 
ZPF Center for Preclinical Research 
γH2AX
+
 γH2AX-positive 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary 
XIII 
 
Summary 
Tumor hypoxia has been widely recognized as a significant factor that increases treatment 
resistance and promotes malignant progression. High linear energy transfer (LET) radiother-
apy (RT), e.g. with carbon ions (
12
C-ions), is expected to overcome this resistance factors as 
its lethality is less dependent on tumor oxygenation as compared to conventional low LET 
photon irradiation. However, the exact interplay between irradiation response, vascular 
changes, perfusion, and hypoxia is still not well understood, especially with respect to high 
LET RT. In the present thesis, the hypoxic status of syngeneic Dunning R3327 rat prostate 
tumor model sublines was characterized prior to and after irradiation with either low LET 
photons or high LET 
12
C-ions by multimodal imaging and histology. 
The initial oxygenation status of three subcutaneously transplanted Dunning tumor sublines 
(H, HI and AT1) was determined by photoacoustic imaging (PAI) which included the devel-
opment and validation of a new PAI analysis protocol. The new protocol enabled the distinc-
tion of the three sublines based on their oxygenation profiles and their response towards 
external changes in oxygen supply. Subsequently, the effects of curative and sub-curative 
single dose irradiations with either photons or 
12
C-ions on the two hypoxic tumor sublines 
(HI and AT1) were investigated by pharmacokinetic modeling of longitudinal dynamic con-
trast-enhanced magnetic resonance imaging (DCE-MRI) data. For this, a novel method for 
estimating the contrast agent’s arrival time was developed in cooperation with the group for 
Image Analysis and Learning of the Interdisciplinary Center for Scientific Computing of 
Heidelberg University. It enables a delay correction of the contrast agent arrival time which 
improves fit accuracy and the reliability of the pharmacokinetic modeling results. The mod-
erately differentiated HI-tumor showed increased vascular permeability 7 days after irradia-
tion without any modality or dose dependency, while the anaplastic and chronic hypoxic 
AT1-tumor revealed an earlier and stronger treatment response after 
12
C-ion irradiation as 
compared to the more delayed response after photon irradiation. Again, no dose dependency 
was detected. Finally, a longitudinal histology study after irradiation of the AT1-tumor with 
curative doses of either photons or 
12
C-ions revealed that hypoxia developed slightly faster 
after 
12
C-ion than after photon irradiation. Furthermore, this study validated the relative bio-
logical effectiveness (RBE) for 
12
C-ions, which was determined previously for the endpoint 
local tumor control, on a microscopic level within the first 10 days. Additionally, reasonable 
time points for a future multimodal imaging study with PAI, sequential positron emission 
tomography (PET) and DCE-MRI measurements as well as histology were determined. 
In conclusion, this thesis proved PAI and the novel analysis protocol to be a feasible method 
for the characterization of the three Dunning tumor sublines with respect to their oxygena-
tion. The different sensitivities of the HI- and AT1-tumors towards the two irradiation mo-
Summary  
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dalities indicate that the irradiation-induced vascular response depends on the structural-
functional status of the tumor vasculature. The dose-independent response of both tumor 
sublines towards the two irradiation modalities suggests that the initial vascular response 
only plays a minor role with respect to local tumor control at high single doses. 
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Zusammenfassung 
Hypoxie ist ein wesentlicher Faktor, der zu erhöhter Behandlungsresistenz und progressivem 
Wachstum von Tumoren führt. Durch Strahlentherapie mit Partikeln wie z. B. Kohlenstoff-
ionen (
12
C-Ionen), die einen hohen linearen Energietransfer (LET) aufweisen, soll die durch 
Hypoxie induzierte Strahlenresistenz überwunden werden, da die Letalität von hoch LET-
Strahlung, im Gegensatz zu konventioneller niedrig LET Photonenbestrahlung, nicht von der 
Oxygenierung des Gewebes abhängt. Die genauen Wechselwirkungen zwischen Bestrah-
lung, insbesondere hoch LET-Strahlung, Blutgefäßen, Perfusion und Hypoxie sind immer 
noch nicht vollständig verstanden. In der vorliegenden Arbeit wurde der hypoxische Zustand 
von syngenen Dunning R3327 Ratten Prostatatumorsublinien vor und nach Bestrahlung mit 
entweder niedrig LET Photonen oder hoch LET 
12
C-Ionen mit Hilfe von multimodaler Bild-
gebung und Histologie charakterisiert. 
Der initiale Oxygenierungszustand der drei subkutan transplantierten Dunning Tumorsubli-
nien (H, HI und AT1) wurde mit photoakustischer Bildgebung (photoacoustic imaging, PAI) 
bestimmt. Ein dafür neu entwickeltes und validiertes Analyseprotokoll ermöglichte die Un-
terscheidung der drei Sublinien aufgrund ihres Oxygenierungsprofils und ihres Verhaltens 
nach externen Veränderungen der Sauerstoffzufuhr. Des Weiteren wurden die Auswirkungen 
kurativer und sub-kurativer Einzeldosisbestrahlungen mit Photonen oder 
12
C-Ionen auf zwei 
hypoxische Tumorsublinien (HI und AT1) mittels pharmakokinetischer Modellierung von 
dynamisch kontrastmittelverstärkter Magnetresonanztomographie (DCE-MRI) untersucht. In 
Kooperation mit der Gruppe für Image Analysis and Learning des Interdisciplinary Center 
for Scientific Computing der Universität Heidelberg wurde dafür eine neue Methode zur 
Bestimmung der Ankunftszeit des Kontrastmittels im Gewebe entwickelt. Diese Methode 
ermöglicht eine Korrektur der Verzögerung zeitlich versetzt ankommender Kontrastmittel-
Boli, was wiederum zu einer verbesserten Anpassungsgüte und Belastbarkeit der Ergebnisse 
der pharmakokinetischen Modellierung führt. Der moderat differenzierte HI-Tumor zeigte 
sieben Tage nach Bestrahlung eine erhöhte vaskuläre Permeabilität, unabhängig von Strah-
lenmodalität und -dosis. Der anaplastische und chronisch hypoxische AT1-Tumor wies hin-
gegen einen früheren und stärkeren Behandlungseffekt nach Bestrahlung mit 
12
C-Ionen im 
Vergleich zur Bestrahlung mit Photonen auf und zeigte ebenfalls keine Abhängigkeit von der 
Strahlendosis. Schließlich ergab eine longitudinale Histologiestudie an mit kurativen Photo-
nen- oder 
12
C-Ionen-Dosen bestrahlten AT1-Tumoren, dass Hypoxie nach 
12
C-
Ionenbestrahlung etwas früher als nach Photonenbestrahlung auftritt. Weiterhin bestätigte 
diese Studie auf mikroskopischer Ebene die zuvor für den Endpunkt lokale Kontrolle be-
stimmte relative biologische Wirksamkeit von 
12
C-Ionen innerhalb der ersten zehn Tage 
nach Bestrahlung. Abschließend konnten sinnvolle Zeitpunkte für eine multimodale Bildge-
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bungsstudie mit PAI, sequentiellen Positronen-Emissions-Tomographie (PET)- und DCE-
MRT-Messungen sowie anschließender Histologie bestimmt werden. 
In dieser Doktorarbeit wurde gezeigt, dass PAI und das neu entwickelte Analyseprotokoll 
praktikable Methoden für die Charakterisierung der Oxygenierung in den drei Dunning Tu-
morsublinien darstellen. Die unterschiedlichen Strahlenempfindlichkeiten der HI- und AT1-
Tumore gegenüber beiden Bestrahlungsmodalitäten weist darauf hin, dass die strahlenindu-
zierte vaskuläre Reaktion vom Zustand der Gefäße im Tumor abhängt. Die Dosisunabhän-
gigkeit der Strahlenantwort beider Tumorsublinien gegenüber beiden Bestrahlungsmodalitä-
ten deutet darauf hin, dass initiale vaskuläre Schäden bei hoher Einzeldosisbestrahlung nur 
eine untergeordnete Rolle für die lokale Tumorkontrolle spielen.  
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1 Introduction 
1.1 Prostate cancer 
In 2018, 13.5 % of all male cancer patients were diagnosed with prostate cancer making it 
the second most frequent cancer with 358 989 deaths worldwide [1]. In Germany, 62 641 
new cases of prostate cancer were diagnosed in 2018, making it the fourth most frequently 
diagnosed cancer [2].  
95 % of all prostate tumors are adenocarcinomas i.e. malignant neoplasia of epithelial tissues 
with glandular origin [3]. With increasing volume, the prostate carcinoma exhibits multiple 
histological patterns within one tumor. Upon suggestion of the World Health Organization, 
the Gleason Score was introduced for staging prostate cancer which rates the tumor’s glan-
dular structure rather than its cytological characteristics. Gleason patterns range from 1 to 5 
where Gleason 1 refers to a highly differentiated adenocarcinoma, Gleason 3 is a moderately 
differentiated tumor, and Gleason 5 is an anaplastic tumor. The Gleason score is obtained by 
summing up the most frequent and the second most frequent Gleason pattern found within 
one tumor. This way, the large morphological heterogeneity of the prostate carcinoma is 
taken into account [4]. In 2014, an update of the Gleason Score was proposed that also 
weights the order of the two Gleason patterns (i.e. Gleason 3 + 4 ≠ 4 + 3) [5]. 
The diagnosis is further manifested by rectal examination of the prostate for size, shape, 
consistency, boundary, prostate specific antigen level, and, in advanced cases, by skeletal 
scintigraphy. Depending on the tumor grading, prostate cancer is either treated with surgery 
(prostatectomy), radiotherapy, hormone therapy (androgen-deprivation therapy) or a combi-
nation of these. In rare cases chemotherapy is performed. Low grade prostate tumors and old 
patients are often subject to watchful waiting meaning that no therapy is started unless the 
patient’s condition impairs [3]. 
1.2 Radiotherapy with photons and carbon ions 
Already at the end of the 19
th
 century, shortly after the discovery of X-rays, the potential of 
ionizing irradiation for the treatment of cancer patients was recognized and exploited by 
various scientists [6]. Nowadays, radiotherapy (RT) has become indispensable for the treat-
ment of oncologic patients, either on its own or in combination with other therapies such as 
chemotherapy and surgery [7]. 
RT aims at a maximal dose deposition in the tumor to induce lethal DNA damages. During 
treatment planning, medical physicists optimize the dose that is delivered to the tumor such 
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that the surrounding normal tissue is maximally spared. Conventional RT uses photon beams 
which exhibit an exponential decrease in dose with increasing tissue penetration depth 
(Figure 1 A). To protect the surrounding normal tissue and organs at risk from undesired 
irradiation exposure, the maximal treatment dose has to be restricted. The introduction of 
intensity-modulated RT (IMRT), that modulates the fluence of the photon beam during 
treatment to conform the dose distribution to the shape of the tumor, allows a certain dose-
escalation without increasing the dose to the surrounding healthy tissue. IMRT is also ap-
plied in the treatment of prostate cancer [8].  
 
 
Figure 1 Depth-dose profiles of photons, protons, and 12C-ions. (A) Representative depth-dose profiles for 
photons (blue), which show an exponential decrease in dose with increasing penetration depth, and for ions (red), 
which deposit the majority of their dose in the Bragg-peak. (B) Spread-out Bragg-peak (SOBP) for conformal 
irradiation of large tumors. The SOBP is achieved by superimposing ion beams of different energies. For the 
same dose in the tumor, the neighboring tissues can be spared better with ions (carbon ions (red) and protons 
(green)) than with photons. Adapted with permission from Springer Nature: Nature Reviews Clinical Oncology 
[9]. All rights reserved. 
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The use of ions instead of photons was introduced to further improve the dose conformity to 
the tumor. Ions are characterized by an advantageous inverted depth-dose profile as com-
pared to photons: a mono-energetic ion beam emits very low dose in the entrance region and 
exhibits a maximal dose peak in the energy-dependent Bragg-peak followed by an immedi-
ate fall-off in dose (Figure 1 A). By superimposing ion beams of different energies, a so-
called spread-out Bragg-peak (SOBP) is formed to cover the entire tumor volume. This al-
lows a precise high-dose tumor irradiation while sparing the surrounding healthy tissue, 
mainly due to the ions’ finite range (Figure 1 B) [10]. The feasibility of proton RT was al-
ready demonstrated for prostate cancer patients in 1979 [11]. Proton RT is a form of low 
linear-energy-transfer (LET) ion RT. The LET indicates the amount of energy per distance 
which is deposited in the tissue by an ionizing particle and is reported in keV/µm. 
The use of heavier ions with higher LETs than protons was already proposed in 1946 [12], 
and its clinical relevance is currently investigated. Among these heavier ions, carbon ions 
(
12
C-ions), which exhibit an even higher dose deposition in the Bragg-peak (Figure 1 B) and 
a higher LET than protons, are under clinical investigation [13, 14]. Furthermore, heavy ions 
have a higher relative biological effectiveness (RBE) compared to low LET photons and 
protons which means that less physical dose is required to achieve the same biological effect 
[15].  
Ionizing radiation holds a therapeutic benefit by damaging the DNA of cancerous cells 
which eventually leads to cell death. It can induce base loss and modification, crosslinks, 
single strand breaks, and DNA double strand breaks (DSBs) [16]. The latter are the most 
complex to repair and, therefore, their occurrence is considered the critical event for lethality 
[17, 18]. 
Low LET photons induce DNA damage through indirect effects. They hydrolyze water pro-
ducing reactive oxygen species (ROS) that induce DNA damage. In the presence of oxygen, 
this damage is fixated leading to persistent DNA breaks and eventually cell death. However, 
in the absence of oxygen, DNA radicals are reduced by thiols and the original DNA is re-
stored [19, 20]. Densely ionizing (high LET) radiation acts directly on the phosphodiester 
bonds inducing more complex and spatially clustered DNA damages which are more diffi-
cult to repair and which increase the chance for immediate DNA DSBs [20, 21]. The result-
ing impaired repair mechanisms are reflected by a faster and higher amount of tumor cell 
inactivation [10], the impairment of quiescent cells [22], and the overcoming of radiore-
sistance factors such as hypoxia [23], leading to a general reduction of tumor heterogeneity 
in complex solid tumors [24]. Additional preclinical data suggest that 
12
C-ions also impact 
the immune system [25, 26], decrease the tumor metastatic potential [27], and suppress the 
process of angiogenesis [15, 28]. 
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The reduced lateral scattering and sharp lateral penumbra together with the increased RBE 
make heavy ions very promising candidates for radiotherapy of deep seated, hypoxic, and 
radioresistant tumors [29]. 
The recognized physical and radiobiological advantages of heavier ions compared to photons 
and protons still require confirmation by clinical trials [29]. Currently, there are 75 clinically 
operating particle therapy facilities worldwide of which the majority is using protons [30]. In 
2017, eleven centers worldwide, situated in Japan, China, Italy, Austria, and Germany, were 
using 
12
C-ions [31] and 15 % of the patients treated with ion RT underwent heavy ion irra-
diation [29]. More heavy ion treatment facilities are in planning, and, along with this rising 
number, there is an increased need for systematic, large-scale, standardized in vivo experi-
ments to obtain parameters related to the effectiveness of ions as a function of physical and 
biological parameters such as RBE values. The European Particle Therapy Network Work 
Package 6 is aiming to form a network of research and therapy facilities to standardize radi-
obiological experiments [32] and to enable the comparison of experimental and treatment 
results from individual centers. 
Clinical trials on the usage of particle therapy for varies cancers (head and neck, lung, central 
nervous system, breast, intestine, prostate, lymphoma, sarcoma) and for pediatric cancers 
(central nervous system, head and neck, brain, medulloblastoma, rhabdomyosarcoma) are 
being performed worldwide [30] with 20 000 patients already having received 
12
C-ion RT by 
2018 [29]. Clinical studies for these malignancies are also running at the Heidelberg Ion 
Therapy Center (HIT), where particle therapy was successfully included into the clinical 
routine in 2009 [33]. The feasibility and safety of active raster-scanning 
12
C-ion RT was 
demonstrated for patients with skull based chondrosarcomas [34], skull based chordomas 
[35], and for accelerated hypofractionation on patients with laryngeal malignancies, showing 
excellent local control rates and only moderate side effects, especially for radioresistant head 
and neck tumors [36]. The prospective IPI trial, which evaluated hypofractionated irradiation 
of the prostate with both protons or 
12
C-ions using active raster-scanning technique, showed 
comparable toxicities and quality of life parameters for both modalities [37]. A retrospective 
study comparing treatment results of irradiation with protons and 
12
C-ions on patients with 
G1 and G2 skull based chondrosarcomas revealed slightly but non-significantly worse over-
all survival and local control after 60 months for 
12
C-ions [38]. However, 3.5 times more 
patients were treated with 
12
C-ions than with protons which might have led to a selection 
bias. 
12
C-ion RT requires advanced and costly infrastructure making the treatment very ex-
pensive. Therefore, Sprave et al. have assessed the financial aspects of 
12
C-ion RT for skull 
based chordoma evaluating long-term (10 year) outcome data. They concluded that 
12
C-ion 
RT is highly cost-effective [39]. Despite the large number of clinical studies, no randomized 
trials directly comparing 
12
C-ion RT with modern photon RT were performed so far [40]. 
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Conventional RT schedules provide fractionated irradiation with 5 fractions à 2 Gy over 6 
weeks. Lately, enhanced effectiveness and reduced side and long-term effects along with less 
health care cost and increased convenience for the patients are attributed to hypofractionated 
treatment schedules, i.e. less fractions with more dose per fraction over a shorter treatment 
period [41, 42]. However, so far it is still unclear whether hypofractionation will provide a 
significant therapeutic benefit [42-46]. Single-fraction treatments were proclaimed feasible 
after performing single-dose escalation studies on patients with inoperable lung tumors using 
a CyberKnife [47] and on peripheral stage I non-small cell lung cancer patients using doses 
of up to 50 Gy of 
12
C-ions [48]. The response of prostate cancer to fractionation is compara-
ble to that of late responding normal tissue suggesting that hypofractionation should be 
equally effective as conventional fractionation for treating prostate cancer while reducing 
costs and increasing patient convenience [49]. Brenner et al. reported a number of studies 
that have demonstrated non-inferiority of moderate hypofractionation (typically involving 15 
to 25 fractions of 2.5 to 3.5 Gy) compared to conventional fractionation patterns (involving 
40 to 45 fractions of approximately 2 Gy each) [49]. The benefits of extreme hypofractiona-
tion (typically involving 4 to 7 fractions at doses of 4 to 10 Gy per fraction) are currently 
investigated [49]. This might lead to a further rethinking of common radiotherapy schedules 
with 2 Gy per fraction. 
1.3 Hypoxia as a resistance factor  
Tumor hypoxia belongs to the original hallmarks of cancer [50]. It has already been identi-
fied as a key factor promoting radioresistance by Gray et al. in 1953 [51] who found that the 
sensitivity of tumor cells to X-rays was about three times greater when cells were irradiated 
in a well-oxygenated medium compared to anoxic conditions. This factor is now called the 
oxygen enhancement ratio (OER) and describes the ratio of the doses required to achieve the 
same biological effect under hypoxic and normoxic conditions [52]. 
Changes in physiology and metabolism of tumors lead to an increased growth rate which 
results in hypoxia as the (immature) vasculature cannot keep up supplying the fast growing 
tumor volume with oxygen. Two main types of hypoxia have been identified that co-exist 
with a high spatial heterogeneity in tumors. Chronic hypoxia is the result of diffusion limita-
tion due to enlarged inter-vessel distances and deteriorated diffusion geometries such as U-
shaped microvessels and arterious-venous shunts [53]. Acute hypoxia, on the other hand, 
results from perfusion limitations induced by severe structural and functional abnormalities 
such as increased vessel permeability, impaired endothelial lining, and microvessel elonga-
tions and dilatations, that induce transient perturbations of the microcirculation [54, 55]. 
Hypoxia-mediated release of pro-angiogenic factors leads to further uncoordinated tumor 
angiogenesis and expansion of the immature vasculature.  
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There is no strict and generally applicable hypoxia threshold for all tissue types [56]. Com-
monly, a partial pressure of oxygen (pO2) below 10 mmHg is assumed to induce the hypox-
ia-related genetic and adaptive changes in tumor cells to overcome and survive hypoxic envi-
ronments [56]. A multitude of genes that regulate e.g. oxygen transport, iron metabolism, 
angiogenesis, glycolysis, transcription factors, growth factors, cell adhesion, and the extra-
cellular matrix are induced by hypoxia leading to unrestrained angiogenesis and glycolysis, 
immortalization, genetic instability, apoptosis, tissue invasion, and the formation of metasta-
sis leading to an overall aggressive tumor behavior [57]. The most prominent transcription 
factor that stabilizes under hypoxic conditions is the hypoxia-inducible factor-1 (HIF-1) that 
consists of the constitutively expressed HIF-1β subunit and the oxygen regulated HIF-1α 
subunit [58]. HIF-1 is a key transcription factor that regulates the expression of more than 30 
genes involved in energy metabolism, hormone regulation, and vasoreactivity [59] and is 
increased in many human cancers [60]. 
Hence, tumor vasculature, hypoxia, and their alterations after treatment are important factors 
when developing treatment strategies for patients [61]. Concerning RT, it would be of up-
most importance to identify hypoxic regions prior to treatment to be able to predict their 
irradiation response and to consider dose escalation to the hypoxic regions by dose painting 
[62]. 
1.4 Imaging of hypoxia 
In the clinical routine, imaging is used for diagnostics, treatment planning, and treatment 
follow-up. As tumor hypoxia is one of the major resistance factors for radiotherapy much 
effort is put into its visualization. However, as of today, there is no measurement technique 
available that reliably quantifies the oxygen content three dimensional (3D). In the follow-
ing, the main approaches for qualitative and quantitative hypoxia imaging are introduced. 
Polarographic oxygen electrodes such as the Eppendorf
®
 electrode enable direct measure-
ments of pO2 in units of mmHg [63]. They measure the current formed at a cathode originat-
ing from ionization of oxygen at -0.7 V versus a normal hydrogen electrode [59]. They have 
been applied in multiple clinical [64-67] and preclinical [68-70] studies where they were 
considered the gold-standard [59]. However, their usage requires an imaging modality to 
guide the electrode placing. Furthermore, they are highly invasive, provide only locally re-
stricted information, and repeatable measurements of the same spot are impossible due to the 
oxygen consumption of the electrode itself [59]. The low signal-to-noise ratio at low oxygen 
tension represents a further limitation. 
Electron spin resonance (ESR) uses reporter molecules to detect species containing unpaired 
electrons such as molecular oxygen [59]. The spectral line width of those reporter molecules 
is highly sensitive to oxygen and can be directly associated with oxygen concentration using 
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calibration curves [59, 63]. O’Hara et al. used ESR to determine the timing of hypoxia and 
re-oxygenation after irradiation in RIF-1 tumors on female mice after single dose and split 
dose irradiation [71].  
Positron emission tomography (PET) visualizes the distribution and accumulation of radio-
labeled hypoxia-sensitive tracers. While exhibiting a high specificity, PET suffers from re-
stricted spatial resolution and involves the handling and injection of costly radioactive trac-
ers. A range of hypoxia-sensitive tracers is available for PET imaging [72] of which 
[
18
F]fluoromisonidazole (FMISO) [73] is most widely used. It accumulates in vivo below a 
median oxygen level of 10 mmHg. However, its slow pharmacokinetic profile only leads to a 
moderate signal ratio between hypoxic and normoxic tissue [74], and the resulting PET sig-
nal is non-linearly connected to the local oxygen tension [75]. The more hydrophilic 
[
18
F]fluoroazomycin arabinoside (FAZA) [76] represents a promising alternative with faster 
clearance and an improved hypoxia-to-normoxia ratio as compared to other tracers [74, 77].  
Magnetic resonance imaging (MRI) offers a variety of possibilities to assess hypoxia non-
invasively while obviating exposure to ionizing radiation. Perfluorocarbons, organic com-
pounds where all hydrogen atoms (
1
H) are replaced by fluorine (
19
F), are used for quantita-
tive oxygen measurement. The non-toxic and chemically inert contrast agents are injected 
intravenously or intratumorally up to a few days before the measurement. The 
19
F longitudi-
nal relaxation rate 1 is oxygen sensitive and enhances proportionally to the dissolved oxy-
gen concentration at a given temperature [59, 78, 79]. Due to the 
1
H comparable MRI sensi-
tivity of 
19
F and the lack of endogenous 
19
F in living organisms [80], 
19
F oximetry potentially 
provides a high image contrast [80]. However, the 
19
F concentration needs to be high 
enough. Also, many fluorinated molecules are insoluble in water. They exhibit long 1 re-
laxation times requiring long repetition times in the acquisition sequences which in turn chal-
lenges the clinical practicability of 
19
F-MRI [80]. Blood oxygen level dependent (BOLD) 
MRI utilizes the paramagnetic property of de-oxygenated hemoglobin as an endogenous 
contrast agent that increases the 2∗	relaxation rate of the 1H in the blood [63, 81]. The 
BOLD signal is of qualitative nature rather than providing absolute oxygen concentrations as 
no absolute relation of BOLD signal to pO2 could be found [63, 82]. The BOLD signal can 
be subject to flow and partial volume effects when investigating small vessels [63]. Hallac 
et al. tried to correlate 1-based tissue oxygen level dependent (TOLD) MRI signals with 
pO2 but found only weak correlations [83]. 
Dynamic contrast-enhanced (DCE)-MRI involves the administration of a contrast agent 
(usually gadolinium-based) and measures concentration-time curves in the tissue of interest. 
By subsequent pharmacokinetic modeling, hemodynamic parameters such as the volume 
transfer constant, plasma volume fraction, interstitial space, vascular permeability, and flow 
can be determined [84]. As low-perfused tissue areas are likely to suffer from oxygen deple-
tion, DCE-MRI is considered to be an indirect measure of tissue hypoxia [85].  
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Optical imaging allows in vivo visualization of fluorescence and bioluminescence signals. 
One drawback of the low-energy optical photons is their high scattering and the correspond-
ing decreased spatial resolution as compared to ionizing photons. As photons in the near 
infrared spectrum are least affected by scattering in tissue, they are favored for optical imag-
ing. Optical imaging can be performed using target-specific reporters such as ligands, anti-
bodies, and enzyme substrates that are linked to fluorescent dyes (e.g. Cy5, Cy7) [86], quan-
tum dots, nanoparticles, or reporter genes (e.g. green fluorescent protein [87], firefly lucifer-
ase [88]). Optical imaging probes can be customized to a high specificity with respect to 
their target. 
Photoacoustic imaging (PAI) is an emerging hybrid imaging modality that comprises the 
high specificity of optical imaging and the spatial resolution of ultrasound [89]. PAI uses 
laser light that induces the emission of a pressure wave after being absorbed by a chromo-
phore. This pressure wave is measured as an ultrasound signal and contains the information 
about the chromophore’s location. Because oxygenated and de-oxygenated hemoglobin ex-
hibit different absorption spectra they can be distinguished and the oxygen saturation can be 
determined by PAI [90]. Its lack of ionizing radiation constitutes a great advantage. Howev-
er, the imaging depth is limited by the central frequency of the ultrasonic transducer and the 
penetration depth of the laser light. 
On a molecular basis, hypoxia can be assessed by staining for endogenous hypoxia markers 
such as HIF-1α or the less hypoxia specific carbonic anhydrase 9 (CA IX). Further, exoge-
nous markers such as pimonidazole [91] and EF5 [92], which can be visualized by immuno-
histochemistry methods on tissue sections, can be used. Effort was also put into the devel-
opment of fluorescence-coupled in vivo detectable tracers that target e.g. HIF-1α [93] and 
CA IX [86]. 
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1.5 Aim of the thesis 
This thesis investigates the temporal development of the treatment response after either pho-
ton or 
12
C-ion irradiation by non-invasive multimodal imaging and histology using sublines 
of the syngeneic Dunning 3327 rat prostate tumor model.  
RT aims at the induction of lethal DNA damage in the tumor. It is known that the effect of 
conventionally used low LET photons is induced by oxygen-dependent indirect effects, 
while high LET 
12
C-ions act directly on the cells’ DNA, independent of the oxygenation. 
Further, in vitro as well as in vivo studies demonstrated that 
12
C-ions exhibit an increased 
relative biological effectiveness (RBE) as compared to photons, especially in highly radiore-
sistant tumors. However, the underlying mechanisms that are responsible for this increased 
RBE as well as their temporal development are still unclear. Thus, it is of high interest to 
investigate the interplay between 
12
C-ions, tumor hypoxia, re-oxygenation, perfusion, and 
tumor vasculature to reveal the mechanisms that lead to the enhanced biological effective-
ness of 
12
C-ions. This information is of great clinical relevance for the identification of pa-
tients that will benefit from such a treatment as well as for the optimization of the respective 
treatment protocols themselves.  
In the first part of this thesis, a new photoacoustic imaging (PAI) protocol is established and 
used for the initial characterization of three Dunning tumor sublines prior to irradiation based 
on their intrinsic oxygenation level and their reaction to changes in the external oxygen sup-
ply. In the second part, the differential effects of single high doses of either photons or 
12
C-
ions on hypoxia, perfusion, and tumor vasculature are investigated in the acute hypoxic HI-
tumor and the chronic hypoxic AT1-tumor by analyzing the data of two longitudinal dynam-
ic-contrast enhanced magnetic resonance imaging (DCE-MRI) studies by pharmacokinetic 
modeling. To increase the fit accuracy of the pharmacokinetic modeling, a novel correction 
method is developed. Finally, temporal changes in vascular density, hypoxia, perfusion, pro-
liferation, and DNA double strand breaks upon curative irradiation with either photons or 
12
C-ions of the highly radioresistant AT1-tumor are histologically investigated.  
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2 Materials and Methods 
2.1 Tumor model 
2.1.1 Animal keeping 
All experiments were approved by the governmental review committee (Regierungspräsidi-
um Karlsruhe) on animal care. Copenhagen rats were kept in individually ventilated cages 
(IVC) with a maximal occupancy of four animals per cage in barrier D of the Center for Pre-
clinical Research (ZPF). Light, temperature, and air humidity were controlled automatically 
in a 12 h rhythm. Food and water was available ad libitum. 
Copenhagen rats used in the experiments in sections 2.2 and 2.5 were purchased from 
Charles River Laboratories Inc. (Wilmington, MA, USA). Copenhagen rats used in the ex-
periments of section 2.7 were bred in-house in the ZPF. 
2.1.2 The Dunning R3327 prostate tumor model 
The original Dunning R3327 tumor arouse spontaneously in the prostate of an aged, Copen-
hagen rat in 1961 and is thus syngeneic in this rat strain. By further transplantations of the 
original tumor onto the male F1 hybrids of male Copenhagen rats and female Fisher rats, in 
vitro passaging, and transplantation onto castrated male Copenhagen rats several tumor sub-
lines emerged. These differ with respect to their volume doubling time (VDT), differentia-
tion, metastatic potential, and hypoxic fraction [94, 95].  
In this project, three of the above-mentioned sublines were used [94]. The Dunning R3327 
H-tumor is well differentiated, normoxic, and hormone sensitive. It grows slowly with a 
VDT of 20 days and does not metastasize. The H-tumors’ morphology is characterized by 
abundant acini with secretions. The Dunning R3327 HI-tumor is moderately differentiated 
and contains mucin-filled prostatic structures. It is acute hypoxic, i.e. its oxygenation status 
can be influenced externally (e.g. by changing the breathing gas). Furthermore, it is hormone 
insensitive, has a VDT of 10 days, and exhibits a low metastatic potential. The Dunning 
R3327 AT1-tumor is anaplastic and does not contain any prostatic structures. It grows rapid-
ly with a VDT of 5 days and is characterized by chronic hypoxia, hormone insensitivity, and 
low metastatic potential [94]. 
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2.1.3 Tumor induction by transplantation  
Tumors were induced by transplantation of fresh tumor fragments. For each experiment, a 
donor animal was transplanted with a fragment from a cryo-preserved stock of the original 
tumor. The cryo-preserved tumor fragment was thawed in RPMI-Medium (Biochrom 
GmbH, Berlin, Germany) and transplanted subcutaneously on the thighs of a male Copenha-
gen rat. To do so, a small incision was made to the skin and a subcutaneous pocket was 
formed with scissors. The tumor fragment was placed in the pocket using forceps (Fine Sci-
ence Tools GmbH, Heidelberg, Germany). The wound was closed by one to two suture clips 
(MikRon® Autoclip® 9 mm, Clay Adams, Sparks, MD, USA) which were removed after 10 
days. When the donor animal’s tumors reached diameters of 2 to 3 cm, the animal was eu-
thanized, and the tumor dissected and cut into small pieces of approximately 1 mm
3
 each in 
RPMI medium. These donor tumor fragments were then transplanted subcutaneously onto 
the experiment rats (male Copenhagen rats, minimum weight 180 g) as described above. This 
way, all experimental tumors originated from one tumor. 
During the transplantation procedure, animals were kept under inhalation anesthesia with a 
mixture of 2 % Isoflurane (Baxter Deutschland GmbH, Unterschleißheim, Germany) and 
2 l/min oxygen (Guttroff GmbH, Wertheim-Reicholzheim, Germany).  
Tumor growth was frequently controlled by measuring the largest diameter and the respec-
tive orthogonal diameter with calipers.  
2.2 Photoacoustic imaging (PAI) 
Photoacoustic imaging (PAI) was performed to characterize the oxygenation status of the 
three Dunning tumor sublines H, HI, and AT1. The text in section 2.2 and the respective 
subsections was taken from reference [96] and has been originally written by myself. 
2.2.1 Basics of PAI 
PAI is an emerging non-invasive imaging technique attracting increasing attention for pre-
clinical and clinical applications in various fields [97-99]. Without using ionizing radiation, 
PAI combines high contrast and specificity of optical imaging with high spatial resolution of 
ultrasound (US) imaging [89, 98]. 
PAI is based on the absorption of pulsed laser light by endogenous and exogenous chromo-
phores. This local energy absorption leads to an increase in temperature and a rapid thermoe-
lastic expansion of the heated tissue. The resulting pressure wave then propagates through 
the tissue and is detected by an US transducer at the surface of the body [89, 100]. Tissue 
comprises several endogenous chromophores such as hemoglobin and melanin which exhibit 
characteristic wavelength dependent absorption spectra. This causes contrast in PAI without 
the need of exogenous contrast agents [89].  
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PAI can be used to determine in vivo oxygen saturations (sO2) in preclinical and, nowadays, 
clinical studies [101]. De-oxygenated and oxygenated hemoglobin can be directly distin-
guished by PAI based on their diverging absorption spectra. sO2 can be calculated by using 
laser light of different wavelengths [102]: 
 =	 [][] + [] = 	  
! −	! !∆  −	∆ !  (1) 
where  is the photoacoustic (PA) signal at the wavelength λ,    and  $  are the molar 
extinction coefficients of de-oxygenated and oxygenated blood, respectively, and ∆ =	 $ −	  [102]. 
2.2.2 Experimental set-up for PAI 
Prior to PAI, the animals’ skin was thoroughly depilated by hair removal creme (Nair™ Hair 
Remover Lotion, Church & Dwight, Ewing, NJ, USA), and animals were placed on a heata-
ble table that allowed real-time monitoring of body temperature, respiration, and heart rate 
(Figure 2 A). US gel (Pharma-Depot GmbH, Versmold, Germany) was transferred to 50 mL 
falcon tubes (Corning®, Fisher Scientific, Pittsburgh, PA, USA) and centrifuged with at 
least 135 × g for 5 to 10 minutes to eliminate air bubbles before it was generously applied on 
the entire tumor volume surface (Figure 2 B). Measurements were performed on the com-
mercial systems Vevo 2100 and Vevo 3100 (both Fujifilm VisualSonics Inc., Toronto, Can-
ada) using a tunable Nd:YAG laser (Vevo LAZR, Fujifilm VisualSonics Inc.). The laser 
emits photons at a 20 Hz pulse rate with a peak energy of approximately 30 mJ and 10 ns 
length [90]. Imaging was performed with the system-specific linear-array US-transducers 
exhibiting a center frequency of 21 MHz (transducer LZ250 for Vevo 2100, transducer 
MX250 for Vevo 3100; both Fujifilm VisualSonics Inc.). For detection of de-oxygenated 
and oxygenated hemoglobin two excitation wavelengths (750 nm and 850 nm) were used. 
The PAI system was calibrated before each imaging session.  
As experiments on the dependency of PAI results on signal gain and thresholding (section 
2.2.4) showed that sO2-distributions were essentially independent of these settings (section 
3.1.2), all measurements were performed with an individually adjusted signal gain and a 
threshold of 20 %. They were optimized for each measurement using the hemoglobin signal 
in the “HemoMeaZure” mode of the Vevo imaging software (Fujifilm VisualSonics Inc.) to 
obtain a homogeneous signal distribution over the entire tumor. All PAI data were acquired 
in 3D “Oxy-Hemo” mode (Vevo imaging software) with a step size of 0.15 mm and low 
persistence if not stated differently. Tumor volumes were determined based on simultaneous-
ly acquired US B-Mode images in VevoLab software (Fujifilm VisualSonics Inc.).  
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During PAI, animals were kept under inhalation anesthesia with a mixture of either 2.5 % 
Isoflurane when measured at the Vevo 2100 or 2.5 % Sevoflurane (Abbott, Wiesbaden, 
Germany) when measured at the Vevo 3100 and 2 l/min oxygen.  
 
 
Figure 2 Set-up for photoacoustic imaging (PAI). (A) The anaesthetized rat is fixed on the heatable table. 
Contact to the golden electrodes allows real-time monitoring of the respiration and heart rates. Temperature is 
measured with a rectal probe (blue cable). The tumor is covered in ultrasound (US) gel and the transducer is set in 
the measurement position. (B) Close-up on the depilated tumor (arrow) on the rat’s thigh which is covered by air 
bubble-free US gel.  
 
2.2.3 A new pixel-based oxygen saturation (sO2) analysis protocol  
A new analysis protocol was developed that reflects the inter- and intra-tumor heterogeneity 
by reporting the pixel-distributions of sO2 rather than volume-based mean values. The results 
of the analysis are displayed as frequency distributions. This new analysis protocol is de-
scribed in detail in the results part (section 3.1.1). The following experiments were analyzed 
using this protocol.  
2.2.4 Dependency of sO2-distributions on signal gain and threshold 
The dependency of the PAI result on signal gain and thresholding was investigated. For this, 
two animals were transplanted with the HI-tumor as described in section 2.1.3. At the imag-
ing time point, one tumor was small (6 mm × 8.5 mm, HI-1) and the other one was large 
(14 mm × 15 mm, HI-2). Measurements were performed at the Vevo 2100 with Vevo-LAZR 
without persistence. The two animals were imaged with three different signal gains (36 dB, 
38 dB, 40 dB). Data was analyzed for three different thresholds (0 %, 15 %, 30 %). Both pa-
rameters were selected within a range applicable for in vivo measurements. Reproducibility 
of sO2-distributions was assessed by repeating this procedure after repositioning of animals.  
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2.2.5 Characterization of the hypoxic status of the H-, HI-, and AT1-tumor  
For the characterization of the hypoxic status of the three Dunning sublines two animals per 
subline were transplanted with H-, HI-, and AT1-tumors on their right thighs as described in 
section 2.1.3. Tumors were imaged by PA at least three times over a period of up to 41 days. 
At each imaging time point animals underwent an oxygen challenge experiment during 
which the animals’ breathing gas was altered (Figure 3). Animals were sequentially imaged 
when breathing 100 % oxygen (O2), ambient air (i.e. 21 % O2), and again 100 % O2. After 
each alteration of oxygen conditions, a delay of 5 min was added allowing for adaption of the 
tumor to the new condition. Subsequently, an additional measurement was performed 10 min 
after clamping the tumor-supplying arteries with a transparent cable retainer which induced 
acute hypoxic conditions in the tumors while the animals were still breathing 100 % O2. Im-
mediately thereafter, the cable retainer was removed and the animals were imaged again. For 
comparison with well-oxygenated normal tissue, these measurements were also performed 
for the skin of two animals (in the following labelled as reference-1 and reference-2). 
 
 
Figure 3 Schematic illustration of the oxygenation conditions during PAI. Color-coded “oxyhemo” images 
show the same region of interest under different experimental conditions. Figure reproduced from [92] under the 
CC BY 4.0 license. 
 
2.2.6 Histology and immunohistochemistry 
After final imaging of the tumors, animals were injected intravenously (i.v.) with pimonida-
zole as described in section 2.6.2.5. After one hour, Hoechst 33342 dye was injected as a 
perfusion marker as described in section 2.6.2.6. Tumors were dissected and cryo sections 
were prepared (section 2.6.1). For evaluation of tumor tissue structures, cryo sections were 
stained with H&E (section 2.6.2.1). Immunofluorescence double stainings were prepared to 
assess tumor hypoxia in correlation to the vasculature (staining for pimonidazole and CD31, 
section 2.6.2.5). All sections were evaluated with an Axio Scan.Z1 microscope (Carl Zeiss 
Microscopy GmbH, Jena, Germany).  
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2.3 Tumor irradiation 
2.3.1 Photon irradiation 
Photon irradiations were performed using a single 6 MV beam of a clinical linear accelerator 
(Artiste, Siemens, Erlangen, Germany) at DKFZ. For irradiation, rats were individually 
placed in a custom-built immobilization device [103]. Laser crosshairs were used to position 
the tumor in the isocenter of the accelerator. The correct position of the tumor in the beam 
field was verified by a light field. 15 mm polymethylmethacrylate (PMMA) boli were posi-
tioned directly in front of and behind the tumor. A field with 15 mm diameter (90 % isodose) 
was generated by a 12 mm tungsten round collimator covering the entire tumor. The tumor 
was irradiated with a horizontal beam parallel to the animal’s longitudinal body axis with a 
dose rate of 10 Gy/min. Rats were kept under inhalation anesthesia with a mixture of 2.5 % 
Sevoflurane and oxygen at 2 l/min using an inhalation mask. 
2.3.2 Carbon ion irradiation 
12
C-ion irradiations were performed at the experimental work place of the Heidelberg Ion 
Beam Therapy Center (HIT) employing active beam scanning technique [104]. As for pho-
ton irradiation, a custom-built immobilization device was used for positioning the rats. The 
irradiation field was chosen slightly larger for 
12
C-ion irradiations than for photons because 
no light field was available to confirm the alignment of the tumor in the beam field.  
The tumor was positioned in the center of a homogeneous 20 mm SOBP with a lateral field 
size of 18 × 18 mm2 (90 % isodose). A 39.9 mm PMMA bolus was positioned directly in 
front of the tumor, and a 15 mm PMMA bolus was positioned directly behind the tumor to 
ensure that the tumor was positioned in the center of the SOBP [103]. Hence, the first 5 mm 
and the last 5 mm of the SOBP were located in the proximal and distal boli, respectively. The 
mean dose-averaged LET in the tumor was 75 keV/µm (range 64 - 96 keV/µm). The tumor 
was irradiated with a horizontal beam parallel to the animal’s longitudinal body axis from 
the rear direction. Rats were kept under inhalation anesthesia with a mixture of 2.5 % 
Sevoflurane and oxygen at 2 l/min using an inhalation mask. 
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2.4 Dynamic contrast-enhanced magnetic resonance imaging 
(DCE-MRI)  
2.4.1 MRI basics 
Magnetic resonance imaging (MRI) is a powerful imaging modality in the clinical as well as 
preclinical setting because of its excellent soft tissue contrast. In contrast to other imaging 
modalities such as computed tomography (CT) and PET, MRI only involves strong magnetic 
fields rather than ionizing radiation. The image contrast rises from nuclear relaxation times 
that differ among morphological structures [105].  
In most cases, the MR signal rises from the nucleus of hydrogen atoms (protons) which have 
a high abundance in the body. Protons possess a nuclear spin which is associated with a 
magnetic moment. By applying a strong static magnetic field &' the spins will precess with a 
characteristic Lamor frequency and will align either parallel or antiparallel to the respective 
field in an energetic equilibrium with a small net magnetization parallel to &'. After apply-
ing an oscillating magnetic field & perpendicular to &' (also called radio frequency pulse) 
that rotates the net magnetization into the transversal plane, an alternating current is induced 
in a close-by receiver-coil, which is the measurable MR signal. The frequency of the &-field 
has to match the Lamor frequency of the spins. When this radio frequency pulse is switched 
off, the spins leave the transversal plane and start to restore their original equilibrium state. 
The time required for that is the longitudinal relaxation time 1. During this restoration the 
spins also start to dephase in the transversal plane. The corresponding transversal relaxation 
time, 2, describes the signal decay caused by this dephasing of the spins. Local field inho-
mogeneities lead to a faster dephasing with the relaxation time 2∗. Each nucleus type, e.g. 
hydrogen, has specific 1 and 2 times. However, due to small magnetic disturbances in the 
hydrogen atoms’ environment, e.g. by the presence of other molecules in the proximate vi-
cinity, the relaxation behavior of the hydrogen atoms slightly changes.This results in tissue 
specific 1 and 2 times that create image contrast. Hence, in a 1-weighted image, a tissue 
structure with a short 1-time appears brighter than a tissue structure with a long 1-time. 
2.4.2 DCE-MRI basics 
Dynamic contrast-enhanced MRI (DCE-MRI) involves the administration of a contrast agent 
(CA) during MR imaging and is often employed to study the perfusion and permeability of 
tumors in clinical and preclinical studies [84, 106, 107]. Gadolinium-based paramagnetic 
contrast agents cause a faster 1 relaxation and, therefore, an enhanced 1 signal; i.e. CA 
accumulating structures “lighten” up in 1-weighted images. Tumors are likely to accumu-
late a large amount of CA due to their immature and leaky vessels which makes them visible 
in contrast-enhanced images.  
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For DCE-MRI, the CA is administered as a bolus and its time course in the tissue of interest 
is recorded by time-resolved imaging. Pharmacokinetic modeling enables the derivation of 
hemodynamic parameters from the CA kinetics in the tissue of interest.  
2.4.3 Pharmacokinetic modeling basics 
Pharmacokinetic modeling aims at the derivation and quantification of physiological pa-
rameters from DCE-MRI concentration-time curves. The analysis comprises two major 
steps: first, changes in MR signal are converted to CA concentrations; second, physiological 
parameters are derived from concentration-time curves by tracer-kinetic theory [108]. 
2.4.3.1  MR signal-to-concentration conversion 
Models used for pharmacokinetic modeling embrace changes in CA concentration rather 
than changes in MR signal which requires a transformation of signal intensity curves into 
concentration curves. In the context of DCE-MRI, 2∗-effects are neglected and the relation-
ship between the relaxation rate ()* = +!(,* and the CA concentration -()* can be assumed 
to be linear in the range of 0 - 5 mM [109] with 
()* = 	,' +	/ ∙ -()*	, (2) 
where / is the relaxivity of the CA and ,' is the initial relaxation rate of the tissue without 
CA. Hence, CA concentration can be expressed as 
-()* = 1/ 1()* − ,'2	. (3) 
The time varying signal intensity 4()* depends on the chosen DCE-MRI sequence and can 
generally be expressed as 
4()* = 5 ∙ 6z1()*2	, (4) 
with 5 being a time-independent constant that combines a number of sequence specific pa-
rameters such as a global calibration constant, the equilibrium magnetization, the position 
dependent coil sensitivity, the flip angle, and 2∗-weighting [108]. Due to variations in coil 
sensitivity, &-fields or proton density, these constants may depend on the voxels’ position 
[108]. The longitudinal magnetization 6z is a function of ()* and further MR sequence 
parameters [108]. Assuming linearity between 6z and ()* and using equation (3) gives an 
approximation for the absolute signal enhancement 48abs()* 
-()* = 48abs()* = : ∙ 14()* − 4(0*2	, (5) 
where : = <!,=>!  is a proportionality constant that depends on the flip angle and the coil sensi-
tivity. 
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2.4.3.2  Tracer kinetics 
Indicator dilution theory describes how an indicator, i.e. a detectable substance that is intro-
duced into a physiological system, behaves when added to a system consisting of numerous 
inlets and outlets [110]. Tracer kinetic modeling is based on the assumption of linear and 
stationary tissues. Linearity means that the tissue response towards a tracer injection at any 
given time point is proportional to the injected dose, and stationary means that this response 
is independent of the time of injection [108, 110].  
MR tracers remain extracellular and, therefore, the concentration -()* always refers to plas-
ma concentration -P()*. However, only whole blood CA concentration levels -B()* can be 
measured. Hence, the blood CA concentration level -B()* must be corrected for the hemato-
crit Hct to obtain the plasma concentration level -P()* 
-P()* = -B()*1 − Hct	. (6) 
Pharmacokinetic modeling uses mathematical models of the tissue architecture which consti-
tute the link between the measured data and the physiological parameters. They are fitted to 
the measured concentration-time curve of the tissue of interest -T()* which can be described 
by the convolution 
-T()* = D()* ⊗	-AIF()*	. (7) 
Here, D()* is the impulse response function that describes the kinetics of the CA in the tissue 
and -AIF()* is the measured arterial input function (AIF) that describes the initial CA inflow 
[108]. The AIF is ideally recorded directly at the supplying artery of the tissue of interest.  
One way to derive the physiological parameters from the concentration-time curves is the 
model-based deconvolution approach. During the fitting process, the model-parameters are 
adapted in a way that the convolution of the AIF and the impulse response function D()* give 
the best possible fit to the measured concentration-time curve -T()*. The model parameters 
correspond to the physiological parameters. There are multiple compartment models availa-
ble for this approach which differ e.g. in the number of compartments and exchange con-
stants. A compartment is a homogeneous and well-mixed macroscopic physiological volume 
that does not necessarily coincide with a single spatially-connected volume. 
The compartment models considered in this work are the two compartment exchange model 
(2CXM) [111] and the extended Tofts model (ETM) [112]. The 2CXM assumes two com-
partments, the plasma compartment and the extracellular, extravascular space (EES) (Figure 
4 A). The plasma compartment contains the CA concentration -p()*, is described by the 
plasma volume fraction Ip, and is perfused with the plasma flow Jp. The permeability-
surface-area product 4 describes the exchange rate through the capillary walls into the EES, 
which has the volume fraction Ie and the CA concentration -e()*. The total tissue concentra- 
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Figure 4 Schema of the two compartment exchange model (2CXM) and the extended Tofts model (ETM). (A) 
In the 2CXM the exchange rate between the two compartments plasma (i.e. plasma volume fraction Ip with the 
contrast agent concentration -p()*), and extracellular, extravascular space (EES, i.e. Ie with the contrast agent 
concentration -e()*) is described by the permeability-surface-area product 4. The plasma compartment has a 
flow Jp. (B) In the ETM the exchange between the two compartments Ip and Ie is described by the volume trans-
fer constant Ktrans and the efflux rate constant Lep. 
 
tion -T()* can be written as [113] 
-T()* = Jp((1 − *MNOP! +  ∙ MNOP* ⊗ -AIF()*, (8) 
with 
K, = 12Q1p + 1e RST1p + 1eU
 − 4 1p 1eW 					and				 = K − B
NK − K 	. (9) 
Here, p	and	e are the plasma and interstitial mean transit times, respectively, and B is the 
mean transit time of an intravascular tracer in blood [113] which are defined by the follow-
ing relations:  
p = Ip4 +	Jp , e = Ie4 , B = IpJp 	.	 (10) 
The ETM can be approximated from the 2CXM for the highly perfused regime (i.e. Jp → ∞) 
or the weakly vascularized regime (i.e. Ip → 0) [114, 115] by substituting the plasma residue 
function by a delta distribution, yielding the total tissue concentration 
-T()* = TIp ∙ [()* + Ktrans ∙ MNOPtrans\e U⊗ -AIF()*. (11) 
In the ETM the volume transfer constant Ktrans has a mixed flow-permeability weighting 
(Figure 4 B) 
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which does not allow for a unique discrimination between permeability and flow [114]. 
When performing pharmacokinetic modeling, the selection of the model is a crucial step to 
ensure meaningful results. First, a priori knowledge about the physiology of the investigated 
tissue should be used to limit the number of considered models. Second, goodness of fit and 
the number of free parameters need to be examined. As a general rule, the best model is the 
simplest model (i.e. least parameters) that fits the data well [116].  
 
2.4.4 Delay correction by bolus arrival time (BAT) estimation 
The text in sections 2.4.4, 2.4.4.1, and 2.4.4.2 was taken from reference [117] and has been 
originally written by myself. 
Accuracy of pharmacokinetic fit results can be impaired due to a delay between the arrival of 
CA bolus in the artery, from where the AIF is extracted, and the arrival of CA in the tissue of 
interest [118-120]. Ideally, the AIF is extracted directly form a tumor supplying artery. 
However, due to limited image resolution and partial volume effects, it is not always possi-
ble to choose an artery in the direct vicinity of the tumor. Hence, the AIF is often extracted 
from a larger artery further upstream or, in the case of small animal imaging, even from the 
left ventricle. This results in a delayed CA arrival in the tissue of interest compared to the 
AIF. There are two standard approaches to determine this delay time: the first approach in-
cludes the delay as an additional free parameter in the fitting process of the pharmacokinetic 
model [121, 122]. The second type estimates the bolus arrival times (BATs) separately for 
the tissue concentration curve (TCC) and for the AIF; that is, the time points where the con-
centration curves start to rise. The time delay is the difference between the BAT of the TCC 
and that of the AIF. The advantage of the second type is that it does not require to including 
the time delay as an additional fit parameter which is likely to decrease fit stability. A study 
by Kershaw and Buckley showed that the second approach gives more accurate results than 
the first one [122]. 
Cheong et al. introduced a method for discrete BAT estimation based on fitting a linear or 
convex quadratic function to the sample points in the neighborhood of the BAT which gives 
excellent results for TCCs with fast upslopes (i.e. the peak of the signal is close to the BAT) 
as often observed in patient data [123]. An extension of this method was proposed by Singh 
et al. giving comparable results [124]. However, applying the method of Cheong et al. to 
TCCs that do not exhibit this characteristic upslope, e.g. TCCs of small animals or weakly 
perfused tissues, may lead to poor results.  
Ktrans = Jp ∙ 4Jp + 4	, (12) 
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A method for continuous BAT estimation of DCE-MRI that do not have a fast upslope – as 
often observed in small animal data and patient data of tissues without a significant intravas-
cular fraction – was developed. The method is based on approximation of TCCs by splines, 
which allow to adapt to a large variety of curve shapes after the BAT. This project was real-
ized in cooperation with Dr. Martin Storath of the group for Image Analysis and Learning of 
the Interdisciplinary Center for Scientific Computing of Heidelberg University. 
In the following, the general concept of smoothing splines, which were used for the new 
BAT estimation method, as well as the generation of the test data sets and the reference 
method that has been used up to now, are described. Details of the new method itself are 
presented in the results part (section 3.2). 
2.4.4.1  Smoothing splines 
Smoothing splines are a classical signal estimation method which have been applied to vari-
ous biomedical problems [125, 126]. A smoothing spline approximates data by a function 
that is the optimal tradeoff between smoothness, measured in terms of the integral over its 
squared Lth derivative, and fidelity to the data, as represented by the residual sum of squares. 
A smoothing spline of order L ∈	ℕ	is	the	solution	of	the	following	optimization	problem:	Find	a	sufficiently	smooth	function	j	on	[), )k]	that	minimizes	the	cost	function:	
l(j()m* − nm* + 	o	p qj(r*(s*t us,OvO!
k
mw 	 (13*	
where nm are the measured data points and j(r* denotes the Lth derivative of the function j. 
The parameter o > 0 adjusts the relative weight of the data fidelity and smoothness: the 
larger the value of o, the smoother the resulting spline. To understand the role of the order L, 
it is instructive to look at the solutions for very large o: For o → ∞, the solution of eq. (13) 
yields an ordinary polynominal of degree L − 1 on	[), )k].	This is because the smoothness 
cost (the second term in eq. (13)) is equal to zero exactly for polynominals of maximum 
degree	L − 1. Thus, for	o → ∞,	 the minimizer of eq. (13) coincides with the least squares 
approximation by a polynomial of degree	L − 1.	Technical details on smoothing splines can 
be found in [127-130]. 
2.4.4.2  Data simulation 
For validation of the new method for BAT estimation, the proposed method was applied to 
simulated TCCs and the respective AIFs with known true BAT and to in vivo acquired rat 
data. TCCs were simulated employing the impulse response functions for the ETM (eq. (11)) 
and the 2CXM (eq. (8)) [111] using the software package “ModelFit” within the “Medical 
Imaging Interaction Toolkit (MITK)” [131, 132]. Rat TCCs were generated using the model-
based AIF proposed by McGrath et al. (model B) [133]. Three physiologically realistic TCC 
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types were simulated for both pharmacokinetic models by varying the input parameters 
(ETM: Ktrans = 15 ml/min/100 ml, Ip = 0.05, and Ie = 0.3, 0.6, or 0.1, respectively; 2CXM: Jp = 25 ml/min/100 ml, 4 = 10 ml/min/100 ml, Ip = 0.05, and Ie = 0.05, 0.15, or 0.3, re-
spectively). 
To show the flexibility of the proposed method, patient data was additionally simulated, 
using the population-average based AIF proposed by Parker et al. [134]. Here, two TCC 
types were investigated (ETM: Ktrans = 10 ml/min/100 ml, Ip = 0.1, and Ie = 0.05 or 0.3, 
respectively; 2CXM: Jp = 25 ml/min/100 ml, 4 = 5 ml/min/100 ml, Ip = 0.1, and Ie = 0.15 
or 0.05, respectively).  
High-resolution TCCs were simulated for an acquisition time of 360 s with a temporal reso-
lution of 0.25 s and BAT at 34.75 s (Figure 5). The true BAT was defined as the last point on 
the concentration curve’s baseline. To evaluate the robustness of the proposed method, simu-
lated TCCs were altered for four temporal resolutions (∆) = 1 s, 2 s, 3 s, 7 s) and three noise 
levels defined by their signal-to-noise ratio (SNR) (SNR = 50, 25, 10). SNR was defined as 
the ratio between the maximum of the concentration curve to the standard deviation of the 
Gaussian noise added to the concentration curve. Different temporal resolutions were real-
ized by respectively down-sampling the original data. 1000 noise realizations per configura-
tion were generated.  
 
 
Figure 5 Simulated concentration curves for bolus arrival time (BAT) estimation: (A, B) Rat TCCs simulated 
with the extended Tofts model (ETM) and the two compartment exchange model (2CXM). (C) Model-based rat 
AIF as proposed by McGrath et al. [133]. (D, E) Patient TCCs simulated with ETM and 2CXM. (F) Population-
average based Parker AIF [134]. ©Institute of Physics and Engineering in Medicine. Reproduced from [117] with 
permission. All rights reserved. 
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2.4.4.3  BAT estimation on simulated data 
Using the developed estimation method, BATs were estimated for the 1000 generated noise 
realizations for each configuration (four temporal resolutions with three noise levels each). 
The results were compared with those of the reference method published by Cheong et al. 
[123]. 
 
Cheong’s method 
To the author’s knowledge, Cheong’s method [123] is the current gold standard for BAT 
estimation of DCE-MRI data. The method is based on a parametric approximation model for 
the concentration curve between the first time frame ) and the peak time denoted by )p. The 
model functions j are assumed to be constant before the BAT and quadratic polynomial 
between the BAT and the peak time: 
j()m* = z{',																																																																						, if	) ≤ )m ≤ )BAT{' + { ∙ ()m − )BAT* + { ∙ ()m − )BAT*, if	)BAT < )m ≤ )p. (14) 
Here, ~ ∈ {1,… ,  − 2} and {',	{, { are the model parameters. Additionally, a linear vari-
ant is proposed which is obtained by setting { equal to zero. It was found that in average 
imposing this restriction did not lead to improved estimates, thus the focus was set on the 
quadratic method. The method proceeds as follows. For each BAT candidate )BAT ∈{), … , )p}, the optimal model parameters are computed by a least squares fit using non-
negativity constraints. The candidate that provides the least residual sum of squares is con-
sidered as the best estimate for the BAT. It should be noted that with this method the esti-
mated BAT is necessarily one of the discrete sampled time points. 
 
Adapted version of Cheong’s method 
Additionally, results were compared to an adapted version of Cheong’s method which only 
considers sample points after the CA injection time for BAT estimation (Cheong et al. 
adapted) [117]. Because the experimental set-up of the DCE-MRI experiments in the follow-
ing studies did not allow for an exact recording of the injection time, a plausible common 
lower boundary was set at the sample point at 25.37 s as it can be assumed that no CA was 
injected before 25 s [117].  
2.4.5 Experimental set-up for DCE-MRI 
In the following, the general DCE-MR imaging protocol is described. The text in sec-
tion 2.5.1 was taken from reference [135] and has been originally written by myself. 
Imaging was performed at a clinical 1.5 T MRI (Symphony, Siemens) using an in-house 
built small animal coil. 2-weighted transversal images (turbo spin echo sequence with repe-
tition time (TR) 3240 ms, echo time (TE) 81 ms, slice thickness 1.5 mm, pixel size 
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0.35 × 0.35 mm2) were recorded and used to position two imaging slices for DCE-MRI 
(TURBO-FLASH, TR 373 ms, TE 1.67 ms, slice thickness 4.5 mm, pixel size 
0.99 × 0.99 mm2, matrix size: 144 × 192). One of the transversal slices was positioned 
through the heart, the other one was positioned through the largest diameter of the tumors. 
20 - 30 s after starting the DCE-MRI sequence, 0.1 mmol/kg Gd-DTPA (Magnevist®, Bayer 
Healthcare Pharmaceuticals, Berlin, Germany) CA was manually injected into the tail vein. 
Images were acquired with a temporal resolution of 0.75 s for a total acquisition time of 
380 s. In addition, 1-weighted reference images of the entire tumors were recorded with a 
spin-echo sequence (TR 600 ms, TE 14 ms, pixel size 0.31 mm × 0.31 mm, slice thickness 
1.5 mm) after (and for the HI-tumors additionally before) the DCE-MRI measurement. 2-
weigthed images were also used to determine the tumor volumes. 
2.4.6 Signal-to-concentration conversion of DCE-MRI data 
All handling of experimental DCE-MRI data was performed in MITK. All experimental 
DCE-MRI data were analyzed voxel-based. Signal intensities were transformed into concen-
tration curves by means of absolute signal enhancement (eq. (5)) with : = 1. CA blood con-
centrations were corrected by the hematocrit level (eq. (6)) using a literature value of 0.45 to 
obtain CA plasma concentrations [111].  
2.4.7 Pharmacokinetic modeling of DCE-MRI data 
DCE-MRI concentration-time curves were fitted by the ETM [115], using the tool “Model-
Fit” [132] within the MITK framework. An image-based AIF was derived from the DCE-
MRI heart slice individually for each animal at each imaging session. The AIF was manually 
chosen as the voxel with the steepest rise, highest signal amplitude, and least noise in the left 
ventricle of the animals’ hearts. Tumor regions of interest (ROIs) were delineated on 2-
weighted MR-images and transferred to the DCE-MRI images. 
Prior to pharmacokinetic analysis, a delay correction was applied to the concentration-time 
curves. For this, BATs were estimated for both, AIF and the respective tumor concentration-
time curves, as described in section 3.2 [117]. AIFs were then shifted according to the delay 
between the BAT of the AIF and the median of BATs of the concentration-time curves of 
each tumor voxel fulfilling the plausibility condition BATAIF < BATtumor per animal.   
Start parameters for the fitting procedure were set to Ktrans = 15 ml/min/100 ml, Ie = 0.5, 
and	Ip = 0.05. Constraints were applied on Ie and Ip such that 0 < Ie, Ip < 1 and Ie +Ip < 1 to exclude unphysiological results and to prevent overfitting. Fitting parameters Ktrans, Ie, and Ip were determined voxel-wise for each tumor. Results of all voxels were 
pooled per treatment group and per imaging time point. 
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2.5 Longitudinal DCE-MRI studies after irradiation 
Longitudinal DCE-MRI studies were performed after irradiation to gain initial quantitative 
information on the impact of high dose 
12
C-ion irradiation compared to photons on tumor 
vasculature and perfusion. The acute hypoxic and moderately differentiated HI-tumor and 
the chronically hypoxic and anaplastic AT1-tumor were chosen for these experiments.  
2.5.1 DCE-MRI study of the AT1-tumor 
The text in section 2.5.1 was taken from reference [135] and has been originally written by 
myself. 
2.5.1.1  Experimental set-up and treatment groups for the AT1-tumor 
AT1-tumors were subcutaneously transplanted on both thighs of 12 male Copenhagen rats as 
described in section 2.1.3. Animals were included in the experiment when their tumors 
reached a size of 9 mm × 9 mm (tumor volume 256 ± 120 mm3). DCE-MRI was performed as 
described in section 2.4.5 one day prior to and 3, 7, 14, and 21 days after irradiation (Figure 
6). Right AT1-tumors were irradiated in four groups as described in sections 2.3.1 and 2.3.2, 
respectively: Curative single doses of either 37 Gy 
12
C-ions or 85 Gy photons (isoeffective 
RBE-weighted doses [24]) were delivered leading to local tumor control. In addition, an iso-
absorbed dose of 37 Gy photons and the corresponding isoeffective RBE-weighted dose of 
16 Gy 
12
C-ions (both are sub-curative doses [24]) were selected. The RBE required for the 
calculation of the isoeffective doses was taken from an earlier conducted dose-response ex-
periment [103]. Left tumors served as non-irradiated controls. Each treatment group consist-
ed of three animals resulting in 12 irradiated and 12 control tumors in total. The longitudinal 
DCE-MRI measurements and corresponding irradiations, as well as animal keeping and ob-
servation were planned and performed by Dr. Christin Glowa. 
2.5.1.2  Non-compartment analysis and pharmacokinetic modeling 
DCE-MRI data were converted to concentration curves as described in section 2.4.6. Area 
under the curve (AUC) values were determined over the entire concentration-time curve for 
each voxel per tumor. AUC values per tumor and time point were normalized to the maxi-
mum AUC value of the respective animal’s main abdominal artery of the same measurement 
to eliminate CA administration related effects. In addition, voxel-based pharmacokinetic 
modeling with the ETM was performed on DCE-MRI data of the AT1-tumor as described in 
section 2.4.7.  
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Figure 6 Schematic illustration of the longitudinal DCE-MRI studies. DCE-MRI was performed one day prior to 
and 3, 7, 14, and 21 days after irradiation. Tumors were irradiated with curative doses of either photons or 12C-
ions (yellow flash). After the last imaging time point, tumors were dissected and prepared for histology. 
 
2.5.1.3  Histology and immunohistochemistry 21 days after irradiation 
At the last imaging time point, tumors were dissected and cyro-preserved slides were pre-
pared as described in section 2.6.1. Histological and immunhistological stainings were per-
formed to assess tumor morphology (H&E), vasculature and pericyte coverage as a maturity 
marker (CD31/SMA/DAPI), and proliferation (BrdU/DAPI) (Table 1). Additionally, one 
animal per dose group was injected with the hypoxia marker pimonidazole consequently 
stained for pimonidazole/CD31/DAPI (Table 1). Vascular density and vascular maturity, 
hypoxic fraction, and proliferative activity were quantified by the protocols listed in Table 1. 
 
Table 1 Histology and immunohistochemistry stainings which were performed on the AT1-tumors of the 
longitudinal DCE-MRI study after irradiation with photons or 12C-ions and references to the respective staining 
and quantification protocols. 
Staining Staining protocol Quantification protocol 
H&E 2.6.2.1  - 
CD31/SMA/DAPI 2.6.2.4 (CD31/SMA) 2.6.4.1 (Vascular density)  
CD31/pimonidazole/DAPI 2.6.2.5  (CD31/pimonidazole) 2.6.4.2 (Hypoxic fraction) 
BrdU/DAPI 2.6.2.7 (BrdU) 2.6.4.4 (Proliferation) 
 
2.5.2 DCE-MRI study of the HI-tumor 
The text in section 2.5.2 was taken from reference [136] and has been originally written by 
myself. 
2.5.2.1  Experimental set-up and treatment groups for the HI-tumor 
HI-tumors were subcutaneously transplanted on both thighs of 16 male Copenhagen rats as 
described in section 2.1.3. Tumors were irradiated when their tumors reached a size of 
10 mm × 10 mm (tumor volume 443 ± 378 mm3). DCE-MRI was performed as described in 
section 2.4.5 one day prior to and 3, 7, 14, and 21 days after irradiation (Figure 6). Animals 
were randomly assigned to one of the four single dose treatment groups: 18 Gy 
12
C-ions 
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(n = 4) or 37 Gy photons (n = 4) (sub-curative isoeffective doses), the respective isodose 
37 Gy 
12
C-ions (n = 5), or the corresponding isoeffective dose of 75 Gy photons (n = 3) as 
described in sections 2.3.1 and 2.3.2, respectively. The latter two doses are curative and lead 
to local tumor control [24]. While the HI-tumors on the right distal thighs were irradiated, 
the HI-tumors on the left thighs served as controls. The longitudinal DCE-MRI measure-
ments and corresponding irradiations, as well as animal keeping and observation were 
planned and performed by Dr. Christin Glowa. 
2.5.2.2  Pharmacokinetic modeling 
DCE-MRI data were converted to concentration curves as described in section 2.4.6. Voxel-
based pharmacokinetic modeling with the ETM was performed on DCE-MRI data of the HI-
tumor as described in section 2.4.7. As pharmacokinetic modeling revealed a large spread of 
the resulting model parameters, which can most likely be attributed to the intrinsic biological 
heterogeneity of this tumor, additional analysis was performed (see section 2.5.2.3). 
2.5.2.3  Principle component analysis of DCE-MRI data 
Voxel-based concentration-time curves of DCE-MRI data were clustered based on results 
from a principle component analysis (PCA) as described by Featherstone et al. [137]. All 
analyses were performed in Matlab 2017b (Mathworks, Natick, MA, USA) and used Matlab 
functions are referenced in italics (e.g. function.m). 
Concentration-time curves were extracted from all evaluable pixels of all tumor ROIs, 
aligned at their BAT, and stored in a single matrix for PCA (pca.m). The first two principle 
components (PCs) represent the main shape of the concentration-time curves (Figure 7) and 
account for 95.1 % (1
st
 PC) and 3.6 % (2
nd
 PC) of the data’s variance. The PCA coefficients 
(loadings) of the first two PCs per concentration-time curve were used to separate the DCE-
MRI data into five cluster by Gaussian mixture modeling (GMM) using fitgmdist.m with a 
diagonal and unshared covariance matrix. The number of cluster was chosen based on quali-  
 
 
Figure 7 First two principle components (PCs) of the DCE-MRI concentration-time curves of the HI-tumors 
which account for 95.1 % (1st PC) and 3.6 % (2nd PC) of the data’s variance. Figure reproduced from [136]. 
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tative assessment of the concentration levels and shapes of the resulting average concentra-
tion-time curves per cluster after GMM. The criteria for finding a reasonable number of clus-
ter were defined as distinguishable levels and curve shapes between mean cluster concentra-
tion-time curves. Satisfactory results were found for five cluster. When choosing more or 
less than five cluster, the clustering of concentration-time curves was dominated by concen-
tration level only rather than curve shape. The fit parameters Ktrans, Ie, and Ip of all tumor 
voxels of all animals of all treatment groups were pooled per cluster. For each tumor and 
subsequently for each group, the fraction of each cluster type was determined per imaging 
time point. 
2.5.2.4  Histology and immunohistochemistry 21 days after irradiation 
Animals were sacrificed after final imaging. Tumors were dissected and prepared as de-
scribed in section 2.6.1. Cryo-preserved slides were stained with H&E (see section 2.6.2.1) 
and immunohistological stainings were performed for CD31/SMA/DAPI (see section 
2.6.2.4) to assess tumor vasculature and pericyte coverage as a maturity marker, and for 
Ki67 (see section 2.6.2.8) to assess proliferative activity.  
2.6 Histology and immunohistochemistry 
2.6.1 Tumor dissection and preparation of cryo sections 
At the designated end point, animals were either sacrificed by CO2 inhalation or by heart 
puncture and subsequent cardiac relief cut when Hoechst 33342 dye was administered (see 
section 2.6.2.6). Tumors were dissected and, if large enough, cut along their largest diameter 
into two parts, frozen in isopentane (Carl Roth GmbH, Karlsruhe, Germany), and stored at     
-80°C. 
For the preparation of cryo sections, tumors were embedded in TissueTek
® 
(Sakura, Alphen 
aan den Rijn, Netherlands) and attached to a specimen stage which was mounted onto a cry-
ostat (Leica CM3050 S, Leica Biosystems, Wetzlar, Germany). Tumors were trimmed with a 
slice thickness of 30 - 50 µm until the slice contained a complete cross section. Sequential 
cryo sections were acquired with a thickness of 7 µm, mounted onto adhesion slides (His-
toBond
®
, Paul Marienfeld GmbH, Lauda-Königshofen, Germany) and fixed in metha-
nol/aceton (1 min methanol, 2 min aceton) at -20°C. Slides were dried and stored at -20°C. 
2.6.2 Staining protocols 
2.6.2.1  Hematoxylin & Eosin 
To assess morphological structures, Hematoxylin & Eosin (H&E) staining was performed. 
Cryo slides were thawed and dried at room temperature (room temp) for 30 min. They were 
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washed in aqua dest. for 5 min und subsequently stained in hematoxylin solution acid ac-
cording to Mayer (Carl Roth GmbH) for 5 min. After a short washing step in aqua dest., the 
slides were blued in lukewarm running water for 10 min followed by staining in eosin Y-
solution (0.5 % in water, Carl Roth GmbH) for 5 min. Slides were washed in aqua dest. again 
before passing through an ethanol chain for dehydration (2 × 2 min 70 % ethanol, 2 × 2 min 
96 % ethanol, 2 × 4 min 100 % ethanol, 2 × 5 min Roticlear® (Carl Roth GmbH)). Slides 
were mounted in Eukitt
®
 (O. Kindler GmbH, Freiburg, Germany) and covered by cover slips 
(Menzel-Gläser, Menzel GmbH + Co KG, Braunschweig, Germany). Slides were dried over 
night. 
Hematoxylin stains acidic structures such as the DNA in the cell nuclei blue, while eosin 
stains alkaline structures such as connective tissue, collagen, cell plasma, muscle, and skin 
pink. Erythrocytes appear red-orange.  
2.6.2.2  Standard immunohistochemistry protocol  
The standard protocol for immunohistochemistry is displayed in (Table 2). Negative controls 
were run with each staining. One negative control was only incubated with the primary anti-
body to assess its background fluorescence. Another negative control was only incubated 
with the secondary antibody to assess its antigen binding specificity. The respective missing 
step was replaced by the vehicle solution (phosphate-buffered saline (PBS, PBS Dulbecco 
w/o Ca
2+
, w/o Mg
2+
, Biochrom GmbH) or bovine serum albumin (BSA, Sigma-Aldrich, 
Taufkirchen, Germany) in PBS (BSA/PBS)). If sections were not investigated for perfusion, 
cell nuclei were counterstained by 4′,6-diamidino-2-phenylindole (DAPI, Sysmex Partec 
GmbH, Münster, Germany). 
2.6.2.3  Antigen retrieval 
For those immunohistochemistry stainings that required antigen retrieval the following steps 
were added in between step 1 and step 2 of the standard protocol (Table 2). Plastic cuvettes 
were filled with sodium citrate buffer and heated to 95°C in a water bath. For the sodium 
citrate buffer 10 mM sodium citrate (Sigma-Aldrich) were dissolved in 900 ml aqua dest., the 
pH was adjusted to 6.0 with 1N HCl (Carl Roth GmbH), and the buffer was replenished to 
1 l. 0.5 ml Tween 20 (Sigma-Aldrich) was added and stirred until fully dissolved. 
After washing for 5 min in PBS, slides were incubated in the 95°C hot sodium citrate buffer 
for 30 min and subsequently allowed to cool down to 37°C under a fume hood. Afterwards 
the standard protocol was continued with step 2 (Table 2). 
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Table 2 Standard protocol for immunohistochemistry. *If tumors contained Hoechst 33342, these steps were 
performed in the dark.  
Nr. Process Product Time Temperature 
1 Drying Air ≥ 30 min room temp* 
2 Washing PBS 5 min room temp* 
3 Blocking Image-iT FX signal enhancer
†
 30 min  room temp* 
4 Washing PBS 3 × 5 min room temp* 
5 Blocking DAKO protein block 30 min room temp* 
6 1
st
 primary anti-
body 
In 3 % or 10 % BSA/PBS over night 4°C* 
7 Washing PBS 3 × 5 min room temp* 
8 2
nd
 primary anti-
body 
In 3 % or 10 % BSA/PBS 2 h room temp* 
9 Washing PBS 3 × 5 min room temp* 
10 1
st
 secondary 
antibody 
Fluorescence-coupled anti-
body in PBS or 3 % BSA/PBS 
1 h room temp, dark 
11 Washing PBS 3 × 5 min room temp, dark 
12 2
nd
 secondary 
antibody 
Fluorescence-coupled anti-
body in PBS or 3 % BSA/PBS 
1 h room temp, dark 
13 Washing PBS 3 × 5 min room temp, dark 
14 Counterstaining DAPI (100 ng/ml) 5 min room temp, dark 
15 Washing Aqua dest. 5 min room temp, dark 
16 Mounting Fluoromount-G
®**
 few hours room temp, dark 
†
     Invitrogen, Eugene, OR, USA 
**  SouthernBiotech, Birmingham, AL, USA 
 
2.6.2.4  Vascular structures and pericyte coverage 
Vascular structures were identified by staining for the endothelial surface marker CD31. 
Pericyte coverage of these structures was appraised as a marker for vessel maturity and was 
assessed by staining for smooth muscle actin (SMA). A rabbit anti-SMA antibody (Abcam, 
Cambridge, UK) was used as the first primary antibody in a concentration of 1:800 (step 6 of 
the standard protocol in Table 2). After overnight incubation, goat anti-CD31 (R&D systems 
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Inc., Minneapolis, MN, USA) was incubated for 2 h (1:2000) as the second primary antibody 
(step 8). Binding of the rabbit anti-SMA and goat anti-CD31 antibodies was visualized by 
incubating with the AlexaFluor 488-coupled secondary antibody donkey anti-rabbit (1:1500, 
Invitrogen, Eugene, OR, USA) and the AlexaFluor 555-coupled secondary antibody donkey 
anti-goat (1:2000, Invitrogen), respectively, for 1 h each (steps 10 and 12). 
2.6.2.5  Hypoxia in correlation with vascular structures 
Pimonidazole hydrochloride (Hypoxyprobe-1 Kit, NPI, Inc., Burlington, MA, USA) is used 
to detect hypoxia in cells and tissues. It is reductively activated depending on the cells’ oxy-
gen-level and forms stable covalent bounds with the thiol-groups of proteins, peptides, and 
amino acids in hypoxic cells [91]. These pimonidazole-protein adducts can be detected by 
histological methods.  
Pimonidazole was dissolved in saline (B. Braun, Melsungen, Germany) and injected in a 
weight-dependent manner (60 mg/kg body weight) i.v. into the animals’ tail vein 2 h prior to 
sacrification. During i.v. injection animals were anesthetized by inhaling 2.5 % Isoflurane 
mixed with 1.5 l/min oxygen.   
Cryo slides were stained according to the standard protocol (Table 2) using a directly FITC-
labelled mouse anti-pimonidazole antibody (NPI Inc.) in 3 % BSA/PBS (1:1000) in step 6. 
The next day, slides were incubated with the second primary antibody goat anti-CD31 in a 
concentration of 1:2000 (step 8) and its binding was visualized by the AlexaFluor 555-
coupled donkey anti-goat secondary antibody (1:2000, step 10). Steps 12 and 13 were omit-
ted.  
2.6.2.6  Tumor perfusion 
Hoechst 33342 fluorescence dye (bisBenzimide H 33342 trihydrochloride, Sigma-Aldrich) 
was used as a perfusion marker and administered to the animals prior to sacrification. There-
fore, animals were anesthetized by inhaling 2.5 % Isoflurane and 1.5 l/min oxygen. The der-
mis and subcutis of the animals’ abdomen were opened up to the sternum. At this point, the 
abdominal wall and diaphragm were opened, and the animal’s heart was localized. Saline 
solved Hoechst 33342 dye was administered in a weight dependent manner at 15 mg/kg body 
weight and was directly injected into the animal’s left ventricle followed by a cardiac relief 
cut. After 30 s, the tumor was dissected from the thigh. Thus, cell nuclei of perfused tissue 
regions were stained by Hoechst 33342 while non-perfused areas remained unstained. Perfu-
sion was assessed in combination with CD31/SMA staining (section 2.6.2.4) and pimonida-
zole staining (section 2.6.2.5). If tissue perfusion was examined, step 14 (DAPI staining) of 
the standard protocol (Table 2) was omitted.  
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2.6.2.7  Identification of proliferating cells by BrdU incorporation 
Proliferative activity was assessed by incorporation of 5-bromo-2'-deoxyuridine (BrdU, 
Sigma-Aldrich) into the cells’ DNA during S-phase [138]. 1 g BrdU powder was dissolved in 
24 ml 0.9 % saline and 8 ml EtOH. Animals were lightly anaesthetized by inhaling Isoflurane 
mixed with oxygen and were injected intraperitoneal (i.p.) with the BrdU solution 
(100 mg/kg body weight) 4 h prior to scarification.  
Antigen retrieval was performed as described in section 2.6.2.3. Afterwards, slides were 
incubated with mouse anti-BrdU (Roche Diagnostics, Mannheim, Germany) as a primary 
antibody in a concentration of 1:800 for 2 h (step 6 of the standard protocol in Table 2). An 
AlexaFluor 555-coupled goat anti-mouse antibody (Invitrogen) was used as a secondary 
antibody in a concentration of 1:2000 (step 10). Steps 8, 9, 12, and 13 were omitted as only 
one primary antibody was used. 
2.6.2.8  Identification of proliferating cells by Ki67 
The nuclear protein Ki67 is associated with cell proliferation [139] and was stained by the 
rabbit anti-Ki67 antibody (1:2000, Abcam) in 3 % BSA/PBS (step 6 of the standard protocol 
in Table 2). The goat anti-rabbit AlexaFluor-555 antibody (1:2000, Invitrogen) was used as 
secondary antibody in step 10. Steps 8, 9, 12, and 13 were omitted, as only one primary anti-
body was used. 
2.6.2.9  DNA double-strand breaks 
The loss of chromosomal integrity through radiation-induced DNA double-strand breaks 
(DSBs) was assessed by staining for γH2AX [140], the phosphorylated form of the histone 
H2AX [140, 141]. First, antigen retrieval was performed on the slides (see section 2.6.2.3). 
Subsequently, the standard protocol (Table 2) was worked off with a rabbit anti-H2AX anti-
body (Cell Signaling Technology, Cambridge, UK) in a concentration of 1:1000 in step 6 
and the AlexaFluor 555-coupled goat anti-rabbit antibody as the secondary antibody 
(1:3000) in step 10. Steps 8, 9, 12, and 13 were omitted as only one primary antibody was 
used. 
2.6.3 Fluorescence microscopy and image preparation for analysis 
All histological stainings were scanned with the reported exposure times (Table 3) at an Ax-
io Scan.Z1 microscope (Carl Zeiss Microscopy GmbH, Jena, Germany) producing bright 
field and multi-channel fluorescence whole-mount images of entire tumor sections.  
For analysis, the individual microscopy channels were converted to 8 bit images, compressed 
to 50 % of their original size in the Zen lite 2012 software (Zeiss), and exported as TIFF 
files. Exported images were manually cleared from artefacts due to reflections of small 
grains, overlapping tissue, and remaining muscle tissue in the open source software 
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ImageJ [142]. Tissue areas with no visible cell nuclei were assumed to be necrotic and were 
cut-out as well. Artefact areas that occurred only in one channel were also removed from the 
unaffected channels. In the following, these images are referred to as “cleared”. 
 
Table 3 Exposure times for fluorescence microscopy. 
Staining Exposure time 
CD31 300 ms 
SMA 200 ms 
Pimonidazole 300 ms 
BrdU 300 ms 
γH2AX 400 ms 
DAPI 30 – 60 ms 
Hoechst 33342 60 ms 
 
 
2.6.4 Quantitative analyses of histological stainings 
2.6.4.1  Vessel density and pericyte coverage 
Cleared images were background subtracted using the ImageJ plugin Subtract background 
with a rolling ball radius of 50 - 200 pixels for CD31 images and 20 - 100 pixels for SMA 
images. Background subtracted images were saved as hdf5-files, and a tumor mask was gen-
erated from the DAPI image. The tumor mask was separated into rim and core regions to 
investigate the spatial distribution of the vessel density. The rim was defined as the outer 
1 mm of tumor tissue and was delineated manually in ImageJ. The core was the remaining 
inner tissue area (Figure 8).  
Semi-automatic vessel segmentation was performed on the cleared and background subtract-
ed CD31 images (hdf5-files) in the open source software Ilastik [143] using the plugin Pixel 
Classification. Various features were selected (Color/intensity, edge, texture: 0.3 px, 1.6 px, 
and 5.0 px) and three labels were delineated in a set of approximately five exemplary imag-
es: CD31, blurry background, and background. Marking of only few pixels was sufficient for 
satisfactory vessel segmentation due to the high contrast of the CD31 images. The segmenta-
tion was applied to an entire stack of images. The Same procedure was performed for SMA 
images. Segmentation results were exported as TIFF images (Figure 8). 
An algorithm was written in Matlab R2017b that automatically counts segmented vessels 
and identifies CD31 and SMA co-expressing vessels (CD31
+
/SMA
+
). The segmentation of 
the CD31-label (or SMA-label, respectively) was loaded by the Matlab program. A median 
filter was applied to the CD31 and SMA segmentations to eliminate noise.  
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Figure 8 Illustration of the automated vessel counting process from multi-channel fluorescence images. Indi-
vidual channels were exported and cleared from artefacts. CD31+- (vessels) and SMA+- (pericyte-covered) struc-
tures were semi-automatically segmented from the respective cleared images in Ilastik. The segmentation images 
were further processed in Matlab to identify and quantify CD31+/SMA+-structures (i.e. mature vessels). Tumor 
masks were derived from the cleared Hoechst 33342 or DAPI images. Rim and core masks were generated by 
manual delineation. Yellow framed images show close-ups of the yellow boxes in the CD31 and SMA whole-
mount images. 
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Objects smaller than 50 pixels (21.125 µm
2
, respectively) were eliminated by using the built-
in Matlab function bwareaopen.m. Subsequently, connected objects were counted by 
bwconncomp.m with a connectivity of 8. Each counted CD31 component was checked for 
overlap with a SMA segmentation to identify CD31
+
/SMA
+
-structures. If an overlap of at 
least 300 pixels was found, the object was counted as CD31
+
/SMA
+
 co-expressing. Objects 
were also counted on the area of the rim and core masks, and the corresponding vascular 
densities were acquired by normalizing the number of objects to the area of the respective 
mask. 
2.6.4.2  Hypoxic fraction 
Tumor regions were classified as either hypoxic or non-hypoxic based on the pimonidazole-
staining intensity of individual areas. An algorithm was written in Matlab R2017b to quanti-
fy the pimonidazole-positive area in relation to the overall tumor section. Tumor masks were 
created from the cleared images of the three channels and read into the Matlab code along 
with the cleared pimonidazole images.  
An intensity threshold for hypoxia was manually set based on visual inspection of the pi-
monidazole images (8 bit images, i.e. intensity range from 0 to 255): Pixels with intensities 
above 30 were classified as hypoxic, remaining pixels were classified as non-hypoxic 
(Figure 9). 
The threshold was applied to the cleared pimonidazole images and the resulting pimonida-
zole-positive image was blurred by Gaussian filtering (σ = 20), followed by an additional 
threshold to avoid overestimation of the pimonidazole-positive area due to fading after the 
blurring. Masks for pimonidazole-positive and pimonidazole-negative parts were generated. 
 
 
Figure 9 Illustration of the quantification of the hypoxic fraction from pimonidazole fluorescence images. (A) 
Cleared fluorescence image with pimonidazole staining (pimo, green), i.e. hypoxic areas. (B) Resulting masks for 
hypoxic (white) and non-hypoxic (gray) areas after thresholding and further processing. (C) Overlay of 
pimonidazole fluorescence image (green) and boundaries of identified hypoxia regions (magenta).  
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2.6.4.3  Perfusion classes and respective vessel densities 
Tumor regions were classified as highly-perfused, intermediately-perfused, and non-perfused 
based on the intensity of the cell nuclei staining by Hoechst 33342. A program was written in 
Matlab R2017b to automatically classify the tumor regions. 
Tumor masks were created from the cleared images of the three channels and read into the 
Matlab program along with the cleared Hoechst 33342 images.  
Intensity thresholds for perfusion classes were set manually after visual inspection of the 
images (8 bit images: i.e. intensity range from 0 to 255). Pixels with intensities higher than 
24 were assigned to the high-perfusion class, pixels with intensity lower than 10 were as-
signed to the non-perfused class. Pixels with intensity between 10 and 24 (including 10 and 
24) were classified as intermediately-perfused (Figure 10). 
The threshold for highly-perfused areas was applied to the cleared Hoechst 33342 images, 
the resulting high-perfusion image was blurred by a Gaussian filter (σ = 30), and an addition-
al threshold was applied to avoid an overestimation of the respective area due to blurring of 
the edges. A mask was generated for the highly-perfused area. 
The procedure was repeated for the non-perfused area: The threshold for non-perfusion was 
applied to the cleared image, followed by blurring of the resulting image with a Gaussian 
filter (σ = 30), and cutting off the blurred edges by an additional threshold. A mask for the 
non-perfused area was generated. Remaining unclassified pixels were assigned to the inter-
mediately-perfused class. 
Furthermore, the vessel density in the three perfusion classes was determined. To this end, 
the images of the segmented vessels (see section 2.6.4.1) were loaded into Matlab. Using 
bwconncomp.m, the number of vessels (connected components) was counted for each perfu-
sion class mask.  
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Figure 10 Illustration of the classification and quantification of perfused areas based on Hoechst 33342 fluores-
cence images. (A) Perfused areas of the tumor were stained by Hoechst 33342 (bright areas). (B) Masks for the 
three classes non-perfused (dark gray), intermediately-perfused (light gray), and highly-perfused (white) tumor 
areas were derived from the fluorescence image. (C) Overlay of the Hoechst 33342 fluorescence image and 
boundaries of the non-perfused (magenta) and highly-perfused (yellow) tissue areas. The remaining area was 
classified as intermediately-perfused.  
 
2.6.4.4  Proliferation rate based on BrdU incorporation 
The total number of cells (DAPI) and the number of cells that had incorporated BrdU were 
quantified using the open source software CellProfiler™ [144]. A script written by Dr. Jörg 
Peter was used to access CellProfiler™ on Linux. Furthermore, the script enabled automatic 
data processing of multiple and very large image files.  
Cleared BrdU images were trimmed and normalized using a script by Dr. Jörg Peter. Nor-
malized images were loaded into CellProfiler™ and processed with the parameters listed in 
Table 4. Those parameters had been optimized on a few randomly chosen exemplary images 
beforehand. Cell segmentations were saved in the images (Figure 11), and each image was 
visually checked for the quality of the segmentation. If necessary, respective images were 
further corrected or the parameters were slightly adapted. The same procedure was repeated 
for the DAPI images with the respective parameters listed in Table 4. Large images had to be 
quartered prior to segmentation in CellProfiler™. The proliferation rate was defined as the 
ratio between the number of BrdU-positive (BrdU
+
) cells and all cells (DAPI count). 
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Table 4 Parameters for cell segmentation and counting in CellProfiler™ for BrdU+-cells and DAPI+-cells. 
Parameter BrdU DAPI 
Typical minimum object diameter [px] 10 10 
Typical maximum object diameter [px] 50 50 
Object declumping method Shape Intensity 
Object declumping separation Shape Intensity 
Threshold strategy Adaptive Adaptive 
Threshold method Minimum variance Minimum variance 
Adaptive window size [px] 100 100 
Threshold smoothing scale 2.0 1.35 
Threshold correction factor 0.5 0.5 
Lower threshold bound 0.15 0.0 
Upper threshold bound 1.0 1.0 
 
 
 
Figure 11 Exemplary cell segmentation results from fluorescence images in CellProfiler™. (A) Fluorescence 
image of BrdU+-cells and (B) the respective DAPI stained cell nuclei. (C) Segmentation results (red lines) of 
BrdU+-cells in CellProfiler™. (D) Segmentation results (red lines) of DAPI stained cell nuclei in CellProfiler™. 
The proliferation rate was defined as the ratio of BrdU+-cells to DAPI stained cells. 
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2.6.4.5  DNA double-strand break classification  
The percentage of cells with DNA DSBs was determined based on the immunohistological 
staining for the histone γH2AX. Cells that stained positive for γH2AX were classified as 
high intensity cells and intermediate intensity cells (Figure 12). A script was written in 
Matlab R2017b to automatically classify and count the cells in the respective classes. 
Cleared γH2AX images were slightly smoothed by a Gaussian filter (σ = 1). Pixels of the 
8 bit images (intensity range from 0 to 255) with intensities lower than 7 were classified as 
background and eliminated leaving behind γH2AX-positive (γH2AX
+
) objects. Depending 
on the background signal, some parameters had to be adapted for individual images (num-
bers in brackets). Objects smaller than 15 (30) pixels were removed using bwareaopen.m. 
ImageJ was called from within Matlab using the implementation “MIJ: Running ImageJ and 
Fiji within Matlab” by D. Sage, which is available at the Matlab File Exchange [145]. The 
ImageJ plugin Watershed was applied to the background subtracted image to separate adher-
ent cells. bwareaopen.m was applied again to eliminate objects smaller than 20 (40) pixels, to 
eliminate small detached cell fragments. Individual cells were counted by bwconncomp.m. 
Finally, counted cells were separated into high and intermediate intensity cells: A threshold 
was manually set for high intensity cells based on the examination of multiple randomly 
chosen exemplary images. Counted cells with a mean intensity higher than 13 were classi-
fied as high intensity, the remaining cells were classified as intermediate intensity cells 
(Figure 12). 
The total number of cells was counted in the cleared DAPI images in CellProfiler™ (see 
section 2.6.4.4 and Table 4). The ratio between γH2AX high intensity cells and all cells, and 
the ratio between γH2AX intermediate intensity cells and all cells were reported. 
 
 
Figure 12 Illustration of the classification of γH2AX+-cells. (A) Fluorescence image of cells that stained posi-
tive for γH2AX. (B) Results of automated classification of these γH2AX+-cells into intermediate (cyan) and high 
intensity cells (yellow). 
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2.7 Longitudinal histology study of the AT1-tumor after 
irradiation  
The effects of curative single dose irradiations with either photons or 
12
C-ions on the vascu-
lature, hypoxic fraction, perfusion, DNA DSBs, and cell proliferation of the AT1-tumor were 
investigated longitudinally by histological methods. The results will be used to choose the 
optimal time points for future multimodal imaging studies. 
AT1-tumors were transplanted subcutaneously on the distal right thighs of adult male Co-
penhagen rats as described in section 2.1.3. Tumors were either investigated in a longitudinal 
manner after irradiation or in a volume-dependent manner without irradiation (non-irradiated 
controls).  
For the longitudinal treatment study, tumors were irradiated with curative doses of either 
37 Gy 
12
C-ions or 85 Gy photons when they reached a size of 10 mm × 10 mm. Animals 
were sacrificed 24 h, 3 days, 7 days, 10 days, 14 days (
12
C-ion RT only), and 21 days (
12
C-ion 
RT only) after irradiation (Figure 13). Each group consisted of five animals.  
 
 
Figure 13 Schematic illustration of the longitudinal histology study of the AT1-tumor. Tumors were irradiated 
with curative doses of either photons or 12C-ions when they reached a size of 10 mm × 10 mm (yellow flash). 
They were dissected and prepared for histology (histo) at the pre-defined time points. The 14 and 21 day time 
points were only performed for 12C-ion treated tumors. 
 
Tumors were dissected as described in section 2.6.1, and the immunohistochemistry stain-
ings that are listed in Table 5 were performed for one cryo slide per staining and tumor, re-
spectively. Due to logistic reasons the experiments were split and the data of the 14 and 21 
day groups with respective controls were obtained in a later separate experiment. Unfortu-
nately, the linear accelerator at DKFZ was not available anymore at that time point which is 
why those time points could only be performed for 
12
C-ion irradiation and not for photon 
irradiation. 
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Table 5 Histology and immunohistochemistry stainings which were performed on the AT1-tumors of the 
longitudinal histology study after irradiation, and references to the respective staining and quantification 
protocols. For the CD31/SMA and CD31/pimonidazole staining an additional slide per tumor was prepared and 
counterstained with DAPI. 
Staining Staining protocol Quantification protocol 
H&E 2.6.2.1 - 
CD31/SMA/ 
Hoechst 33342 (DAPI) 
2.6.2.4 (CD31/SMA)        
2.6.2.6 (Hoechst 33342) 
2.6.4.1 (Vascular density)  
2.6.4.3 (Perfusion) 
CD31/pimonidazole/ 
Hoechst 33342 (DAPI) 
2.6.2.5 (CD31/pimonidazole) 
2.6.2.6 (Hoechst 33342) 
2.6.4.2 (Hypoxic fraction) 
BrdU/DAPI 2.6.2.7 (BrdU) 2.6.4.4 (Proliferation) 
γH2AX/DAPI 2.6.2.9 (γH2AX) 2.6.4.5 (DNA DSBs) 
 
For the volume-dependent study, non-irradiated tumors were dissected at pre-defined sizes 
of 10 mm × 10 mm (n = 10, mean diameters: 9 - 10.75 mm), 15 mm × 15 mm (n = 10, mean 
diameters: 14.75 - 16 mm), 20 mm × 20 mm (n = 5, mean diameters: 19 - 21 mm), 
25 mm × 25 mm (n = 6, mean diameters: 21 - 24.25 mm), and 30 mm × 30 mm (n = 6, mean 
diameters: 24 - 29 mm). Tumors were stained for hypoxia (pimonidazole, see section 2.6.2.5 
for staining protocol and section 2.6.4.2 for quantitative analysis protocol). Results are re-
ported as mean ± standard error of the mean (SEM).  
2.8 Statistical analysis 
Longitudinal DCE-MRI study of the AT1-tumor after irradiation 
For the longitudinal DCE-MRI study of the AT1-tumor after irradiation (section 2.5.1), the 
Kruskal-Wallis test and post hoc Bonferroni correction were performed in Matlab R2017b 
on pooled DCE-MRI voxel results of the control and treatment groups per imaging time 
point. Due to the large number of voxels per group the significance level was set to 0.1 %. 
Differences in vessel density and vessel maturity between rim and core per treatment group 
were tested by the Mann-Whitney U test with a significance level of 5 %. Differences be-
tween vascular density and maturity in the rim and core were tested by one-way ANOVA 
with Bonferroni correction. The significance level was set to 5 %. 
 
Longitudinal histology study of the AT1-tumor after irradiation 
The Kruskal-Wallis test and post hoc Bonferroni correction for multiple testing were per-
formed to test for significant differences between all groups in Matlab R2017b. The signifi-
cance level was set to 5 %. 
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3 Results 
3.1 Photoacoustic imaging (PAI) 
PAI was used to characterize the initial oxygenation status of the three Dunning tumor sub-
lines H, HI, and AT1. To exploit the maximum potential of PAI, a new data analysis proto-
col was developed and validated. This was employed to obtain the sublines’ characteristic 
sO2-distributions and to investigate their behavior towards external changes in oxygen sup-
ply. The text, figures, and tables in section 3.1 and respective subsections were taken from 
reference [96] and have been originally written and created by myself. 
3.1.1 New protocol for the assessment of sO2-distributions  
Commercial PAI systems, such as the software VevoLab available at DKFZ, often only al-
low the evaluation of mean values of predefined regions of interest (ROI). However, tumors 
often exhibit highly heterogeneous structures, especially with respect to oxygenation. There-
fore, a protocol has been developed to assess pixel-based oxygen saturation (sO2-) distribu-
tions over entire 3D tumor volumes [96]. The following steps were performed on the beam-
formed raw PA data acquired at 750 nm and 850 nm and the calculated hemoglobin image 
which were exported from VevoLab and transformed into image stacks: 
I. Data filtering: A 3D Gaussian filter (σ = 2) was applied to the beam-formed PA raw data 
of both wavelengths using the image processing software ImageJ [142]. 
II. Oxygen saturation calculation: Employing eq. (1), sO2 was calculated pixel-wise from 
the PA signal at 750 and 850 nm using the molar extinction coefficients of de-oxygenated 
and oxygenated hemoglobin [146] in Matlab R2016a for each slice of the 3D image stack. 
III. Data thresholding: The hemoglobin image was calculated in VevoLab [90] and was 
then converted into a likelihood-map representing the probability that the signal of one pixel 
originated from hemoglobin. The likelihood-map was applied to the sO2 images in Matlab. 
Only pixels whose probability in the likelihood-map exceeded a predefined threshold were 
included into further analysis. Pixels whose probability was too low were set to zero. 
IV. Region of interest analysis: Tumor ROIs were delineated manually in every 5
th
 image 
of the 3D stack according to simultaneously acquired B-mode images. Remaining ROIs were 
generated using the ROI interpolation tool in ImageJ.  
V. sO2-histogram derivation: The sO2-values of all pixels within the ROIs were condensed 
into normalized histograms using a bin size of 0.5 %. For comparison of sO2-distributions, 
the median as well as the 25
th
 and 75
th
 percentiles (25
th
/75
th
) were extracted. Due to the 
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measurement uncertainty and noise, some of the measured sO2-distributions showed a negli-
gible amount of histogram entries above 100 % sO2. 
VI. Earth mover’s distance calculation: To quantify the similarity of two histograms, the 
Earth mover’s distance (EMD) [147-149], a recognized measure of distance between two 
probability distributions [150], was calculated. It represents the minimal cost of transferring 
one distribution into another, when the cost is defined as the sum of the histogram entries 
times the distance they have to be moved [151]. Recently, it has also been applied in various 
fields of biological and medical research [152-154]. For the present application in PAI, the 
EMD can be expressed as follows: 
8 =	 p|J(* −	J (*|u,N  (15) 
where J(*	and	J (* are the cumulative distribution functions of the probability densities 5	and	, respectively [148]. For identical distributions, the EMD is equal to 0, while the 
maximum EMD is 1, which is only the case for two single-bin histograms located at 0 % and 
100 % sO2. 
3.1.2 Dependency of sO2-distributions on signal gain and threshold 
To investigate the robustness of the resulting sO2-distributions towards measurement set-
tings, the effect of signal gain and thresholding on the resulting sO2-distributions were inves-
tigated on two HI-tumors. The sO2-distributions for both tumors for all tested settings are 
displayed in Figure 14, and the quantitative results (i.e. median and 25
th
/75
th
 percentiles) are 
summarized in Table 6. 
The tumor HI-1 exhibited a homogeneous PA signal with a clearly detectable skin line. Vis-
ual inspection of the normalized sO2-distributions revealed only minor differences in the 
shape of the distributions for the different settings (Figure 14, 1
st
 and 2
nd
 row). Regarding the 
25
th
/75
th
 percentile ranges, the distributions became slightly narrower with increasing thresh-
old, however, without affecting the medians (Table 6). Repeating the imaging procedure 
after repositioning the animal did not reveal any differences in shape, medians, and 25
th
/75
th
 
percentile ranges (Figure 14 and Table 6). Depending on the signal gain during measurement 
and threshold during analysis the number of pixels included into analysis ranged from 40 % 
to 100 %.  
Tumor HI-2, exhibited a very weak PA signal with a hardly detectable skin line, even at a 
signal gain of 40 dB. Table 6 reveals that even though medians were not affected, the shape 
and 25
th
/75
th
 percentile ranges of the sO2-distributions changed somewhat depending on 
threshold and signal gain (Figure 14, 3
rd
 and 4
th
 row): While the histograms at 0 % threshold 
were identical for all signal gains even after repositioning of the animal (Figure 14 and Table 
6), a large variability was observed for higher thresholds, especially in combination with a 
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low signal gain. Under these conditions only a negligible fraction of pixels with signals near 
the noise-level could be analyzed (e.g. only 10 % of the pixels for all three signal gains at a 
threshold of 30 %). To obtain reliable and reproducible results, it is therefore important to 
adjust the measurement settings, especially the signal gain, individually for each animal and 
each imaging session. The skin layer had been selected as a reliable reference for those ad-
justments.  
 
Table 6 Medians and 25th/75th percentiles of the PAI sO2-distributions for the investigated combinations of 
signal gain and threshold. Values are given for two HI-tumors (small and large volume) and two independent 
positions of the animal (Repos = second positioning). The asterisk (*) indicates measurements where the percent-
age of pixels unequal to zero was below 10 % resulting in sO2-distributions which are not anymore representative 
for the tumor. Table reproduced from [96] under the CC BY 4.0 license.  
   HI-1 (600 mm3)  HI-2 (740 mm3) 
Gain Threshold  sO2 median sO2 median 
Repos 
 sO2 median sO2 median 
Repos 
[dB] [%]  [25 %, 75 %]     [25 %, 75 %]    [25 %, 75 %]   [25 %, 75 %] 
36 0 88 [83, 90] 86 [83, 88]  46 [39, 52] 50 [42, 57] 
36 15 89 [85, 91] 86 [83, 88]  44 [32, 59] 49 [36, 65] 
36 30 90 [87, 91] 87 [84, 89]  44 [29, 74]* 61 [34, 83]* 
38 0 88 [84, 91] 86 [83, 88]  46 [38, 52] 47 [39, 56] 
38 15 89 [84, 91] 86 [83, 88]  44 [33, 54] 45 [34, 58] 
38 30 89 [86, 91] 87 [85, 89]  43 [29, 70]* 50 [27, 76]* 
40 0 86 [82, 88] 87 [84, 90]  47 [39, 53] 47 [38, 55] 
40 15 86 [81, 89] 87 [84, 90]  45 [35, 53] 44 [35, 55] 
40 30 87 [83, 89] 88 [85, 90]  45 [31, 68]* 45 [28, 71]* 
 
3 Results 
46 
 
 
Figure 14 Normalized PAI-derived sO2-distributions of two HI-tumors for three signal gains and three thresh-
olds at two positions of the animals. Tumor HI-1 exhibited sO2-distributions that were essentially independent of 
all measurement settings. The large tumor HI-2 (rows 3 and 4) exhibited identical sO2-distributions for a 0 % 
threshold only. With increasing threshold, the variability of the distribution increased due to the very low number 
of evaluated pixels. Figure reproduced from [96] under the CC BY 4.0 license.  
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3.1.3 Characterization of the tumor sublines H, HI, and AT1  
The oxygenation status of the three Dunning tumor sublines H, HI, and AT1 was character-
ized by PAI experiments with the new developed data analysis protocol (section 3.1.1).  
3.1.3.1  Characteristic sO2-distributions per tumor subline 
Figure 15 displays the pooled sO2-distributions of two tumors of comparable size per subline 
while the animals were breathing air. The well oxygenated H-tumor exhibited a narrow and 
well-defined peak with a median of 73 % (25
th
/75
th
 percentile range: 69 %/ 76 %). Similarly, 
the HI-tumor exhibited a median of 71 % with a somewhat wider distribution (25
th
/75
th
 per-
centile range: 62 %/ 76 %). By contrast, the distribution of the AT1-tumor was located 
around a median of 40 % and exhibited a different shape, however, with a comparable 
25
th
/75
th
 percentile range (34 %/ 47 %). 
 
 
Figure 15 Pooled normalized sO2-distributions of two tumors per subline while animals were breathing air. The 
sublines show clearly distinguishable sO2-distributions for the H-, HI-, and AT1-tumor. Figure reproduced from 
[96] under the CC BY 4.0 license. 
 
 
3.1.3.2  Temporal development of sO2-distributions per tumor subline 
PAI was repeated several times over a period of up to 41 days and, as an example, sO2-
distributions at different time points are displayed in Figure 16 A - C. Median values and 
25
th
/75
th
 percentiles for all measurement time points are provided in Table 7.  
Repeating the measurement, the tumor H-2 (Figure 16 A) essentially maintained the shape of 
the distribution; however, the distributions shifted slightly towards lower sO2-values with 
time. During the observation period, the volume of this tumor did not change (Figure 16 D). 
For tumor H-1, the width of the sO2-distribution increased slightly and the median values 
shifted slightly towards higher sO2-values (Table 7). 
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Tumor HI-3 exhibited a more heterogeneous sO2-distribution with a peak at high sO2-values 
at day 1, which then became broader with an increasing fraction of pixels at low sO2-values 
(< 40 % sO2, Figure 16 B). While the peak of the tumor did not shift significantly, the frac-
tion of low sO2 pixels changed considerably with time. Figure 16 E illustrates the sO2-
distributions of the same tumor when the animal was breathing 100 % O2. This tumor exhib-
ited an increased heterogeneity as compared to the air-breathing condition. Distinct regions 
of different sO2 levels can be identified in the respective color maps (Figure 16 F). The 
strong reduction of pixels with low sO2-values at day 41 spatially correlates with the occur-
rence of the central region without PA signal.  
Although the volumes of the AT1-tumors increased up to sevenfold in 12 days (Figure 
16 D), their sO2-distributions experienced only minor changes in sO2 medians and 25
th
/75
th
 
percentile ranges (Figure 16 C, Table 7). 
 
 
Figure 16 Temporal development of sO2-distributions for one tumor per subline: (A) H-2, (B) HI-3, and (C) 
AT1-1 tumor, imaged when the animals were breathing air. Results at other time points and for additional tumors 
are given in Table 7. (D) Development of tumor volume with time. As tumor HI-4 was only imaged once, it is not 
listed in D. Black circles indicate imaging time points that are depicted in A - C. (E) sO2-distributions and (F) 
representative sO2 color maps of tumor HI-3 when the animal was breathing 100 % O2. Figure reproduced from 
[96] under the CC BY 4.0 license. 
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Table 7 Summary of oxygen challenge and clamping experiments for the H-, HI-, and AT1-tumor and the 
skin. Results are displayed as median and 25th/75th percentiles for each tumor and skin for each oxygenation 
condition. Table reproduced from [96] under the CC BY 4.0 license. 
Animal   Day Size 
[mm
3
] 
100 % O2 pre Air 100 % O2 post 100 % O2 
clamped 
100 % O2             
post clamping 
H        
H-1 Day 1 40  68 [65, 71]    
 Day 9
a
 50 93 [87, 97]
b
 73 [70, 76]
b
 96 [91, 99] 57 [48, 68]
b
 96 [91, 98] 
 Day 14 40 84 [75, 92] 76 [69, 81] 85 [75, 93] 36 [29, 42] 97 [92, 100] 
H-2 Day 1 20 92 [88, 96] 78 [74, 81]    
 Day 11 20 94 [89, 97]
b
 72 [67, 75]
b
  50 [42, 58]
b
  
 Day 17 40  66 [62, 68]    
HI        
HI-3 Day 1 80 75 [57, 91] 66 [56, 77]  30 [21, 45] 87 [62, 96] 
 Day 6 140 92 [73, 97] 82 [64, 82] 91 [76, 96] 25 [18, 41] 96 [76, 96] 
 Day 15 250 83 [60, 94] 68 [53, 78] 73 [53, 88] 23 [15, 43] 83 [60, 94] 
 Day 21
a
 320 69 [49, 85] 61 [45, 72] 70 [53, 85] 37 [29, 50] 74 [54, 89] 
 Day 31 460 85 [71, 93]
b
 72 [60, 79]
b
 82 [64, 91] 43 [35, 55]
b
 73 [54, 89] 
 Day 41 770 84 [68, 91] 70 [61, 76] 79 [67, 88] 28 [18, 47] 79 [66, 90] 
HI-4
c
 Day 1 580 85 [82, 91] 71 [64, 74]  25 [17, 35] 87 [81, 93] 
AT1        
AT1-1 Day 1 110 40 [35, 46] 40 [36, 45] 41 [36, 47] 43 [35, 50] 43 [38, 49] 
 Day 4
a
 330 41 [36, 47]
b
 40 [36, 45]
b
 42 [37, 49] 42 [37, 46]
b
 40 [36, 44] 
 Day 12 580 37 [31, 44] 37 [32, 43] 38 [32, 45] 40 [30, 48] 42 [36, 49] 
AT1-2
d
 Day 1 460 42 [35, 49]
b
 40 [32, 48]
b
    
 Day 4 1100 45 [38, 51] 46 [39, 52]    
 Day 12 3300 45 [39, 51] 44 [38, 51]    
Skin        
Skin-1 - - 83 [69, 92]
b
 67 [56, 75]
b
 77 [63, 86] 16 [12, 22]
b
 63 [53, 73] 
Skin-2
a
 - - 82 [67, 91]
b
 69 [58, 77]
b
 78 [66, 87] 18 [12, 27]
b
 84 [73, 90] 
 
a Distribution displayed in Figure 17 middle column. 
b Data included in pooled distributions in Figure 17 left column. 
c Animal could only be imaged once due to scab formation on the skin. 
d Location of the tumor did not allow clamping experiment. 
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3.1.3.3  Sensitivity of tumor sublines to external changes in oxygen supply 
Figure 17 displays the changes in sO2-distributions for the three tumor sublines as well as for 
the skin when changing the external oxygen supply of the animals. For each of the cases, 
pooled data of two tumors (left column) and one exemplary full experiment performed in a 
single tumor (middle column) are shown. All medians and 25
th
/75
th
 percentiles are listed in 
detail in Table 7. 
After switching the external gas supply from 100 % O2 to air, the PA-signal of the H-tumor 
immediately shifted to lower sO2-values while still maintaining its narrow and well-defined 
peak (Figure 17 A, B and Table 7). When clamping the tumor-supplying arteries, the sO2-
distribution shifted to even lower values, while broadening significantly although the ani-
mals were still breathing 100 % O2. When executing the full oxygen challenge experiment 
(Figure 17 B), the initial sO2-distributions were restored after switching back from air to 
100 % O2 (“100 % O2 post”) and after releasing the clamping (“100 % O2 post clamping”), 
respectively.  
When changing the external oxygen supply from 100 % O2 to air, the broad sO2-distributions 
of the HI-tumors were shifted to lower values (Figure 17 C, D). Clamping of tumors led to 
further shift and broadening of the peak. Again, when performing the full oxygen challenge 
experiment (Figure 17 D), the initial sO2-distributions were essentially restored after switch-
ing back from air to 100 % O2 and after releasing the clamping, respectively.  
In contrast to the H- and HI-tumors, essentially no differences were detected for the sO2-
distributions of the AT1-tumors after switching from 100 % O2 to air and after clamping 
(Figure 17 E, F). 
The skin showed a broad distribution at high sO2-values when the animals were breathing 
100 % O2 (Figure 17 G, H). When switching to air, the peak of the distribution was shifted to 
lower sO2 and clamping lead to a further significant shift and broadening of the distributions. 
Again, when performing the full oxygen challenge experiment (Figure 17 H), the initial sO2-
distributions were essentially restored after switching back from air to 100 % O2 and after 
releasing the clamping, respectively. 
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Figure 17 sO2-distributions of oxygen challenge and clamping experiments for each of the three sublines and the 
skin (reference tissue). Pooled sO2-distributions per subline and exemplary distributions of the full experiment for 
single animals: (A) H (20 and 50 mm3), (C) HI (460 and 580 mm3), (E) AT1 (330 and 460 mm3, for the 
“clamped”-measurement, the distribution represents only AT1-1), and (G) the skin. Exemplary full oxygen 
challenge experiments performed for a single tumor per subline and the skin of one animal are shown in the 
middle column (B, D, F, H). The right column displays representative frames from 3D PAI sO2 measurements 
which illustrate the characteristics of the response of the tumors after external changes in O2 supply. The highly 
non-uniform response of the HI-tumor exhibiting regions without changes during oxygen challenge (e.g. low sO2 
region in the center of the tumor) and responding regions in the periphery of the tumor (with high initial sO2) 
should be noted. Figure reproduced from [96] under the CC BY 4.0 license. 
 
Changes of the sO2-distributions during the oxygen challenge experiment were quantified by 
the similarity measure EMD (Figure 18). Using the first measurement, where animals were 
breathing 100 % O2, as a reference it can be clearly seen that all other measurements with 
100 % O2 exhibit very low EMD-values (i.e. high similarity), while air breathing and even 
more clamping exhibited much larger values (decreasingly low similarity). The AT1-tumor 
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on the other hand showed no response to any external changes and their EMDs remained 
below 0.05 for all experiments. 
 
 
Figure 18 The similarity measure earth mover’s distance (EMD) for the oxygen challenge experiment: The 
EMD was calculated for all sO2-distributions measured for the three tumor sublines and the skin using the sO2-
distributions of the first measurement with 100 % O2 (“100 % O2 pre”) as reference. Figure reproduced from [96] 
under the CC BY 4.0 license. 
 
3.1.4 Histology and immunohistochemistry 
After the final imaging tumors were dissected and prepared for immunohistochemistry. Fig-
ure 19 displays representative stainings of these tumors. The H-tumor showed to be highly 
differentiated with glandular structures comparable to normal prostate glands (Figure 19 A) 
and exhibited mature vessels (Figure 19 D, G). The whole tumor was well perfused, indicat-
ed by a uniformly distributed Hoechst 33342 staining. Both H-tumors exhibited only a small, 
locally confined hypoxic region (Figure 19 D). Apart from those locally confined areas both 
tumors were negative for pimonidazole. 
The moderately differentiated HI-tumor contained mucin secreting glandular structures 
(Figure 19 B) with immature vessels, though not all of them were perfused (Figure 19 E, H). 
Hypoxic areas were found to surround vessels at a certain distance (Figure 19 H).  
The anaplastic AT1-tumor exhibited only capillaries, but no mature vessels, and showed to 
be completely undifferentiated without any prostate-specific cells (Figure 19 C). The entire 
tumor was pervaded by very short and thin capillaries of which only a minority was perfused 
(mainly at the periphery of the tumor) (Figure 19 F, I). Additionally, prominent hypoxic are-
as were found (Figure 19 F, I).  
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Figure 19 Histological images of the H-, HI-, and AT1-tumors (left, middle, and right column, respectively): 
(A - C) H&E staining revealed tumor morphology. Scale bars 500 µm. (D - F) Whole-mount fluorescence images 
of tumors stained for vessels (CD31, red), hypoxia (pimonidazole, green), and perfusion (Hoechst 33342, blue). 
Scale bars 1000 µm. (G - I) Close-ups of the marked areas in D - F. Scale bars 500 µm. Figure adapted from [96] 
and used under the CC BY 4.0 license. 
 
3.2 DCE-MRI: a novel method for bolus arrival time (BAT) 
estimation 
A new spline-based method for bolus arrival time (BAT) estimation was developed. It is 
required for delay correction of DCE-MRI data prior to pharmacokinetic modeling to ensure 
accuracy of the resulting fit parameters. This project was realized in cooperation with Dr. 
Martin Storath from the group for Image Analysis and Learning of the Interdisciplinary Cen-
ter for Scientific Computing of Heidelberg University. The text, figures, and tables in section 
3.2 and respective subsections were taken from reference [117].  
3.2.1 The new approximation model for BAT estimation 
The text in subsection 3.2.1 was taken from reference [117] and has been originally written 
jointly by Dr. Martin Storath and me. The images of the DCE-MRI measurement are as-
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sumed to be acquired at time points )m	(~ = 1, 2, … ,*. After a number of images, the CA is 
given as a bolus. In the following it is assumed that the MR-signal intensities are already 
converted into concentrations of the contrast agent (CA). (However, the proposed method is 
also applicable to the MR data before conversion to concentration.) Thus, the given data nm 
are noisy samples of a true tissue concentration curve (TCC) -()*: 
nm =	-()m* +	m,									for	~ = 1,… ,	, 
where the m represent error terms. For simplicity, it is focused on the case of uniformly 
sampled time points, i.e. )m = (~ − 1*∆), noting that the proposed method could also be 
extended to the more general case of unevenly sampled time points.  
The goal is to estimate the BAT )BAT from the noisy data nm which is the time point where 
the true TCC, -()*, starts to rise. It should be noted that )BAT does not necessarily coincide 
with one of the sample time points )m. The BAT naturally divides a TCC into two parts: Pri-
or to the bolus arrival, the TCC is constant-valued at zero (unless previous boluses were 
injected), whereas after the BAT, it rises and adopts different shapes depending on the un-
derlying physiology.  
This discussion on the characteristics of a TCC motivates to approximate a TCC by a contin-
uous function that is constant on the interval [), )BAT], and by a smooth function that is able 
to adapt to the concentration curve on [)BAT, )k]. A suitable type of such smooth functions 
are smoothing splines (see section 2.4.4.1). 
Thus, it is proposed to approximate the TCC by a function j∗ that is constant until the (un-
known) BAT, )BAT, and a smoothing spline afterwards. The function j∗ is defined by the 
minimizing condition  
j∗ =	argmin l(j()m* − nm* + 	op (j(r*(s**us,OvOBAT
k
mw  
subject to j is constant on [), )BAT]. 
(16) 
A graphical illustration is given in Figure 20. As the approximation function j∗ is not re-
quired to be smooth at the joint, it typically has a kink at )BAT. 
Since j is constant on [), )BAT], eq. (16) can be reduced to  
j∗ =	argmin l(j()+* − nm* + l (j()m* − nm*
k
mwk + 	op qj(r*(s*t
 us,OvOBAT
k
mw  
(17) 
where 	is the index of the last time frame before	)BAT; that is,  = max{~: )m ≤ )BAT}. 
There is a simple relation between the solutions of the constrained variant in eq. (16) and that 
of the unconstrained variant in eq. (17):  
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j∗()* = 	j∗()BAT*	for	)	 ∈ [), )BAT]						and							j∗()* = 	j∗()*	for	) ∈ ()BAT, )k]. (18) 
The principal interest is to estimate the parameter )BAT from the concentration curve. Along-
side the estimation of )BAT, the spline parameters o and L have to be determined as well be-
cause these are needed for adapting the model to the curve shape after the BAT. All three 
parameters will be estimated automatically (section 3.2.3).  
 
 
Figure 20 Graphical illustration of the proposed approximation model for bolus arrival time (BAT) estimation 
(eq. (16)). The given noisy TCC data (blue crosses) are approximated by a continuous piecewise defined function j∗. It is a constant function before the BAT, )BAT, and afterwards a smoothing spline which is able to adapt to the 
shape of the curve by adjusting its stiffness parameters o and L. An estimate for )BAT is determined automatically 
along with suitable spline stiffness parameters o and L by generalized cross validation. It should be noted that )BAT does not need to coincide with one of the sample times ), … , )k. ©Institute of Physics and Engineering in 
Medicine. Reproduced with permission from [117]. All rights reserved. 
 
3.2.2 Discretization and computation of the approximating function 
The text in subsection 3.2.2 was taken from reference [117] and has been originally written 
jointly by Dr. Martin Storath and me. To numerically compute the approximating functions, 
the optimization problem in eq. (17) is discretized. First, a finite difference approximation of 
the k
th 
 derivative j(r* is employed. A natural choice for the set of discretization nodes  are 
the BAT and the subsequently sample time points, i.e.  = ()BAT, )k, )k, … , )k*. Let I 
be the vector that contains the ordinates of j  at these discretization nodes; that is, I =j(*	for	 = 1,…	, D	with	D =  −  + 1. A first order finite difference approximation of 
the k
th
 derivative is given by 
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j(r*(* ≈ 	l(r,OBAT*I,	for	 = 1,… , D − L,rNw'  (19) 
where the (r,OBAT* ∈ ℝ are weights which are specified in the following. First, note that the 
weights depend on )BAT because the first discretization node coincides with )BAT. Determin-
ing the weights (r,OBAT* is a standard procedure; see e.g. [155]. Further, the integral in eq. 
(17) is approximated by a Riemannian sum. In summary, the following discretized problem 
is obtained: 
I∗ = argmin\∈ℝ l(I − nm* + l (ImNk − nm*
k
mwk
k
mw
+ ol( − * Ql(r,OBAT*IrNw' W
Nr
w 	 . 
(20) 
Just as	I∗ is a discrete approximation to the continuous function j∗, the expanded vector I∗ = (I∗, … , I∗, I∗, … , I∗* (of length ) is a discrete approximation to j∗.  
Eq. (20) is a least squares problem in I. Reformulated in matrix notation:  
I∗ = argmin\∈ℝ 	‖&I − n‖ + o‖¡¢I‖ (21) 
where ‖I‖ denotes the squared Euclidean norm, ‖I‖ = ∑ Imm , and the involved matrices 
are as follows. ¡ is a diagonal matrix with the entries ¡ = ¤ −  	for	 = 1,… , D − L. 
The matrix & ∈ ℝk× is defined by   
& = ¥¦kNM+8 §	, (22) 
where ¦kN = (1,… , 1*+ denotes a vector of ( − 1* ones, M+ = (1, 0, … , 0* is the first 
unit vector in ℝkN and 8 is the identity matrix of size D. Further, Ω implements the dis-
crete approximation to the LO© derivative given in eq. (19). It is explicitly given by ¢, =(r,OBAT* for  = 1,… , D, ª = 0,… , L − 1, and zero otherwise. For readability, the dependence 
of the involved matrices on )BAT and L are omitted in the following notation. 
A standard computation (differentiation of the functional in eq. (21) with respect to I and 
setting it equal to zero) reveals that I∗ is the solution of the linear system 
(&+& + o(¡¢*+¡¢*I∗ = &+n. (23) 
Solving this equation for I∗ and using the relation I∗ = &I∗ gives the explicit solution 
I∗ = (OBAT,«,r*n, (24) 
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where (OBAT,«,r* ∈ ℝk×¬ is the influence matrix given by  
(OBAT,«,r* = &(&+& + o(¡¢*+¡¢*N&+	. (25) 
 depends on )BAT, on o, and on L because the right hand side in eq. (25) does so.  
3.2.3 Parameter estimation by generalized cross validation 
The text in subsection 3.2.3 was taken from reference [117] and has been originally written 
jointly by Dr. Martin Storath and me. The principal interest is to determine the BAT by esti-
mating the parameter )BAT. For this, the spline parameters o and L need to be estimated as 
well, because these affect the adaption of the model to the curve shape after the BAT. A 
widely used approach for determining such parameters is generalized cross validation (GCV) 
[125, 156] which has shown to provide good performance for spline-based estimators [157, 
158]. The GCV score is a ratio of the mean squared error (MSE), given by ‖I∗ − n‖/, 
and a quantity based on the degrees of freedom (DOF) of the estimator. As the proposed 
model leads to a linear estimator, the DOF coincide with the trace of the influence matrix (OBAT,«,r*. Thus, the GCV score has the explicit form 
GCV(n; )BAT, o, L* = MSEq1 − 1DOFt
=	 1 ·(OBAT,«,r*n − n·	q1 − 1 trace	(OBAT,«,r*t
	. (26) 
The optimal set of parameters ()BAT∗ , 5∗, L∗* in the sense of GCV is the one that provides the 
minimum GCV score: 
()BAT∗ , 5∗, L∗* = argminOBAT,«,r GCV(n; )BAT, o, L*	, (27) 
where )BAT is searched in the continuous interval [), )kNr], o in the continuous interval [0,∞*, and L in a set of positive integers {Lmin, … , Lmax}. For the considered TCCs, Lmin = 3 
and Lmax = 6 gave satisfactory results. A minimizer )BAT∗  is the proposed estimate of BAT. 
Further technical information can be found in reference [117]. A reference implementation is 
provided online at https://github.com/mstorath/DCEBE. 
3.2.4 Assessment of BAT estimation accuracy on simulated data 
The text, tables, and figures in subsection 3.2.4 and respective subsections were taken from 
reference [117] and have been originally written and created by myself. 
3.2.4.1  BAT estimation on simulated rat data 
BAT estimation accuracy of the new method was evaluated on data that was simulated with 
the impulse response functions of the extended Tofts model (ETM) and the two compartment 
exchange model (2CXM) providing data with known ground truth (section 2.4.4.2). Exem-
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plary fits by the proposed method to one TCC type for all temporal resolutions and noise 
levels are displayed in Figure 21. Results for all TCCs and all configurations are displayed in 
Figure 22 along with the results from the state-of-the-art method by Cheong et al. [123].  
Cheong’s method provided accurately estimated BATs for AIFs with high temporal resolu-
tions. The accuracy was diminished for AIFs with low temporal resolutions. For curves with 
a less significant peak in the vicinity of the BAT, such as TCC type 3 for the ETM and TCC 
type 1 for the 2CXM, the estimated BATs were relatively far off the ground truth and were 
scattered over a wide range. Cheong’s method gave poor results for estimated BATs of the 
remaining TCCs. 
The proposed method gave comparable results for the AIFs at high temporal resolutions and 
performed better for the AIFs at the lowest temporal resolution. For the TCCs, the proposed 
method could precisely estimate BATs of all shapes, and the results were robust towards 
increased noise levels and low temporal resolution of the input data. In most cases, the esti-
mated BATs did not exhibit much variability as indicated by the small range between the 
5 % and 95 % percentiles. A slight overestimation of BATs was observed for TCCs simulat-
ed with the 2CXM, which exhibited a shallow initial rise in concentration. In almost all con-
figurations the proposed method significantly improved the accuracy of BAT estimation 
upon the state-of-the-art method for the tested TCCs. 
 
 
Figure 21 Exemplary results for BAT estimation in rats: type 3 TCCs (black dots) simulated with the extended 
Tofts model (ETM) are displayed for all temporal resolutions (columns) and signal-to-noise ratios (SNRs, rows) 
together with the respective fit by the proposed method (red line) and estimated BAT (green circle). ©Institute of 
Physics and Engineering in Medicine. Reproduced with permission from [117]. All rights reserved. 
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Figure 22 Illustration of the accuracy of BAT estimation for rat data simulated with the ETM and the 2CXM, 
varied for various signal-to-noise ratios (SNRs) and temporal resolutions (∆ t). Results are presented as medians 
with 5 % and 95 % percentiles of 1000 repetitions of BAT estimation per TCC type with the proposed method 
(blue symbols) and Cheong’s method (red symbols). The green line indicates the true BAT. ©Institute of Physics 
and Engineering in Medicine. Adapted with permission from [117]. All rights reserved.  
 
3.2.4.2  BAT estimation on simulated patient data  
The BAT estimation accuracy was also tested on simulated patient data and was compared to 
the BATs estimated by Cheong’s method (Figure 23). Cheong’s method gave accurately 
estimated BATs with only small variation for low temporal resolution TCCs. Some major 
variation in the obtained results could only be observed for data simulated with the 2CXM at 
the lowest SNR. Cheong’s method performed equally well for all simulated patient TCCs. 
The proposed method gave results close to the ground truth with a slight overestimation of 
BATs for low SNR TCCs and data simulated with the 2CXM. Thus, for patient data, the 
proposed method gave competitive results, yet Cheong’s method performed slightly better. 
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Figure 23 Illustration of the accuracy of BAT estimation for patient data simulated with the ETM and the 
2CXM, varied for various signal-to-noise ratios (SNRs) and temporal resolutions (∆ t). Results are presented as 
medians with 5 % and 95 % percentiles of 1000 repetitions of BAT estimation per TCC type with the proposed 
method (blue symbols) and Cheong’s method (red symbols). The green line indicates the true BAT. ©Institute of 
Physics and Engineering in Medicine. Adapted with permission from [117]. All rights reserved. 
 
3.2.5 Assessment of BAT estimation accuracy on in vivo data 
The text, tables, and figures in subsection 3.2.5 were taken from reference [117] and have 
been originally written and created by myself. 
Finally, the proposed method for BAT estimation was validated on in vivo DCE-MRI data of 
five HI-tumor bearing rats from the longitudinal DCE-MRI study (section 2.5.2). The BATs 
were estimated for each voxel of the ten tumors (Table 8). DCE-MRI curves of animal 2 with 
estimated BATs for both tumors and the AIF are displayed as exemplary results in Figure 24. 
The compared methods estimated virtually identical BATs for the rats’ AIFs (Table 8 right 
column, Figure 24 E, F). However, for the TCCs the BATs estimated by Cheong’s method 
are implausible as almost all of them were estimated to occur even before the lower bound of 
injection times. The adapted version of Cheong’s method which excludes implausible sam-
ple points below the lower bound of 25.37 s for BAT estimation (see section 2.4.4.3) resulted 
in this lower bound in most cases. However, visual inspection reveals that the TCCs did not 
rise significantly before approximately 35 s. This means that the results of the adapted ver-
sion remained uninformative in most cases.  
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The BATs estimated by the proposed methods were very close to each other within one ani-
mal and appeared to be at reasonable time points by visual inspection (Table 8, Figure 24 A -
D). Despite the noticeable variation in TCC shapes occurring even within one tumor, the 
proposed method fitted all curves equally well and estimated reasonable BATs. It is noted 
that the proposed method does not require a lower bound of injection times as a priori in-
formation.  
 
Table 8 Estimated BATs for five HI-tumor bearing rats of the longitudinal DCE-MRI study (in seconds) by 
Cheong's original and adapted approach and the proposed method. For the tumor TCCs, the medians and 5 % and 
95 % percentiles are reported. The second and the third column indicate the number of evaluated voxels (i.e. 
TCCs) in the right and in the left tumor, respectively. For Cheong’s adapted method a plausible lower boundary 
of 25.37 s was chosen. Table reproduced from [117]. 
Animal MR ML Method Right tumor  Left tumor  AIF 
1 18 94 Cheong et al. 0.00 [0.00, 4.93] 0.00 [0.00, 6.57] 34.33
   Cheong et al. (adapt.) 25.37 [25.37, 25.37] 25.37 [25.37, 25.37] 34.33
   Proposed 37.13 [36.24, 37.77] 36.63 [35.64, 37.75] 34.36
2 13 39 Cheong et al. 0.00 [0.00, 19.93] 0.00 [0.00, 11.42] 32.09
   Cheong et al. (adapt.) 25.37 [25.37,128.77] 25.37 [25.37, 25.37] 32.09
   Proposed 36.17 [35.14, 37.29] 35.54 [34.61, 36.19] 32.04
9 7 31 Cheong et al. 0.00 [0.00, 0.00] 0.00 [0.00, 6.68] 32.84
   Cheong et al. (adapt.) 25.37 [25.37, 25.37] 25.37 [25.37, 25.37] 32.84
   Proposed 35.47 [34.88, 36.04] 35.41 [34.60, 36.60] 32.82
12 32 26 Cheong et al. 0.00 [0.00, 0.00] 0.00 [0.00, 4.63] 33.58
   Cheong et al. (adapt.) 25.37 [25.37, 25.37] 25.37 [25.37, 25.37] 33.58
   Proposed 36.90 [35.00, 38.28] 36.81 [35.94, 37.86] 33.81
13 13 7 Cheong et al. 0.00 [0.00, 13.92] 0.00 [0.00, 14.18] 30.60
   Cheong et al. (adapt.) 25.37 [25.37, 25.37] 25.37 [25.37, 25.37] 30.60
   Proposed 33.32 [33.04, 34.10] 33.47 [33.22, 33.86] 30.50
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Figure 24 Exemplary pixel-based concentration curves of animal 2 with HI-tumors: (A) right tumor with close-
up of the BAT region (B); (C) left tumor with close-up of the BAT region (D); (E) AIF and close-up of the BAT 
region (F). BATs estimated by the proposed method, by Cheong's original approach, and by Cheong’s adapted 
approach are marked by green and yellow circles and blue squares, respectively. The black arrows indicate the 
lower boundary used for the injection times (needed for the adapted version of Cheong’s method). ©Institute of 
Physics and Engineering in Medicine. Reproduced with permission from [117]. All rights reserved. 
 
3.3 Longitudinal DCE-MRI study of the AT1-tumor after 
irradiation 
A longitudinal DCE-MRI study was performed to gain initial quantitative information on the 
impact of high single dose 
12
C-ion irradiation compared to photon irradiation on vascular 
damage and perfusion in the anaplastic AT1-tumor (section 2.5.1). The experiments had 
been planned and conducted by Dr. Christin Glowa while the evaluation of the data has been 
performed by myself. The text and figures in section 3.3 und respective subsections were 
taken from reference [135] and have been originally written and created by myself.  
3.3.1 Tumor growth after irradiation 
Non-irradiated control tumors grew rapidly reaching more than 9 times their initial volume 
after 21 days (Figure 25). After RT, tumor volumes increased further until day 7 for all 
treatment groups before their growth stagnated.  
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Figure 25 Relative tumor volumes of AT1-tumors up to 21 days after irradiation with either photons or 12C-ions 
derived from 2-weighted images. Tumor volumes were pooled, i.e. n = 3 for treatment groups and n = 12 for 
control groups per time point. The field of view for 2-weighted imaging was kept at constant size over all meas-
urements which resulted in control tumors exceeding the field of view at the last imaging time point. Hence, 
reported control tumor sizes are underestimated. Data is displayed as mean ± standard deviation. Figure repro-
duced from [135]. Data was acquired by Dr. Christin Glowa.  
 
3.3.2   Non-compartment analysis and pharmacokinetic modeling 
DCE-MRI data was fit with the ETM as described in sections 2.4.6 and 2.4.7. 21 days after 
RT, control tumors had developed central non-perfused areas like the area of no CA en-
hancement in the 1-weighted images and the deep blue voxels in the tumor parameter maps 
(Figure 26). At this time point parameter maps of photon treated tumors were rather hetero-
geneous compared to the 
12
C-ion treated groups.  
Non-irradiated control tumors experienced decrease in all four parameters (normalized AUC, Ktrans, Ie, and Ip) over the five imaging time points (Figure 27) and exhibited significantly 
different parameter distributions than the treated tumors (see Appendix A.1, Table 9, for 
detailed results of statistical analyses). This decrease was especially apparent in Ktrans and Ip.  
Overall, irradiated tumors experienced an increase in normalized AUC over the observation 
period (Figure 27 A). 3 days after RT the normalized AUC in 
12
C-ion treated tumors in-
creased significantly as compared to the controls and the photon treated groups whose in-
crease was prolonged to day 7 (37 Gy) or day 21 (85 Gy) after RT. This delay in treatment 
response was even more distinct in the temporal development of the parameter Ktrans com-
prising perfusion and permeability (Figure 27 B). 
12
C-ions induced strong changes indicated  
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Figure 26 1-weighted MR-images of AT1-tumors after contrast agent injection along with their calculated 
ETM parameter maps from DCE-MRI measurements for one representative tumor per group at three designated 
time points. For this illustration, some 21 day results had to be replaced by 14 day results as the corresponding 
21 day results suffered from measurement artefacts. Ktrans = volume transfer constant, Ie = extravascular, extra-
cellular volume fraction, Ip = plasma volume fraction. Figure reproduced from [135]. Measurements were per-
formed by Dr. Christin Glowa. 
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Figure 27 Pooled longitudinal results of voxel-wise non-compartment analysis and pharmacokinetic modeling 
after irradiation for 3 AT1-tumors per treatment group and 12 controls. Estimated parameters are (A) the normal-
ized area under the curve (AUC), (B) the volume transfer constant Ktrans, (C) the extravascular, extracellular 
volume fraction Ie, and (D) the plasma volume fraction Ip. Box plots (25/75 % percentiles) are displayed with 
medians (line), 10/90 % percentiles (whiskers), and 5/95 % percentiles (dots). Figure adapted from [135]. 
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by significantly increased Ktrans values already 3 days after RT. The large variations in pa-
rameters at this time point, i.e. the wide boxes, reflect the intra-tumor variability (Figure 26) 
and the fact that one out of three animals for both 
12
C-ion treated groups did not exhibit an 
increase in Ktrans values 3 days after RT (see tumors 14 and 20 in Appendix A.2, Figure 53). 
Photon treated tumors of both dose groups exhibited constant Ktrans values until 14 days after 
RT that only increased to levels comparable to those of 
12
C-ion treated tumors after 21 days 
when differences between treatment groups became insignificant. 
The low dose 
12
C-ion group showed the earliest increase in Ie at day 3, followed by the two 
37 Gy dose groups (7 days after RT), and the latest response by the 85 Gy photon group at 
day 21 after RT (Figure 27 C). At the last imaging time point, the photon treated tumors ex-
hibited a broader range of Ie values than 12C-ion treated tumors. Except for the two high 
dose groups, all treatment groups exhibited comparable Ie distributions. 
The vascular fraction Ip exhibited plausible values, however, without apparent temporal 
changes (Figure 27 D). The 37 Gy 
12
C-ion and the 85 Gy photon treated groups exhibited 
slightly increased but significantly different values compared to the other groups at the final 
imaging time point, that were comparable to their pre-treatment values.  
Altogether, photon treated tumors exhibited a delay in treatment response in all parameters 
as compared to 
12
C-ions. It is noticeable that all treatment groups experienced comparable 
parameter values for normalized AUC, Ktrans, and Ie at the end of the observation period 
regardless of applied dose and RT modality (Figure 27 and Appendix A.1, Table 9).  
Temporal development of fit parameters was also analyzed for each animal individually to 
ensure that groups exhibited a uniform treatment response (Appendix A.2, Figure 53). One 
tumor (tumor 23) treated with 85 Gy photons differed from the rest of its group in all meas-
urements and was thus excluded from the pooled histological analyses. Histological results 
for tumor 23 can be found in the Appendix A.3, Figure 54.  
3.3.3 Histology 21 days after irradiation 
3.3.3.1  AT1-tumor morphology  
H&E staining revealed that 21 days after RT, non-irradiated controls exhibited very dense 
and heterogeneous tissue structures with large fiber-rich and cell-depleted areas infiltrated 
with lymphocytes, as well as necrotic areas seamed by irregularly shaped cells (Figure 
28 A). 
12
C-ion treated tumors exhibited loosened, homogeneous tissue structures infiltrated 
by lymphocytes at 21 days after RT. There were no signs of necrosis (Figure 28 B, D). In 
contrast, photon treated tumors exhibited more heterogeneous tissue structures, consisting of 
loosened tumor tissue infiltrated by lymphocytes and intermitted by areas with developing 
necrosis that was surrounded by enlarged and highly irregularly shaped cells (Figure 28 C, 
E). Enlarged cells were found independent of radiation dose and quality. 
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Figure 28 Histological images of AT1-tumors 21 days after irradiation with either photons or 12C-ions and non-
irradiated controls. (A - E) Tumor morphology was assessed by H&E staining. Whole-mount images (scale bars 
1000 µm) with close-ups (scale bars 200 µm) of the marked areas are displayed. (F - J) Fluorescence images of 
CD31 (vessels, red), pimonidazole (hypoxia, green), and DAPI (cell nuclei, blue) stained AT1-tumors. Scale bars 
500 µm. (K - O) Fluorescence images of CD31, SMA (smooth muscle actin (pericytes), green) and DAPI stained 
AT1-tumors to assess vessel maturity. Scale bar 200 µm. (P - T) Proliferation was detected via BrdU incorpora-
tion (orange) relative to the whole cell count (DAPI). Scale bar 200 µm. Figure reproduced from [135]. 
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3.3.3.2  Vascular density and maturity 
Control tumors exhibited the highest microvascular density (Figure 29 A), but the lowest 
vessel maturity (Figure 29 B). The second highest microvascular density was found in the 
37 Gy 
12
C-ion treated tumors, followed by the 16 Gy 
12
C-ion group (Figure 29 A). Photon 
treated tumors exhibited least microvessels. Differences between the control group and all 
treated groups except the 37 Gy 
12
C-ion group were significant for vascular density in the 
rim. Vessel maturity (CD31
+
/SMA
+
-structures) was comparably low between the two dose 
groups and the two modalities (Figure 28 K - O, Figure 29 B). The difference between the 
rim and core density of CD31
+
/SMA
+
-structures was only significant for the control group. 
 
 
Figure 29 Quantitative results of immunohistochemistry stainings of AT1-tumors 21 days after irradiation with 
either photons or 12C-ions. (A) Microvascular density calculated as the number of CD31+-vessel structures ex-
ceeding an area of 21.125 µm2 (50 pixels). Tumor sections were separated into a rim (outer 1 mm) and core (re-
maining inner area) region. (B) Vessel maturity was assessed for tumor rim and core by the number of vessels 
that co-expressed CD31 and SMA. (C) Percentage of hypoxic area compared to the total tumor area was assessed 
for one animal per dose group. (D) Proliferative activity was marked by BrdU incorporation in relation to the 
overall cell count. + One animal had to be excluded from the analysis due to complications during tumor dissec-
tion. In the 85 Gy photon group tumor 23 was excluded from analysis. * p < 0.05, ** p < 0.001. Data is displayed 
as mean ± standard deviation. Figure adapted from [135]. 
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Staining for endothelial cells and pericytes showed small partially SMA
+
-capillaries with a 
clearly identifiable lumen in the treated tumors (Figure 30 B - E, arrow heads) which were 
rarely seen in non-irradiated controls at 21 days (Figure 30 A).  
 
 
Figure 30 Fluorescence images of AT1-tumors stained for CD31 and SMA. (A) Control tumors exhibited tiny 
capillaries (CD31, red) without pericyte (SMA, green) coverage while (B - E) small, fully or partially SMA+-
capillaries with clearly identifiable lumen were found in treated tumors (arrow heads). Scale bars 50 µm. Figure 
adapted from [135]. 
 
In non-irradiated controls, locally concentrated capillaries with relatively large diameters and 
slim endothelial linings were found primarily in the vicinity of hypoxic areas and tissue areas 
undergoing necrosis (Figure 31 A). These capillaries exhibited inner diameters of up to 
300 µm and deviated from the otherwise tiny AT1 characteristic microvessels (Figure 31 B). 
Few capillaries with large diameters were also found in photon treated tumors, though with a 
partially disrupted CD31-lining. 
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Figure 31 Fluorescence images of AT1-tumors stained for CD31 and pimonidazole. (A) In control tumors, 
capillaries (CD31, red) with exceptionally large diameters were found in the vicinity of on-setting necrosis (area 
with few DAPI+-cells (blue) in upper part) and hypoxic areas (pimonidazole (pimo, green) in right part). Some of 
the diameters were measured: (1) 53 µm, (2) 47 µm, (3) 48 µm, (4) 44 µm, (5) 58 µm, (6) 102 µm. Scale bar: 
200 µm. (B) Area of the same tumor with tiny and chaotic capillaries that are characteristic for the AT1-tumor. 
Scale bar: 200 µm. Figure adapted from [135]. 
 
3.3.3.3  Tumor hypoxia 
One animal per dose group was injected with pimonidazole as described in section 2.6.2.5. 
Control tumors exhibited the highest hypoxic fraction (Figure 28 F, Figure 29 C). 
12
C-ion 
treated tumors comprised no hypoxic areas (Figure 28 G, I, Figure 29 C) while photon treat-
ed tumors exhibited very low hypoxic fractions (< 7 %, Figure 28 H, J, Figure 29 C).  
3.3.3.4  Proliferative activity 
Non-irradiated control tumors exhibited the highest proliferative activity with approximately 
10 % proliferating cells (Figure 28 P, Figure 29 D). The proliferation rate in treated tumors 
was generally rather low, but slightly higher after photons than after 
12
C-ions, irrespective of 
the applied dose (Figure 28 Q - T, Figure 29 D). Significance was only reached between the 
control group and the 37 Gy 
12
C-ion group. For 
12
C-ion treated tumors, BrdU
+
-cells were 
distributed homogeneously throughout the tumor sections, while they followed the pattern of 
on-setting necrosis in photon treated tumors leading to a rather heterogeneous distribution of 
BrdU
+
-cells. 
3.4 Longitudinal DCE-MRI study of the HI-tumor after irradiation 
Longitudinal DCE-MRI experiments were conducted to compare the impact of high dose 
12
C- ion and photon irradiation on vascular permeability in the moderately differentiated and 
acute hypoxic HI-tumor (section 2.5.2). The experiments had been planned and conducted by 
Dr. Christin Glowa while the development of the evaluation strategy as well as the evalua-
tion of the data itself had been performed by myself.  
The text and figures in section 3.4 and respective subsections were taken from reference 
[136] and have been originally written by myself.  
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3.4.1 Tumor growth after irradiation 
During the observation period of three weeks the volume of non-irradiated control tumors 
increased almost tenfold (Figure 32). The volume of treated tumors increased until 3 days 
after RT and declined or remained constant thereafter for all treatment groups. It has to be 
noted that the further increase in the 75 Gy photon group results from a single tumor that 
continued growing after irradiation although its growth rate was decreased.  
 
 
Figure 32 Relative tumor volumes of HI-tumors up to 21 days after irradiation with either photons or 12C-ions 
derived from 2-weighted images. Tumor volumes were pooled per group and time point (n = 3 for 75 Gy pho-
tons, n = 4 for 18 Gy 12C-ions and 37 Gy photons, n = 5 for 37 Gy 12C-ions, n = 16 for controls). The field of view 
for 2-weighted imaging was kept at constant size over all measurements which resulted in control tumors ex-
ceeding the field of view at the last imaging time point. Hence, reported control tumor sizes are underestimated. 
Data is displayed as mean ± standard deviation. Figure reproduced from [136]. Data was acquired by Dr. Christin 
Glowa. 
 
3.4.2 Pharmacokinetic modeling of DCE-MRI data 
DCE-MRI data was fit with the ETM as described in sections 2.4.6 and 2.4.7. The pharma-
cokinetic parameters Ktrans, Ie, and Ip of the different groups and time points revealed no 
significant differences (Appendix A.4, Figure 55). This finding reflects neither the observed 
morphological changes in the images, nor the histological changes at the end of the observa-
tion period. Therefore, DCE data was further analyzed by principle component analysis 
(PCA). 
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3.4.3 Principle component analysis and Gaussian mixture modeling 
Based on the loading matrix of the first two principle components (PCs) of the PCA, the 
tumors’ voxels were separated into five cluster. Each of the five cluster is characterized by 
an average concentration-time curve (Figure 33 A) and a corresponding characteristic set of 
ETM parameters (Figure 33 B). Cluster 1 (blue) comprises concentration-time curves with a 
high initial increase followed by a rapid decrease described by high Ktrans, high Ie, and high Ip values. The average concentration-time curve of cluster 2 (red) exhibits a lower initial 
concentration maximum and a slightly shallower decrease as compared to the curve of clus-
ter 1. The curve of cluster 3 (yellow) exhibits a slower CA uptake followed by a plateau at 
about 150 s. The average concentration-time curves of cluster 4 (purple) and 5 (green) follow 
the same shape as that of cluster 3 but at lower concentration levels. Except for Ie of clus-
ter 3, all ETM fit parameters decrease steadily from cluster 1 to cluster 5 (Figure 33 B). 
 
 
Figure 33 Results for principle component analysis and clustering of DCE-MRI data of HI-tumors. (A) Average 
concentration-time curves (± SEM) per cluster over all tumor voxels and time points. (B) ETM fit parameters per 
cluster for all tumor voxels and time points: volume transfer constant Ktrans, extracellular, extravascular volume 
fraction Ie, and plasma volume fraction Ip. Figure reproduced from [136]. 
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3.4.4 Treatment response after irradiation 
Exemplary 1-weighted images after CA administration and their corresponding clustering 
results are displayed in Figure 34. The longitudinal development of the fraction of each clus-
ter is displayed in Figure 35.  
At the initial imaging time point before RT, tumors were characterized mainly by cluster 2 
and 4 with minor contributions of the other cluster (the high fraction of cluster 3 for the 
75 Gy 
12
C-ion treated group results from a single animal). Control tumors maintained the 
initial cluster distributions over 21 days (Figure 35 A). 
7 days after RT, the fraction of cluster 3 started increasing and became dominant at 21 days 
after RT, while the fractions of cluster 1 and 2 decreased to essentially zero for almost all 
dose groups. As an exception, the increase in cluster 3 was delayed for the 75 Gy photon 
group and was first observed at the fourth imaging time point 14 days after RT. The tumor in 
this group, that continued growing with a reduced growth rate until 21 days after RT, showed 
no further increase in cluster 3 voxels after day 14.  
No pronounced differences in the temporal development of this treatment response were 
found between 
12
C-ions and photons, and between curative and sub-curative doses of 
12
C-
ions. The lower fraction of cluster 3 for the two photon treated groups was found to originate 
from a single animal in both groups. 
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Figure 34 1-weighted images of HI-tumors after CA administration with respective clustering results for one 
exemplary animal per dose group for each imaging time point. Figure reproduced from [136]. Measurements 
were performed by Dr. Christin Glowa. 
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Figure 35 Pooled clustering results for the HI-tumor at different time points after irradiation for (A) non-
irradiated controls, and (B) 18 Gy 12C-ions, (C) 37 Gy photons, (D) 37 Gy 12C-ions, and (E) 75 Gy photons treat-
ed tumors. Results were pooled for all tumor voxels per treatment group and time point and are displayed with 
their relative abundance. Figure reproduced from [136].  
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3.4.5 Histology 21 days after irradiation 
H&E staining revealed that non-irradiated controls exhibited typical large mucin filled pros-
tatic structures (Figure 36 A, F). Irradiated tumors exhibited severe structural damages which 
additionally impeded histological preparation of the tissue. H&E staining revealed that the 
remaining tumor parts mainly consisted of large vessels embedded in stromal parts contain-
ing intact tumor cells, cells with enlarged cell nuclei, and tumor cell fragments (Figure 36 B -
E, G - J). For the high dose photon group (75 Gy) only one tumor could be histologically 
examined at day 21. This tumor showed vessel fragments and enlarged cells. Histological 
results were comparable among all treatment groups. 
 
 
Figure 36 Histological images of HI-tumors 21 days after irradiation with either photons or 12C-ions and non-
irradiated controls. (A - E) Tumor morphology was visualized by H&E staining. While mucin-filled structures 
(asterisks), characteristic for the HI-tumor, were found in non-irradiated controls and to some extent in the low 
dose treated tumors, the tissue structure has mostly dissolved for the high dose treated tumors. Arrows point at 
residual vessel structures. Scale bars 500 µm. (F - J) Close-ups on the marked areas in A-E revealing the disrupted 
tissue structure pervaded by residual vascular structures at 21 days after RT. Scale bars 100 µm. (K - O) Fluores-
cence images of CD31 (vessels, red) and SMA (smooth muscle actin (pericytes), green) stained HI-tumors reveal 
the remaining immature vessel fragments that survived RT. Scale bars 100 µm. (P - T) Fluorescence images of 
Ki67 stained HI-tumors showing isles of proliferating cells in control tumors but only few Ki67+-cells in treated 
tumors. Scale bars 100 µm. Figure adapted from [136]. 
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Staining for CD31 and SMA showed that non-irradiated controls were pervaded by large, 
mostly immature, vessels (arrows) (Figure 36 K). Irradiated tumors comprised small, mostly 
SMA-negative, vessel fragments at 21 days (Figure 36 L - O).  
The proliferative activity in irradiated and control tumors was assessed by staining for Ki67. 
Isles of proliferating cells were found throughout the control tumors (Figure 36 P). 21 days 
after RT, proliferative active cells were found only very sporadically in irradiated tumors 
(Figure 36 Q - T). 
3.5 Longitudinal histology study of the AT1-tumor after 
irradiation  
A longitudinal histology study was performed on the AT1-tumor after irradiation with cura-
tive single doses of either photons or 
12
C-ions for a better understanding of the longitudinal 
changes that occur to the tumor tissue and vasculature on a microscopic level. Therefore, 
AT1-tumors were irradiated when they reached a size of 10 mm × 10 mm and were subse-
quently dissected at pre-defined time points. Tumor sections were stained for various mark-
ers, and microscopic fluorescence images of these were quantitatively analyzed. The AT1-
tumor, which is the most radioresistant tumor of the three Dunning sublines used in this 
work, was chosen as it is chronic hypoxic and exhibits the largest RBE for local tumor con-
trol.  
3.5.1 Tumor growth after irradiation 
In the first week after irradiation with curative isoeffective doses of either photons or 
12
C-
ions, tumors continued growing comparably to non-irradiated controls. After 7 days, their 
growth decelerated and stagnated so that irradiated tumors reached a maximum of up to 2.7 
times their original volume (Figure 37). Tumor shrinkage was finally observed after 18 days 
in the 21 day 
12
C-ion treated group.  
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Figure 37 Relative tumor volumes of AT1-tumors after irradiation. AT1-tumors were irradiated with curative 
doses of either photons (blue) or 12C-ions (red) and dissected after predefined time points. Their volume was 
calculated from measuring the largest tumor diameter and the corresponding orthogonal diameter. The displayed 
control group consists of five randomly chosen animals with non-irradiated tumors of the volume-dependent 
hypoxia study. Data is displayed as mean ± SEM (n = 5). 
 
3.5.2 Tumor morphology 
Non-irradiated AT1 control tumors comprised homogeneously distributed and densely 
packed tumor cells and little stromal parts (Figure 38). With increasing volume, central parts 
of non- irradiated AT1-tumors became necrotic, leaving only connective tissue behind (data 
not shown). 
Overall, the temporal progression of tumor morphology after irradiation was comparable 
between isoeffective curative doses of photons and 
12
C-ions until day 10. An invasion of 
leukocytes (small round cells whose cytoplasm is almost entirely taken up by the nuclei) was 
observed as early as 24 h after irradiation with both modalities. Starting at day 3, a decrease 
in tumor cell density was detected that progressed further until day 7 after irradiation. At this 
time point, hardly any intact tumor cells were found while the amount of bloated cells was 
increased. 10 days after irradiation, tumors exhibited a colloidal texture. At this time point, 
H&E staining revealed areas that mainly consisted of connective tissue with embedded im-
mune cells. Hardly any tumor cells were left. This degraded tissue structure was sustained 
until 14 and 21 days after 
12
C-ion irradiation. 
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Figure 38 Structural changes in AT1-tumors at several time points after irradiation with either photons or 12C-
ions assessed by Hematoxylin/Eosin (H&E) staining. For comparison the morphology of two non-irradiated 
controls is displayed (10 mm × 10 mm and 15 mm × 15 mm, respectively). Scale bar 100 µm. 
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3.5.3 Tumor hypoxia 
3.5.3.1  Volume dependent tumor hypoxia in non-irradiated controls 
Figure 39 exemplarily illustrates the hypoxic microregions that developed in a certain dis-
tance to the perfused capillaries of the AT1-tumor. 
 
 
Figure 39 Exemplary fluorescence image of hypoxic microregions in the AT1-tumor. Shown are the AT1-
characteristic capillaries (CD31, red) which were partially perfused (Hoechst 33342, blue) and hypoxic microre-
gions (pimonidazole, green), which had developed in undersupplied areas at a certain distance to the perfused 
capillaries. Scale bar 500 µm. 
 
AT1-tumors became hypoxic when they reached a certain size (Figure 40). Exemplary imag-
es of the spatial distribution of the hypoxic regions are displayed in Figure 41. 
 
 
Figure 40 Quantification of the hypoxic fraction in AT1-tumors of different volumes. AT1-tumors were as-
signed into groups based on their size at dissection which was determined by measuring the largest and the re-
spective orthogonal tumor diameter. Hypoxia was assessed by pimonidazole. The pimonidazole-positive area was 
set in relation to the overall tumor area for one whole-mount image per animal (necrotic regions were excluded). 
Statistically significant differences were only found in comparison with the 10 mm × 10 mm control group.        
** p < 0.01, *** p < 0.001 with regard to the 10 mm × 10 mm group (10 × 10, 15 × 15: n = 10; 20 × 20, 25 × 25, 
30 × 30: n = 5).  
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While tumors in the 10 mm × 10 mm control group accumulated no pimonidazole, the slight-
ly larger tumors (15 mm × 15 mm control group) exhibited varying hypoxic fractions rang-
ing from 0 % to 23 %. Tumors with a size of 20 mm × 20 mm and larger exhibited signifi-
cantly higher hypoxic fractions than the 10 mm × 10 mm group. Their hypoxic fractions 
ranged from 16 % to 57 %. 
 
 
Figure 41 Fluorescence images of the hypoxic fraction in AT1-tumors of different volumes. Tumors were as-
signed to groups based on their size at dissection which was assessed by measuring the largest diameter and the 
respective orthogonal tumor diameter (numbers above tumor sections). Hypoxia was detected by pimonidazole 
(green) and one representative tumor per group is displayed. Necrotic parts were cropped from the images. 
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3.5.3.2  Tumor hypoxia after irradiation  
Quantitative results of the hypoxia development after irradiation with curative doses of either 
photons or 
12
C-ions are displayed in Figure 42 and exemplary images are displayed in Figure 
43.  
At irradiation size of 10 mm × 10 mm, tumors were pimonidazole negative (control group 
data taken from section 3.5.3.1). 24 h after photon irradiation, hypoxia occurred very irregu-
larly in tumors and ranged from 0 % to 16 % hypoxic fraction. The hypoxic fraction re-
mained below 5 % until AT1-tumors exhibited significantly but non-uniformly increased 
hypoxic fractions 10 days after irradiation (range 0 - 16 %). 24 h after 
12
C-ion irradiation, 
AT1-tumors were pimonidazole-negative but became increasingly hypoxic until a significant 
maximum was reached at day 7 (range 5 - 13 % hypoxic fraction). During the following two 
weeks, the hypoxic fraction continuously dropped below 5 % at day 21.  
The detected maximum hypoxic fraction was comparable between the two irradiation modal-
ities but was reached faster after 
12
C-ions (after 7 days) than after photons (after 10 days). 
 
 
Figure 42 Quantification of the hypoxic fraction in AT1-tumors at several time points after irradiation. Tumors 
with diameters of 10 mm × 10 mm were irradiated with curative doses of either photons (blue) or 12C-ions (red) 
and their hypoxic fraction was assessed at several time points from pimonidazole staining. The pimonidazole-
positive area was set in relation to the overall tumor area for one whole-mount image per animal (necrotic areas 
were excluded from analysis). The size-matched control group (green) was taken from Figure 40. Statistically 
significant differences were only found in comparison with the 10 mm × 10 mm control group, * p < 0.05 (n = 5; 
controls: n = 10). 
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Figure 43 Fluorescence images of the hypoxic fraction in AT1-tumors at several time points after irradiation. 
Tumors were irradiated with curative doses of either photons or 12C-ions at a size of 10 mm × 10 mm and hypoxia 
was assessed by pimonidazole (pimo, green) at several time points thereafter. Non-irradiated tumors with a size 
of 10 mm × 10 mm served as controls. Necrotic parts were cropped from the images. 
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3.5.4 Vascular density and maturity  
No significant differences in vascular density between tumor rim and core were found (data 
not shown) and therefore, only data of entire tumor sections is shown. The AT1-tumor com-
prises a high density of tiny and immature capillaries (229 ± 11 vessels/mm
2
) without con-
siderable SMA staining (Figure 44, Figure 45). Within the first 24 h after photon and 
12
C-ion 
irradiation the vascular density dropped to 73 ± 4 % and 77 ± 6 %, respectively, normalized 
to the vascular density of the 10 mm × 10 mm control group (Figure 44 A). The vascular 
density decreased further until day 10 when it became significantly lower than 24 h after 
irradiation. No significant differences in the longitudinal changes of the vascular density 
between photon and 
12
C-ion irradiated tumors were found. The vascular density increased 
significantly between day 14 and day 21 after 
12
C-ion irradiation (Figure 44 A).   
 
 
Figure 44 Quantification of the vascular density and maturity in AT1-tumors at several time points after irradia-
tion. Tumors were irradiated with curative doses of either photons or 12C-ions at a size of 10 mm × 10 mm and 
non-irradiated tumors of the same size were used as controls. (A) CD31+-structures were semi-automatically 
segmented and objects larger than 21.125 µm2 (50 pixels) were counted. Vascular density was determined by 
normalizing the number of vessels to the tumor section area excluding necrotic areas. (B) Smooth muscle actin-
positive (SMA+)-structures were semi-automatically segmented and when they overlapped with at least 300 
pixels with CD31+-segmented objects those were counted as SMA co-expressing. All results were normalized to 
the vascular density and the number of SMA-co-expressing vessels, respectively, of the control tumors 
(10 mm × 10 mm group). Results are displayed as mean ± SEM, * p < 0.05, ** p < 0.01, *** p < 0.001, (n = 5). 
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Figure 45 Fluorescence images of CD31 and SMA stained AT1-tumors at several time points after irradiation. 
Tumors were irradiated with curative doses of either photons or 12C-ions at a size of 10 mm × 10 mm. Non-
irradiated tumors of the same size were used as controls. Vessels were stained by the endothelial cell marker 
CD31 (red), pericytes were associated with vessel maturity and were stained by SMA (smooth muscle actin, 
green). Direct overlay of CD31 and SMA appears yellow. The upper right image shows a mature, pericyte cov-
ered capillary (arrow) in the rim of a control tumor in comparison to the high amount of SMA in the tumor that is 
not associated with vascular structures. Scale bars: 100 µm.  
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Overall, irradiated AT1-tumors greatly expressed SMA, however mostly un-associated with 
CD31
+
-structures (Figure 45, upper right panel). Control tumors comprised 2.2 ± 1.5 
CD31
+
/SMA
+
-vessels per mm
2
. Within 24 h after irradiation, the percentage of SMA co-
expressing vessels had increased to 242 ± 135 % (5 ± 3 CD31
+
/SMA
+
-vessels/mm
2
) and 
119 ± 47 % (3 ± 1 CD31
+
/SMA
+
-vessels/mm
2
) after photons and 
12
C-ions, respectively, nor-
malized to the percentage of SMA co-expressing vessels of the 10 mm × 10 mm control 
group (Figure 44 B). The mean fraction of SMA co-expressing vessels was higher after pho-
tons than after 
12
C-ions within the first week, however with a large error indicating heteroge-
neous response within this group. At day 10, 
12
C-ion and photon treated tumors comprised 
comparable densities of pericyte covered capillaries. The fraction of SMA
+
-vessels increased 
until 21 days after 
12
C-ions, again showing the small and partially SMA
+
-capillaries with 
clearly identifiable lumen. No significant differences were found between both modalities. 
3.5.5 Tumor perfusion  
Results of the perfusion classification and quantification are displayed in Figure 46. Exem-
plary Hoechst 33342 images are displayed in Figure 47.  
Control tumors of size 10 mm  × 10 mm and 15 mm  × 15 mm were mainly intermediately 
perfused (71 ± 8 % and 65 ± 12 %, respectively) with only 20 ± 11 % and 26 ± 14 % non-
perfused areas, respectively, and 10 ± 10 % highly-perfused areas for both sizes (Figure 
46 A). 
24 h after photon irradiation, the highly-perfused fraction increased at the cost of the non-
perfused and intermediately-perfused fraction. At day 3, this perfusion peak had already 
declined and the initial perfusion proportions were restored (Figure 46 B, G). 
12
C-ion treated 
tumors experienced a decline in perfusion 24 h after irradiation (Figure 46 C, H), followed by 
a hyperperfusion at day 3. Tumor perfusion was recovered by day 7, facing further perfusion 
impairment 10 and 14 days after irradiation. Tumors became highly-perfused by day 21.  
Overall, the highly-perfused areas expressed the highest vessel density in control tumors and 
after irradiation (Figure 46 D - F). Non-perfused and intermediately-perfused areas com-
prised lower but comparable vascular densities. The vascular density decreased continuously 
after irradiation with both modalities and evenly among the three perfusion classes until day 
10 (Figure 46 I, J). Intermediately-perfused areas of 
12
C-ion treated tumors experienced a 
final increase in vascular density until day 21.  
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Figure 46 Quantification and classification of the perfusion in AT1-tumors at several time points after irradia-
tion. Tumors at a size of 10 mm  × 10 mm were irradiated with curative doses of either photons or 12C-ions. Tu-
mor perfusion was assessed by Hoechst 33342 which stained perfused areas and left non-perfused areas un-
stained. (A - C) One whole-mount fluorescence image was analyzed per tumor and sub-classified as non-perfused 
(cyan), intermediately-perfused (yellow), and highly-perfused (dusky pink) based on the intensity of the 
Hoechst 33342 stain. (D - F) The vessel density per perfusion class was determined by counting the number of 
CD31+-objects and normalizing them to the respective perfusion area. (G - H) The change in perfusion area rela-
tive to the 10 mm  × 10 mm control group was determined for each time point. (I - J) The change in vessel density 
relative to the 10 mm  × 10 mm control group was determined for each time point. Results are displayed as 
mean ± SEM, (n = 5).  
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Figure 47 Fluorescence images and perfusion classification of AT1-tumors at several time points after irradia-
tion. Tumors at a size of 10 mm  × 10 mm were irradiated with curative doses of either photons or 12C-ions and 
tumors of the same size served as non-irradiated controls. Perfusion was assessed by Hoechst 33342 which 
stained perfused areas (bright gray) and left non-perfused areas unstained (dark areas). Tumor regions were clas-
sified as non-perfused (blue), intermediately-perfused (yellow), and highly-perfused (red). Necrotic parts were 
cropped from the images and neglected during perfusion classification and quantification. 
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3.5.6 Proliferation  
Non-irradiated control AT1-tumors exhibited the highest proliferative activity just below 
20 % (Figure 48).  
Both irradiation modalities induced the same changes on the proliferative activity. 24 h after 
irradiation, the proliferative activity had dropped to half of its initial value. Proliferative ac-
tivity resumed its initial value by day 3 and declined from there on. 21 days after 
12
C-ion 
irradiation, approximately 4 % of detected cells still proliferated.  
BrdU
+
-cells were distributed homogeneously over entire tumor sections, and no differences 
in the pattern of proliferating cells could be identified between the two modalities until day 
10. The absolute percentage of BrdU
+
-cells was identical for both modalities within the first 
10 days after irradiation. Exemplary fluorescence images of BrdU incorporation are dis-
played in Figure 49.  
 
 
Figure 48 Quantification of the proliferative activity in AT1-tumors at several time points after irradiation. AT1-
tumors with a size of 10 mm  × 10 mm were irradiated with curative doses of either photons (blue) or 12C-ions 
(red). Additionally, results of two control groups (10 mm  × 10 mm and 15 mm  × 15 mm diameters, respectively) 
are shown (green). Proliferation was assessed by BrdU incorporation. The ratio between cells that stained positive 
for BrdU and all cells marked by DAPI was determined for one whole-mount fluorescence image per tumor. 
Results were summarized per group and are displayed as mean ± SEM. + One animal was excluded from analysis 
due to incomplete BrdU injection. Results for 14 days and 21 days were not significantly different, * p < 0.05,    
** p < 0.01, *** p < 0.001, (n = 5, controls: n = 10).  
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Figure 49 Fluorescence images of BrdU stained AT1-tumors at several time points after irradiation. Tumors 
were irradiated with curative doses of either photons or 12C-ions at a size of 10 mm × 10 mm. Non-irradiated 
tumors with a size of 10 mm  × 10 mm and 15 mm  × 15 mm served as controls. Proliferation was assessed by 
BrdU incorporation (orange) into the cells’ nuclei (DAPI, blue). Scale bar 100 µm. 
 
 
 
3 Results  
91 
 
3.5.7 DNA double-strand breaks 
Approximately 15 % of all cells in non-irradiated control tumors were classified as interme-
diate intensity cells and approximately 0.5 - 1 % were classified as high intensity cells 
(Figure 50). 24 h after irradiation, the incidence of intermediate γH2AX
+
-cells doubled for 
both modalities and returned to initial values until day 3 (Figure 50 A). Thereafter, the inci-
dence of intermediate γH2AX
+
-cells continuously dropped and stagnated at less than 5 % for 
12
C-ion treated tumors. The incidence of high intensity γH2AX
+
-cells peaked 24 h after irra-
diation (Figure 50 B). At day 3, it dropped below 2 % and remained low until 21 days after 
irradiation. Exemplary fluorescence images of irradiation-induced DNA DSBs are shown in 
Figure 51. 
 
 
Figure 50 Quantification and classification of DNA double strand breaks in AT1-tumors at several time points 
after irradiation. AT1-tumors with a size of 10 mm  × 10 mm were irradiated with curative doses of either photons 
(blue) or 12C-ions (red). DNA DSBs were assessed by staining for γH2AX. The γH2AX+-cells were classified as 
intermediate or high intensity and set in relation to the overall cell count (DAPI cell count) for one whole-mount 
image per tumor. Additionally, results of two control groups (10 mm  × 10 mm and 15 mm  × 15 mm diameters, 
respectively) are shown (green). Results are displayed as mean ± SEM. + Two animals missing due to analysis 
problems, * p < 0.05,       ** p < 0.01, *** p < 0.001 (n = 5, controls n = 10). 
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Figure 51 Fluorescence images of γH2AX stained AT1-tumors at several time points after irradiation. Tumors 
were irradiated with curative doses of either photons or 12C-ions at a size of 10 mm × 10 mm. Non-irradiated 
tumors with a size of 10 mm  × 10 mm and 15 mm  × 15 mm served as controls. DNA double-strand breaks were 
identified by staining for γH2AX (orange) in cell nuclei (DAPI, blue). Scale bar 100 µm.  
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4 Discussion 
Within the scope of this thesis, the hypoxic status of the syngeneic experimental prostate 
tumors Dunning R3327-H, -HI, and -AT1 was investigated by multiple imaging modalities. 
First, the tumors’ oxygenation profiles were characterized by PAI utilizing a newly devel-
oped analysis protocol. Second, the longitudinal perfusion and vascular changes of the acute 
hypoxic (HI-) and the chronic hypoxic (AT1-) tumor were examined from DCE-MRI data 
after irradiation with sub-curative and curative single doses of either photons or 
12
C-ions, 
including the development of a new method for bolus arrival time (BAT) estimation. Finally, 
a longitudinal histology study with the AT1-tumor disclosed the alterations in vascular den-
sity, hypoxia, perfusion, proliferation, and DNA double strand breaks (DSBs) that occurred 
after curative irradiation with either photons or 
12
C-ions on a microscopic level.  
In the following, first the methodical aspects of PAI and BAT estimation are discussed, and 
second the biological investigations are elaborated. 
4.1 New analysis protocol for photoacoustic imaging (PAI)  
The text in section 4.1 and respective subsections was taken from reference [96] and has 
been originally written by myself. 
PAI is gaining increased interest for preclinical and clinical applications especially in the 
field of oncology [97-99, 101, 159-162]. It combines the high contrast and specificity of 
optical imaging with the high spatial resolution of ultrasound (US) imaging avoiding radia-
tion [89, 98]. While many preclinical PAI studies on oxygen saturation provide only ROI-
based mean values [163-166], others have developed more advanced imaging and analysis 
protocols using multispectral PAI [159, 160, 167]. First approaches for pixel- rather than 
ROI-based analyses were introduced by May et al. [168] and Hysi et al. [169]. To enable a 
more detailed display of the tumors’ oxygenation status the existing approaches were ex-
tended to analyze pixel-based sO2-distributions of the entire 3D-tumor volumes.  
4.1.1 Feasibility of the new analysis protocol 
The new protocol enables the characterization of the tumor sublines H, HI, and AT1 based 
on their sO2-distributions rather than just mean values. This was used to study the tumor 
sublines’ response after external changes of oxygen supply. Furthermore, it could be investi-
gated whether this response occurs within the entire tumor or only locally and whether this 
behavior is changing with time indicating morphological or functional changes within the 
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tumor. This detailed analysis would not have been feasible if only mean values per tumor 
had been considered.  
Tumor HI-3 especially illustrates the potential of the established protocol: During the 41 
days of observation, this tumor underwent major morphological changes which were reflect-
ed in the changing shapes of the corresponding sO2-distributions. This makes the developed 
protocol especially interesting for longitudinal studies (e.g. after treatment), where changes 
in oxygenation are expected. 
The study was conducted using two commercial PAI-systems: the Vevo 2100 and Vevo 
3100, both employing the laser Vevo-LAZR. According to the manufacturer, the two sys-
tems are largely comparable with respect to system electronics and PA-specific performance 
(penetration depth, system dynamic range, signal-to-noise ratio, contrast sensitivity). There-
fore, the resulting sO2-distributions should not be affected by the choice of the PAI-system. 
4.1.2 Dependency of sO2-distributions on signal gain and threshold 
The dependence of the results on the measurement settings had to be investigated prior to 
any systematic investigations of the tumor sublines. These investigations confirmed that the 
resulting sO2-distributions were largely independent of signal gain, applied threshold, and 
positioning of the animals. The higher variability of the sO2-distributions observed for HI-2 
can be explained by the overall weak PA signal and the low number of pixels that remained 
after thresholding which cannot be considered as being representative for the tumor. Hence, 
the signal gain was adjusted individually per animal and imaging session taking the strong 
and distinct PA signal of the well oxygenated healthy skin as a reference. This approach is 
justified by the fact that tumors were always transplanted at the same location according to a 
fixed protocol while environmental factors such as room temperature, temperature of the 
animal heating table, and gel temperature were kept constant. Based on these measures, the 
skin can be considered as reliable and reproducible reference tissue for the selection of indi-
vidual measurement parameters. Overall, the suitability, sensitivity, and feasibility of the 
new PAI analysis protocol were demonstrated. 
4.2 New method for BAT estimation of DCE-MRI data 
Before performing pharmacokinetic modeling of the DCE-MRI data that was acquired for 
the AT1- and the HI-tumor, the problem of accurate delay correction was addressed. Among 
other factors, the accuracy of the fit parameters from pharmacokinetic modeling depends 
critically on the temporal alignment of the arterial input function (AIF) and the tissue con-
centration curves (TCCs). The bolus arrival in the TCCs is often delayed with respect to its 
arrival in the AIF due to practical reasons such as the acquisition of the AIF from the left 
ventricle instead of from a tumor feeding artery. The reason for using the ventricle is that it 
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provides a larger and easier accessible blood volume and, hence, the AIF is less likely affect-
ed by partial volume effects. A new method for bolus arrival time (BAT) estimation which 
can be used for the alignment of the concentration curves was developed within this thesis. 
The following text in this section was taken from reference [117] and has been originally 
written by myself. 
The simulation study showed that the state-of-the art method by Cheong et al. [123] works 
very well for BAT estimation of patient TCCs and AIFs, but that it gives unsatisfactory re-
sults for rat TCCs. The main reason for this is that Cheong’s method heavily relies on a fast 
upslope from the BAT to the peak of the concentration curve, which is frequently not the 
case in small animals such as rats and patient data of tissues lacking a significant intravascu-
lar fraction. In contrast, the proposed method estimated BATs that were very close to the 
ground truth for rat TCCs under all conditions. A central advantage of the proposed method 
is that it does not require a special curve characteristic after the BAT as the smoothing spline 
is able to adapt to a large variety of curve shapes. 
The arrival of the contrast agent (CA) does typically not coincide with one of the time points 
of the image acquisition. Cheong’s method, however, limits estimation of BATs to those 
time points which imposes a systematic upper limit to the estimation accuracy. The proposed 
method estimates BATs on a continuous scale; i.e. the estimated BAT can lie in between the 
time points of the image acquisition. This improves the accuracy of the results especially for 
image data with low temporal resolution. Even though the proposed method was developed 
for small animal data, its feasibility for high temporal resolution and high SNR patient data 
was demonstrated as the results were competitive with those obtained by the method of 
Cheong et al. [123]. Yet, for lower temporal resolutions and lower SNRs Cheong’s method 
gave more accurate results in patient data. The proposed method was also applied to in vivo 
acquired rat data of the DCE-MRI study with the HI-tumor. As the ground truth is not known 
for this data only qualitative statements could be made on the results. In these cases, 
Cheong’s approach gave reasonable results for the AIFs which fulfill the criterion of a fast 
upslope from the BAT to the concentration maximum. For the TCCs, however, the estimated 
BATs were implausible because they lay before the actual injection time. Adapting Cheong’s 
method to consider only BATs after a plausible lower time point mostly resulted in that low-
er bound. In either case, the estimates for the BATs were mostly not informative. In contrast, 
the BATs estimated for the TCCs by the proposed method were found to be very close to 
each other, for each tumor and each animal, respectively. When evaluating the location of 
the BATs within the TCCs, they appeared to be set at reasonable positions. 
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4.3 Characterization of the three sublines H, HI, and AT1 by PAI 
PAI and the new protocol were used to characterize the initial oxygenation status of the three 
tumor sublines H, HI, and AT1. The text in subsection 4.3.1 was taken from reference [96] 
and has been originally written by myself. 
4.3.1 Initial oxygenation, temporal changes, and response to external changes 
in oxygen supply 
The three tumor sublines H, HI, and AT1 are known to differ with respect to several parame-
ters, most importantly their oxygenation status [94, 95, 170]. The highly differentiated and 
slowly growing H-tumor is most similar to normal prostate tissue. The narrow peaks of the 
sO2-distributions at high sO2-values indicate homogeneously oxygenated tumors, which were 
confirmed by immunohistochemistry, revealing mature vessels ensuring a sufficient blood 
supply. The shape of the sO2-distributions was maintained during the observation period 
without developing a shoulder at lower sO2-values as found for the HI-tumor. PAI was sensi-
tive enough to detect the acute changes in oxygenation induced by changing the breathing 
gas from 100 % O2 to air as well as by clamping of the tumor-supplying arteries. The re-
sponse of different animals was highly uniform. A similar finding was described by Zhao 
et al. [171]. The small hypoxic fraction found in immunohistochemistry staining of the H-
tumors is also in accordance with previously published work [172] and is negligible in com-
parison to the other sublines. 
The sO2-distributions of small HI-tumors exhibited narrow sO2-peaks comparable to those of 
the H-tumors but showed an additional shoulder in the low sO2-region. HI-tumors are known 
to develop hypoxia with time [172], which was also confirmed by the immunohistochemistry 
staining and by the increasing fraction of low-sO2 pixels during the long-term observation. 
The immediate response to external changes in oxygen supply and the presence of respond-
ing and non-responding tumor regions has also been described by Zhao et al. [173].  
The anaplastic AT1-tumor exhibited narrow peaks in the low sO2-region which remained 
essentially unchanged with respect to time point and oxygenation conditions (EMD < 0.05 
for all comparisons). Immunohistochemistry staining revealed that the immature and hardly 
perfused capillaries could not sufficiently supply the AT1-tumors, which explains the chron-
ically low sO2-values [172]. While the results of the oxygen challenge experiment are in 
accordance with those of Mason et al. [68] and Zhao et al. [171], other investigators found a 
very small but statistically significant change in perfusion after changing the external oxygen 
supply from 100 % O2 to air [174]. As the results were reproducible over a period of 12 days 
and since the comparison of different tumor-sublines is based on measurements performed 
on the same day, any PAI-system related artefacts can be ruled out. The non-responsiveness 
of the AT1-tumor towards external changes in oxygen supply points at its chronically low 
oxygenation and its adaption towards this condition (see discussion in section 4.7.2). 
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4.3.2 Comparison of tumor sublines and normal tissue (skin) 
Changing the breathing gas from 100 % O2 to air showed comparable responses in sO2-
distributions of the H- and HI-tumors as well as the normal tissue (skin) [96]. Similar results 
were found by Smith et al. who investigated the response of several vessel types to different 
breathing conditions by PAI [175]. Using clamping to restrict perfusion, tumors and normal 
tissue showed different responses: While the skin showed a strong response towards the per-
fusion restriction and became acute hypoxic, the H- and HI-tumors’ sO2-distributions were 
shifted to less extreme sO2-values after clamping, indicating a reduced oxygen consumption 
due to an adapted and less oxygen-dependent metabolism compared to the normal tissue 
skin.  
4.4 Longitudinal DCE-MRI study of the AT1-tumor 
PAI confirmed the chronic hypoxic status of the AT1-tumor, known to resemble a major 
resistance factor for conventional photon RT. However, there are indications that this can be 
overcome by 
12
C-ion irradiation [24, 176]. Therefore, DCE-MRI and histological techniques 
were used to gain initial information on treatment-induced functional and morphological 
alterations after high single doses of 
12
C-ions or photons in the anaplastic AT1-tumor up to 
21 days post-irradiation. While other researcher found changes in perfusion and vascular 
parameters at early time points after photon RT [71, 177, 178], this study examined a longer 
time frame of up to 21 days after irradiation. The four-armed study consisted of two isoeffec-
tive curative dose groups (37 Gy 
12
C-ions and 85 Gy photons) and two isoeffective sub-
curative dose groups (16 Gy 
12
C and 37 Gy photons). Moreover, the study design allowed 
also for an iso-absorbed dose comparison at 37 Gy.  
The text in subsections 4.4.2 to 4.4.6 was taken from reference [135] and has been originally 
written by myself. 
4.4.1 Selection of pharmacokinetic model  
The extended Tofts model (ETM) was selected for pharmacokinetic modeling of the TCCs 
following the recommendation for data-driven model selection to always choose the simplest 
model that sufficiently describes the data [114, 116]. However, it needs to be kept in mind 
that the ambiguity of the parameter Ktrans, which is composed of the plasma flow Jp and the 
permeability PS, marks a limitation of the ETM. Only in the limit where either flow or per-
meability dominates the CA transport into the tissue, Ktrans	can be directly associated with 4 or Jp, respectively [114]. In all other situations Ktrans	resembles a mixture of both param-
eters with unknown contributions. However, the two compartment exchange model [116], 
which comprises all four parameters Jp, 4, Ie, and Ip independently, was refused as the fits 
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were found to be instable and provided parameter values in non-physiological ranges. Rejec-
tion of this model due to its instability was also reported in other studies [179].  
4.4.2 Longitudinal monitoring of treatment response by DCE-MRI 
The treatment groups’ initial distributions of normalized AUC, Ie, and Ip already varied 
significantly before irradiation. Hence, the longitudinal development of the fit parameter 
needs to be evaluated with respect to their initial values. 
In control tumors, a decrease of all ETM parameters was observed, presumably attributed to 
a progressive decline of perfusion within the tiny, immature microvessels characterized by 
reduced blood flow resulting in a decreased transport of CA. Within the tumor core this pro-
cess is reflected by an increasing number of hypoxic regions and areas of necrosis which 
were found in histology.  
For all irradiated tumors, an initial increase in tumor volume followed by a steady state up to 
day 21 is the typical behavior after RT and is in accordance with earlier published results 
[103]. This might result from irradiation-induced edema formation. Belfatto et al. reported 
comparable results on tumor growth within the first three weeks after sub-curative photon 
irradiation of AT1-tumors for both, air and O2 breathing animals [180]. Yet, photon and 
12
C-
ion irradiated tumors differed in their histological appearance and ETM parameters. 
12
C-ion 
RT resulted in increased normalized AUC, Ktrans, and Ie values at day 3, while treatment 
response was prolonged and less pronounced for photon treated tumors with a tendency to 
even higher protraction with increasing dose. This effect might be related to the more pro-
nounced complex DNA damage after high LET irradiation inducing enhanced cell death 
[15]. A comparable increase in Ktrans	one week after photon irradiation was also described 
by Lin et al. [181] and was attributed to either an increase in capillary permeability or perfu-
sion. The normalized AUC value, which is a rather descriptive parameter, cannot be directly 
associated with a defined physiological process; hence, its increase indicates solely a higher 
amount of CA reaching the tumor.  
The initial increase in the parameter Ie after 12C-ion RT can be attributed to an increased 
vascular permeability immediately following high LET-irradiation while vascular damage 
was prolonged after photon RT. A recent study showed that increased vascular permeability 
occurs 14 days after single high dose photon irradiation [182]. Zhou et al. found no increase 
in Ie in the first week after sub-curative irradiation of AT1-tumors [178]. The elevated Ie 
values that were observed for all four treatment groups at the last imaging time point, inde-
pendently of beam quality and dose, reflect well the decreased cell density in the tumors at 
this point (see section 4.4.4).  
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The findings of this initial DCE-MRI study are also in line with a fractionated 
12
C-ion study 
of prostate cancer patients by Bonekamp et al. [106], where the highest elevated Ktrans	and Ie values were detected 10 days after the first RT fraction and decreased thereafter. 
4.4.3 Re-oxygenation after irradiation 
The AT1-tumor is a rapidly growing, anaplastic tumor with poorly perfused microvessels 
[94], which leads to a considerable number of hypoxic regions preferentially in the central 
core. At day 21, the hypoxic fraction was lower in irradiated tumors than in the correspond-
ing control tumors compared to no hypoxia at all in 
12
C-ion treated tumors. Even though only 
limited conclusions can be drawn from the results of one animal per group, the findings are 
in accordance with the results of other researchers showing clear signs of re-oxygenation in 
NFSa fibrosarcomas after a single fraction of 16 Gy 
12
C-ions 1 to 5 days after RT, which was 
not observed after treatment with photons [183]. On the histological level, this process was 
characterized by the disappearance of huge-caliber vessels detected in the vicinity of hypoxic 
and necrotic areas. These vessels were also found by other researchers [184, 185] and are 
assumed to be the result of a constant hypoxia-induced stimulus by angiogenic factors [186] 
and increased levels of nitric oxide that maintain the dilator tone [184, 187, 188]. 
4.4.4 Correlation with histology after 21 days 
The non-perfused areas that were visible in 1-weighted images and DCE-MRI parameter 
maps correlated with necrotic areas that were shown by H&E staining. Photons and 
12
C-ions 
evoked differential effects with respect to tumor morphology 21 days after RT: Photon irra-
diation led to heterogeneous tissue structures which were reflected by wider distributions of Ie, while 12C-ion treatment resulted in loose and homogeneous tissue structures with narrow-
er Ie distributions. This led to the conclusion that the response to photon irradiation is much 
more influenced by the local tumor environment than the radiation response to 
12
C-ions, 
confirming earlier findings [24].  
4.4.5 The role of endothelial cells 
In the last three decades, the focus of RT has been expanded by the crucial role of endotheli-
al cells in response to RT [189]. However, results on the exact mechanisms are still incon-
sistent [190-193] and the extent of endothelial cell contribution to the RT response remains a 
controversial issue [194, 195]. Several studies were published, indicating that the intrinsic 
radiosensitivity of tumor cells is the major determinant of tumor response to photon irradia-
tion [194-198] and not the stromal part.  
In the investigated anaplastic tumor, a higher microvascular density was found 21 days after 
12
C-ion RT compared to photons. Yet, independent of the radiation quality, there is evidence 
of small, but mature capillaries with clearly identifiable lumen showing signs of normaliza-
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tion of the tumor vasculature, comparable to observations by Lan et al. [199]. Radiation may 
affect tumor vasculature and maturity in two ways: either the fraction of mature vessels is 
increased as only the mature vessels are able to survive RT at high doses or these vessels are 
the product of RT-induced angiogenesis and maturation. This issue will be addressed later in 
the context of the longitudinal histology study (section 4.7.2). In contrast to the presented 
results, many authors proclaim that photon RT induces angiogenesis and upregulates endo-
thelial cell conserving factors such as the vascular endothelial growth factor and the basic 
fibroblast growth factor [200-202], while 
12
C-ion irradiation inhibits angiogenesis and relat-
ed actions [28, 203, 204]. Still, a direct correlation with the reported results is difficult, be-
cause of the lower doses and the shorter observation times after irradiation used in the refer-
enced studies. Tsai et al. [185] have found that even though ionizing radiation increased 
endothelial cell proliferation, resulting angiogenesis was ineffective as vessel density did not 
increase in the K1735 murine melanoma model. However, their last examined time point 
was 14 days after 12 Gy photon irradiation and according to the obtained DCE-MRI results, 
the time between 14 and 21 days after RT might be crucial for low LET treated tumors as 
most changes in ETM parameters occurred within this period.  
4.4.6 Curative vs. sub-curative doses 
Within the selected time window of the study, an ETM-based discrimination between cura-
tive and sub-curative doses per modality was not possible. Surprisingly, histological parame-
ters at the final observation day did not reveal striking differences either, leading to the con-
clusion that at least for this tumor model a longer follow-up is needed to discriminate re-
sponse differences at different dose levels. When comparing the two groups with the same 
absorbed isodoses (37 Gy photons and 37 Gy 
12
C-ions), 
12
C-ions resulted in a faster and 
stronger effect on Ktrans	and Ie, and higher vessel density, and less hypoxia and proliferation 
at day 21 as expected for the biologically more effective 
12
C-ions. 
4.4.7 Statistical analysis 
The results of the statistical analysis should be regarded with caution as statistically signifi-
cant results do not necessarily imply biological relevance, and vice versa, especially for this 
pilot-study-like experiment. Due to the large number of voxels, the significance level was 
lowered to 0.1 % for the ETM fit parameters. Furthermore, significance tests could not be 
performed for longitudinal differences as no statistical test is available for dependent data 
with varying number of data points.  
 
4 Discussion  
101 
 
4.5 Longitudinal DCE-MRI study of the HI-tumor 
DCE-MRI and histological techniques were also used to gain initial information on treat-
ment-induced functional and morphological alterations after high single doses of 
12
C-ions 
and photons in the moderately differentiated HI-tumor up to 21 days post-irradiation. The 
HI-tumor is better oxygenated than the chronic hypoxic AT1-tumor, comprises larger ves-
sels, and is less radioresistant. This four-armed study consisted of two isoeffective curative 
dose groups (37 Gy 
12
C-ions and 75 Gy photons) and two isoeffective sub-curative dose 
groups (18 Gy 
12
C and 37 Gy photons). Again, the study design allowed for an iso-absorbed 
dose comparison at 37 Gy.  
The text in section 4.5 and respective subsections was taken from reference [136] and has 
been originally written by myself. 
4.5.1 Principle component analysis for the HI-tumor 
Again, the ETM was chosen for pharmacokinetic modeling as it gave satisfying curve-fits 
and reasonable fit parameters in physiological ranges. However, despite the good fit quality, 
the obvious treatment-induced changes in tumor volume and histology were not reflected by 
the fit parameters. Endothelial cell apoptosis has been proposed to occur above threshold 
doses of 8 to 10 Gy [205-207] which was found in histology but not in the ETM parameters 
of the HI-tumor. The earlier study on the AT1-tumor (section 3.3.2) had shown that DCE-
MRI is in fact suitable to measure the radiation response; see also [135, 208]. The very large 
inherent heterogeneity of the HI-tumor is suspected to mask potential differences of the fit 
parameters between the different treatment groups. Therefore, the analysis for the HI-tumor 
was extended by a principle component analysis (PCA) as demonstrated by Featherstone 
et al. [137]. This allows to classify voxels with similar concentration-time curves, i.e. similar 
physiology, into the same cluster and to investigate the fractions of each cluster for the dif-
ferent treatment groups and time points.  
The five cluster were correlated with possible underlying morphologies on the histological 
level (Figure 52 A, B). Due to the high initial increase and the subsequent drop of the con-
centration level, voxels of cluster 1 are presumed to comprise large, intact vessels (Figure 
52 C). The related high Ktrans	values therefore correspond to a high perfusion. Voxels of 
cluster 2 exhibit lower maximum concentration and shallower decrease in concentration as 
compared to cluster 1. Therefore, they are assumed to comprise large but less-perfused im-
mature tumor vessels which frequently occur in untreated HI-tumors (Figure 52 D). The 
delayed increase and the plateau found for the curves of cluster 3 together with the associat-
ed high Ie value indicate an increased vascular permeability relative to cluster 1 and 2. This 
signal, however, cannot be unambiguously assigned as it could originate either from a few 
poorly perfused large or a bunch of poorly perfused small vessels (Figure 52 E). Due to the 
lower concentration level, voxels classified into cluster 4 are associated with a lower density 
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of small, permeable vessels (Figure 52 F). Voxels classified into cluster 5 accumulate almost 
no CA and are therefore assumed as barely perfused or potentially necrotic voxels (Figure 
52 G). It should be kept in mind that, as a consequence of the low spatial resolution of the 
DCE-MRI data, the concentration-time curve of one voxel reflects an average value over 
4.5 mm
3 
tumor tissue.  
4.5.2 Treatment response 
PCA revealed that the vasculature of non-irradiated tumors mainly consisted of small leaky 
vessels occurring with low spatial density (cluster 4) intermitted by few large and immature 
vessels (cluster 2). Additionally, small regions of elevated vessel density (cluster 3) and mu-
cin filled prostatic structures/necrosis (cluster 5) were found. Only very few voxels were 
assigned to the first cluster reflecting the overall immaturity of the vasculature. Irrespective 
of their size, non-irradiated control tumors maintained their vascular characteristics over 
time. 
Irradiated tumors revealed vascular changes 7 days after RT (except for the slightly later 
responding 75 Gy photon group) when large vessels became more permeable. This is indi-
cated by the decrease in the frequencies of cluster 1 and 2 voxels and the on-setting increase 
of the cluster 3 fraction. Considering the histological results at day 21, it can be concluded 
that the dominance of the third cluster originates from the remaining large vessels. At the 
same time, the further increase in the cluster 3 fraction is the combined result of tumor cell 
death, the subsequent shrinkage of the tumor (i.e. increase of the density of the remaining 
vessels), and further vessel degradation. No revascularization was observed in histology and 
DCE-MRI data. For the 75 Gy photon group, the increase in vascular permeability was 
slightly prolonged. However, the relevance of this delay is debatable due to the long interval 
between the fourth and the last imaging time point. Changes in vascular parameters, permea-
bility, and blood flow depend highly on the investigated system and were observed as early 
as within the first 48 h [177, 198] up to 14 days [182] after single high dose photon irradia-
tion by other researchers. 
As mentioned in section 4.4.5 the contribution of endothelial cells and the vasculature to the 
irradiation response is still not fully uncovered and is discussed controversially. The findings 
of the present study on the HI-tumor accredit only a minor contribution of the vascular com-
ponent towards overall tumor response as early vascular damage cannot explain the higher 
effectiveness of 
12
C-ions in terms of local tumor control which was described earlier for this 
moderately differentiated tumor and the applied high single doses [24]. 
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Figure 52 Correlation of the HI-tumor histology with the determined cluster. (A) Whole-mount image of a non-
irradiated control tumor stained for vessels (CD31, red), pericytes (smooth muscle actin, SMA, green), and cell 
nuclei (DAPI, blue). The colored squares mark the positions of the representative close-up cluster images C - G. 
Their size (edge length of 0.7 mm) coincides with the size of a DCE-MRI voxel (edge length of 1 mm) including 
a correction factor that accounts for the tissue shrinkage during freezing. (B) Clustering of the same tumor visual-
ized in A. It should be noted that the DCE-MRI slice does not coincide with the histological slide. (C - G) Close-
ups of the marked colored squares for cluster 1-5. Figure reproduced from [136]. 
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4.6 Comparison of the AT1- and HI-tumor’s treatment response 
Even though the ETM was used for both DCE-MRI studies, its parameters should be treated 
as qualitative rather than quantitative parameters impeding a direct quantitative comparison.  
PCA revealed that non-irradiated control HI-tumors maintained their vascular architecture 
over the three-week observation period despite strongly increasing their volume. In contrast, 
AT1 control tumors showed a decrease in perfusion especially in the tumor core. This can be 
attributed to the slower growth rate and the more pronounced vasculature of the HI-tumor 
which enables the supply of large tumor volumes. Further differences between the tumor 
sublines were observed for treatment response. 
The content of the following section was taken from reference [136] and has been originally 
written by myself.  
The anaplastic AT1-tumor, exhibiting the highest RBE [24], showed a modality dependent 
treatment response as vascular perfusion/permeability increased already 3 days after 
12
C-ion 
irradiation. Furthermore, 
12
C-ions led to a slightly increased vascular density, lower amount 
of proliferating cells, and less hypoxia as compared to photons 21 days after RT [135]. In 
comparison, the moderately differentiated HI-tumor showed a simultaneous permeability 
increase 7 days after irradiation with both modalities revealing no modality dependency that 
could be resolved within the performed DCE-MRI study or visualized by immunohistochem-
istry after 21 days. 
The different observed modality-dependencies and treatment response onsets of the two tu-
mor sublines might be explained by differences in their vascular structures. The early re-
sponding and modality-sensitive AT1-tumor exhibits mainly small, immature capillaries 
while the HI-tumor comprises larger vessels of varying sizes. The high LET 
12
C-ions are 
more effective on the immature capillaries of the AT1-tumor compared to photons. Howev-
er, this does not seem to be the case for the larger vessels of the HI-tumor where the increase 
in vascular permeability was observed at the same time point after 
12
C-ions and photons in-
dicating elevated radiation tolerance of larger vessels. This is supported by Solevski et al. 
who showed in a human malignant melanoma xenograft that vessels with larger diameters 
did not lose their functionality after single doses of 15 Gy photons as opposed to smaller 
vessels, for which the fraction of functional vessels decreased by up to 35 % at 0.5 to 1.5 
weeks after irradiation [186]. Interestingly, the results for both tumor sublines were inde-
pendent of the applied dose (curative or sub-curative). This underpins the hypothesis that 
early vascular response cannot be the key mechanism that determines the tumors’ fate with 
regard to local control. 
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4.7 Longitudinal histology study of the AT1-tumor after 
irradiation 
A longitudinal histology study on the anaplastic and radioresistant AT1-tumor after irradia-
tion with curative doses of either photons or 
12
C-ions was performed to reveal the irradiation-
induced changes in tumor perfusion, hypoxia, vascular density, proliferation, and DNA dam-
age on a microscopic level. The time points were chosen in accordance with the DCE-MRI 
study including additional time points at 24 h and 10 days, respectively. 
4.7.1 General tumor development after irradiation 
As observed earlier, the AT1-tumors continued growing like the non-irradiated control tu-
mors for one week after RT independent of the irradiation modality, before their growth 
stagnated and then declined [103, 135, 180]. Edema formation as a consequence of irradia-
tion-induced increased vessel permeability and subsequent transudation of plasma compo-
nents into the EES [209] might have led to the maintenance of the volume while tumor cells 
started disintegrating.  
No differences in tumor morphology and immune response after single high dose photon and 
12
C-ion irradiation could be identified on H&E stainings within the first 10 days. However, 
slight differences were found at day 21 of the DCE-MRI study suggesting that they mani-
fested at a later stage at this high dose level.  
4.7.2 Tumor hypoxia, vascularization, and perfusion  
Non-irradiated controls 
The volume-dependent study of non-irradiated AT1-control tumors revealed hypoxic micro-
regions beyond a tumor size of 15 mm × 15 mm illustrating the tumor’s diffusion limited 
oxygen supply. Increasing hypoxic fractions with increasing AT1-tumor size were also 
found by Eble et al. [210], and large hypoxic fractions in large AT1-tumor were also de-
scribed by other researchers [68, 83, 172]. 
Tumors with a size of 10 mm × 10 mm showed no pimonidazole-positive areas which is 
commonly interpreted as normoxia. On the other hand, there are indications suggesting that 
the AT1-tumor is not normoxic at this size. The clamping experiments of the PAI study 
demonstrated an overall reduced oxygen signal (median values of sO2-distributions ranged 
from 37 to 46 % sO2) as well as an unchanged PAI-signal after clamping of the AT1-tumor 
[96]. These findings are in line with the preliminary results of ongoing experiments, where 
clamping of AT1-tumors of the same size before and during irradiation with photons results 
in a maximum OER of 1.05 compared to non-clamped AT1-tumors (unpublished data by Dr. 
Christin Glowa). Both experiments imply that the AT1-tumor comprises an intrinsically low 
oxygenation status to such an extent that clamping could not further reduce the oxygen sup-
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ply. Nevertheless, the AT1-tumor exhibits a high proliferative rate which might be enabled 
by the altered enzymatic profile [94] that marks the tumor’s adaption to oxygen-depletion.  
Generally, pimonidazole has to be considered as a surrogate-marker for hypoxia. Pimonida-
zole gets reductively activated under hypoxic conditions and subsequently forms adducts 
with the cells’ thiol groups that can be detected by histological methods. In the presence of 
oxygen, the initially reduced form of pimonidazole gets re-oxidized inhibiting adduct for-
mation [211]. Adduct formation is proclaimed to take place at an pO2 of 10 mmHg or lower 
[212, 213] which means that moderate hypoxic regions with an pO2 slightly above 10 mmHg 
cannot be identified by pimonidazole [212]. Taking into account the above mentioned exper-
imental findings, this might be the case for the pimonidazole-negative 10 mm × 10 mm AT1-
tumors. The ground truth could in principle be detected by electrode measurements; however 
this method was not available at the DKFZ. 
Despite the low fraction of CD31
+
/SMA
+
-capillaries, tumors expressed a SMA-rich texture 
that might mark myofibroblasts, which are a sign of reactivated stroma associated with tu-
morigenesis and progression in human prostate cancer [214, 215]. The high fraction of in-
termediately-perfused tumor areas is the result of vascular immaturity and the absence of 
large vessels. Overall, the perfused area (combining the intermediately- and highly-perfused 
regimes) corresponds to that of large AT1-tumors as determined by Mena-Romano et al. 
[172]. Intermediately- and non-perfused tumor areas comprised comparable vessel densities 
suggesting that a large fraction of capillaries in both classes are non-functional. The vessel 
density was significantly larger than that reported by Zhao et al. (45 ± 13 vessels/mm
2
) who 
counted vessels in selected light microscopy images [171] and Mena-Romano et al. 
(101 ± 131 vessels/mm
2
) who manually counted vessels in selected fluorescence images 
[172]. However, the automatic counting of contrast-rich whole-mount fluorescence images 
as performed in this study presumably gives superior statistics and thus more reliable results 
as compared to the previous studies.  
 
Photon irradiation 
Photon treated tumors showed pimonidazole staining after 24 h. However, when inspecting 
the whole-mount images with the three highest hypoxic fractions (16 %, 8 %, and 6 %, re-
spectively), it should be noted that their pimonidazole staining exceeded only slightly the 
threshold that was set for the analysis and that they were in close vicinity to the still slightly 
visible original transplantion fragments (identified as continuous avascular areas). This chal-
lenges the assumption that the pimonidazole-positive areas are irradiation-induced. No pi-
monidazole-positive regions were found in the remaining tumor areas. Hence, the hypoxic 
fractions at 24 h after photon irradiation should be treated with reservation.   
Credible pimonidazole staining revealed hypoxia 10 days after photon irradiation when the 
vascular density was reduced to approximately 40 % of the control’s density. The fact that 
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the preceding steady decrease in vascular density did not go along with any perfusion altera-
tions in the tumors and did not show any dependency on the perfusion class further under-
pins the assumption that the majority of the CD31
+
-structures is non-functional and does not 
contribute to the tumor’s supply [55, 186]. A comparably late increase in hypoxia was also 
found by Bussink et al. 11 days after 10 Gy photon irradiation of a human squamous cell 
carcinoma xenograft [216] and by Goda et al. after 20 Gy photon irradiation of MTG-B and 
RIF-1 tumors [217]. Kallman et al. attributed this late occurring hypoxia to eventually mani-
fested stromal injuries and inadequate perfusion through the remaining vasculature [218]. 
The rapid drop in vascular density within the first 24 h can be attributed to the high irradia-
tion doses [184] and the large number of non-functional vessels [186].   
Hyperperfusion after 24 h was also described by Brown et al. [177] and conforms to the post-
irradiation perfusion changes observed by Bussink et al. [216]. It can be assumed that this 
led to a re-oxygenation shortly after irradiation [217, 219, 220]. The subsequent constant 
tumor perfusion until 10 days after RT is in accordance with the parameters Ktrans and nor-
malized AUC of the DCE-MRI study where the hyperperfusion at 24 h was missed. Un-
changed perfusion was also found by Tsai et al. for the first week after single-fraction and 
fractionated radiation [185]. 
 
12
C-ion irradiation 
Compared to photons, 
12
C-ions led to an earlier onset of hypoxia with a maximum at day 7. 
The temporal decrease in the density of CD31
+
-structures was identical to that after photon 
irradiation suggesting that the earlier oxygen depletion originated from functional rather than 
structural disruptions. Taking the early rise in Ktrans of the DCE-MRI study at day 3 into 
account, it can be assumed that 
12
C-ions increased the capillaries’ permeability more than 
photons did without completely destroying them. In the following this increased permeabil-
ity might have pandered edema formation which in turn led to compressed capillaries due to 
the elevated interstitial pressure, eventually leading to reduced blood flow and return to ini-
tial values [209]. After its maximum, the hypoxic fraction declines at day 10 and 14 even 
though the non-perfused tumor fraction is very high. This is due to the intensely reduced 
number of intact tumor cells that could potentially be hypoxic. 
Endothelial turnover in tumors is much faster than in normal tissue [221], so that the increase 
in vascular density and maturity at day 21 after 
12
C-ion irradiation could result from neoan-
giogenesis with coinciding tumor shrinkage rather than survival of SMA
+
-vessels. This final 
increase in vascular density was also reflected in the parameter Ip of the DCE-MRI study 
which also revealed an elevated vascular fraction at that time point. 
To further understand the irradiation-induced oxygenation changes, staining for endogenous 
hypoxia markers such as the transcription factor HIF-1α [222] and the thereby augmented 
expression of glucose transporters (e.g. Glut-1) [223] and CA IX [224] should be considered. 
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To better distinguish the temporal changes in vascular perfusion and permeability, the use of 
differently sized perfusion markers could be considered. Potiron et al. used Hoechst 33342 
(616 Da) to assess vessel permeability in relation to large dextran molecules (2 MDa), which 
remained intravascular as a perfusion marker, and medium dextran molecules (10 kDa) to 
assess interstitial diffusion [225]. 
Major alterations in hypoxia occurred after one week which would make 7 and 12 days after 
irradiation suitable candidates for measurement time points of future multimodal imaging 
studies. 
4.7.3 Cellular response 
Irradiation-induced DNA DSBs were identified by staining for γH2AX. However, γH2AX 
foci also form during normal physiological processes such as DNA fragmentation during 
apoptosis and occur as transitional DSBs during S-phase [226]. Therefore, γH2AX
+
-cells 
were divided into intermediate intensity cells and high intensity cells to distinguish intrinsic 
γH2AX foci already present in non-irradiated AT1 tumors from irradiation-induced γH2AX 
foci. This analysis approach is supported by the finding that irradiation-induced γH2AX foci 
are significantly bigger than irradiation-unrelated foci [227, 228]. Although the spatial reso-
lution of the microscopic images was not sufficient to identify individual foci in cell nuclei, 
the accumulation of many large foci, which is expected after single high dose irradiation, 
displays as overall bright, i.e. high intensity, nuclei [141]. Nuclei with few small γH2AX foci 
exhibit low intensities. 
The high percentage of initial intermediate intensity γH2AX
+
-cells underlines the anaplastic 
and rapid proliferative characteristics of the AT1-tumor [229]. The peak observed after 24 h 
resembles cells with few irradiation-induced DNA DSBs that were subject to subsequent 
repair mechanisms. However, it can be assumed that tumor cells accumulated more DNA 
errors due to mismatching with every cell cycle [230] until undergoing mitotic death [231]. 
This is mirrored by a steady decrease of γH2AX
+
-cells below control tumor levels.  
The high intensity peak represents cells with a dense incidence of irradiation-induced DNA 
DSBs. Presumably, this peak was even higher shortly after irradiation as other studies have 
demonstrated the occurrence of discrete γH2AX foci within minutes after irradiation [141, 
226]. The rapid decline of the fraction of high intensity γH2AX cells to 1 % is the joint re-
sponse to high-single dose-induced instant cell death and partial cellular repair. Averbeck 
et al. observed very efficient rejoining after 
12
C-ion irradiation and proclaim that misrepair of 
DNA DSBs plays a major role towards the increased RBE of heavy ions [232]. This is in 
accordance with the ongoing, but decreasing, proliferative activity of the tumor cells.  
BrdU is incorporated into the DNA during S-phase and hence reflects the cells’ proliferative 
activity. The drop in BrdU
+
-cells within the first 24 h indicates an irradiation-induced cell 
cycle arrest which is in accordance with the increased γH2AX
+
-cell fraction at that time 
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point [233, 234]. Proliferation rates returned to initial values at day 3 which can be consid-
ered as the joint result of (i) tumor cells that have died due to severe irradiation-induced 
DNA damage, (ii) sub-lethally damaged cells that continued proliferation after overcoming 
cell cycle arrest [235], and (iii) survived tumor cells that were stimulated to proliferate by 
paracrine signaling of dying cells [236]. As DNA damages manifest to eventually become 
lethal with every following cell-cycle, the proliferation rate steadily decreases for the later 
time points. The BrdU
+
-cells that were found at the late time points were bloated so-called 
“doomed to die” cells. 
A limitation of the analysis protocol is the normalization of the γH2AX
+
- and BrdU
+
-cells to 
the overall DAPI cell count because DAPI non-selectively stains all cell nuclei. This way, 
not just tumor cells but also the invading immune cells that were identified on H&E stains 
are included in the overall cell count leading to an underestimation of the fraction of 
γH2AX
+
- and BrdU
+
-cells. With respect to the overall cell count, the identification of AT1-
tumor cells would be of upmost interest. In earlier studies, Glowa et al. have found that 
77.7 % of AT1-tumor cells expressed CK19 [229] which could be used as a tumor cell mark-
er for a rough estimation of remaining tumor cells. Additionally, immune cells could be 
identified by staining for CD45 [237] to eliminate them from the overall cell count. The im-
mune response could be further assessed by specific staining for macrophages [238] and NK 
cells (CD16, CD56) [239] which might also give insights into differential effects of photons 
and 
12
C-ions on the immune response [25]. Furthermore, the cellular response towards irra-
diation should be examined in more detail by staining for apoptotic markers such as caspa-
se 3 [240, 241] or by performing a TUNEL assay. 
To investigate cell proliferation in hypoxic areas and differentially perfused areas, staining 
for BrdU in combination with pimonidazole and Hoechst 33342 should be considered for 
future studies. Furthermore, the proliferation of endothelial cells after irradiation could be 
assessed by double staining for CD31 and BrdU. 
4.8 High LET vs. low LET irradiation 
The differential effects of high LET 
12
C-ions and low LET photons on the anaplastic and 
chronic hypoxic AT1-tumor and the moderately differentiated HI-tumor were investigated.  
The isoeffective doses for 
12
C-ions and photons of the AT1-tumor were calculated based on 
the RBE for 100 % local tumor control that was determined by Glowa et al. [24]. The identi-
cal results for vascular density, proliferation, and DNA DSBs after both, photons and 
12
C-
ions within the first 10 days, confirm this RBE on a histological level. Differences were only 
observed in the temporal progress of hypoxia and perfusion changes in the DCE-MRI study 
and on a histological level. Minor histological differences manifested at later time points. 
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For the HI-tumors, histological data was only available for the time point 21 days after irra-
diation when tumor degradation was already advanced. No differences between high LET 
and low LET irradiation were found, neither in the results of the PCA nor on a histological 
level at day 21. 
Photons and 
12
C-ions act through different mechanisms: while photons damage the DNA 
mostly through indirect, oxygen-sensitive effects, 
12
C-ions directly induce clustered DNA 
DSBs largely independent from the presence of oxygen [21]. In spite of these differences, 
the differential effects measured by imaging as well as on the histological level were rather 
subtle for both tumor sublines. This may be explained by the fact that the applied high single 
doses masked those differences in the response to photon and 
12
C-ion irradiation. With this 
respect, even the sub-curative doses that were used in the DCE-MRI studies can be consid-
ered as being too high to resolve any differential effects as only dose-independent treatment 
responses were found. Based on these results, fractionated experiments would be of high 
interest to further examine the differential effects of photons and 
12
C-ions on hypoxia. 
4.9 Conclusion 
In this thesis, novel technical developments as well as biological investigations have been 
performed. On the technical side, a novel analysis protocol for PAI was developed and has 
been demonstrated to be feasible for the characterization of the oxygenation status of the 
three Dunning tumor sublines H, HI, and AT1 under ambient conditions as well as for al-
tered external oxygen supply. Furthermore, a novel method for BAT estimation of DCE-
MRI data based on a flexible spline-based approximation model and automatic parameter 
estimation by generalized cross validation was developed which is able to adapt to various 
types of TCCs. Its broad applicability was demonstrated. 
On the biological side, two longitudinal DCE-MRI studies, which were performed for the 
AT1- and HI-tumor after irradiation with single curative and sub-curative doses of either 
photons or 
12
C-ions, were analyzed to investigate irradiation-induced functional vascular 
changes. For the anaplastic AT1-tumor, a delayed response after irradiation with photons 
compared to 
12
C-ions was found. For the moderately differentiated HI-tumor vascular per-
meability increased at the same time for both modalities. The different radiation sensitivities 
of the HI- and AT1-tumor for the two irradiation modalities indicate that the irradiation-
induced vascular response depends on the structural-functional status of the tumor vascula-
ture. In addition, the results of both studies were dose-independent, suggesting that the initial 
vascular response only plays a minor role for local tumor control at high single doses. For 
the AT1-tumor the RBE for local tumor control was confirmed on a microscopic level within 
the first 10 days after irradiation. The obtained results suggest that the high single doses 
mask potential differential mechanistic effects that result from the different microscopic dose 
deposition patterns of photons and 
12
C-ions.  
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5 Outlook 
The DCE-MRI studies and the longitudinal histology study provide a first important charac-
terization of the development of hypoxia-related parameters prior to and after irradiation 
with either photons or 
12
C-ions. Nevertheless, there were some ambiguous results that re-
quire further research. A dedicated longitudinal multimodal imaging- and histology-study 
after irradiation is expected to contribute significantly towards the understanding of the dif-
ferential effects of photon and 
12
C-ion irradiation with regard to tumor hypoxia and perfu-
sion. Such a study is planned for the future taking into account the results of the present the-
sis for its study design. For each modality and dose level, AT1-tumors will be imaged one 
day before irradiation and at two time points afterwards. Based on the performed histology 
study, suitable time points to detect changes in hypoxia were identified to be 7 and 12 days 
post-irradiation. Each imaging session should consist of PET, DCE-MRI, and PAI measure-
ments. PET measurements will enable the direct visualization of hypoxia with the hypoxia-
sensitive tracer [
18
F]FMISO, PAI will be used to assess overall tumor oxygenation employ-
ing the newly developed analysis protocol, and DCE-MRI will give insights into the tumors’ 
perfusion. Further MRI measurements such as diffusion weighted imaging may be added. 
MRI and PET measurements will be sequentially conducted at the new 9.4 T small animal 
PET/MRI scanner allowing spatial correlation of the two measurements which was not pos-
sible up to now. Furthermore, a higher spatial resolution as compared to the presented stud-
ies, which were performed at a clinical 1.5 T MRI scanner, is expected from the higher mag-
netic field strength. Additionally, after each imaging session a sufficient number of animals 
will be drawn from the study for histological examinations enabling a direct correlation of 
the imaging modalities to histology for each time point.  
As a further step, it would be of great interest to perform the same multimodal imaging study 
for the moderately differentiated and acute hypoxic HI-tumor to reveal the influence of the 
underlying tissue characteristics on the differential irradiation response between low LET 
photons and high LET 
12
C-ions. 
As the results of the performed studies suggest that the single dose irradiations are so high 
that differential effects between photons and 
12
C-ions are masked, fractionated experiments 
should also be considered for the future. 
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Appendix 
A.1 Statistical analysis of pharmacokinetic modeling results of the 
AT1-tumor 
Normalized AUC values and ETM parameters of the longitudinal AT1 DCE-MRI study 
(section 3.3.2) were tested for significance by the Kruskal-Wallis test and post hoc Bonfer-
roni correction per imaging time point. Results are displayed in Table 9. 
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Table 9 Results from the Kruskal-Wallis test and post hoc Bonferroni correction on normalized AUC, Ktrans, Ie, 
and Ip values for each imaging time point after irradiation (RT) with either photons (ph) or 12C-ions (12C). 
Significant differences between groups are marked by red entries, insignificant differences are marked by blue 
entries. Significance level was set to p < 0.001. 
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A.2 Individual ETM parameters for each AT1-tumor of the DCE-MRI 
study 
 
Figure 53 Individual results per animal and imaging time point from non-compartment analysis and ETM pa-
rameters. For clarity, the data of the control groups are pooled over all control tumors per time point. Estimated 
parameters are (A) normalized AUC values, meaning AUC values per animal and time point were normalized to 
the maximum AUC value of the respective animal’s main abdominal artery to eliminate CA administration relat-
ed effects, (B) the volume transfer constant Ktrans, (C) the extravascular, extracellular space Ie, and (D) the plas-
ma volume fraction Ip. Boxes mark the 25/75 % percentiles and are displayed with medians (line), 10/90 % per-
centiles (whiskers), and 5/95 % percentiles (dots). 
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A.3 Quantitative immunohistochemistry results of the AT1-tumor 
including tumor 23 
 
Figure 54 Results of quantitative immunohistochemistry analysis for non-irradiated control tumors and treated 
tumors 21 days after RT including tumor 23. (A) Microvascular density calculated as the number of CD31+-
vessel structures exceeding an area of 21.125 µm2 (50 pixels). Tumor sections were separated into a rim (outer 1 
mm) and core (remaining inner area) region. (B) Vessel maturity was assessed for tumor rim and core by the 
number of vessels that co-expressed CD31 and SMA (CD31+/SMA+). (C) Proliferative activity was marked by 
BrdU incorporation in relation to the overall cell count. + One animal had to be excluded from the analysis due to 
complications during tumor dissection. 
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A.4 Pooled ETM parameters of the HI-tumor  
 
Figure 55 ETM fit parameters of the DCE-MRI study of the HI-tumor pooled per treatment group and imaging 
time point: the volume transfer constant Ktrans, the extravascular, extracellular fraction Ie, and the plasma volume 
fraction Ip. Box plots (25/75 % percentiles) are displayed with medians (line), whiskers representing 10/90 % 
percentiles, and dots representing the 5/95 % percentiles. 
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